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The growth and maintenance of the human skin and its appendages is 
warranted by the constant, dynamic changes in epidermal cell populations, 
epidermal proliferation, and differentiation. In normal, healthy epidermis 
there is a delicate balance between the production of young basal cells, and 
the shedding of terminally differentiated epidermal scales at the surface of 
the skin. In skin diseases like psoriasis, this balance is disturbed, resulting in 
changes in the various epidermal cell compartments. Also, very little is known 
about this differentiation process in the human nail apparatus.
This thesis focused on the dynamics of epidermal cell populations in healthy, 
diseased skin, and its appendages using a novel quantitative imaging technique. 
Furthermore, the effects of various treatments on the changes in these cell 
compartments were assessed.
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1.1 The human skin
1.1.1 Form and function
The skin is the largest organ of the human body, it serves a multitude of functions, 
but its main function is probably to maintain the internal environment of the 
human body. To successfully fulfil this function the skin sustains a mechanical 
and immunological barrier between the body and the outer world, and repairs 
injury when this barrier is compromised. Further functions of the skin are 
to regulate the body temperature, communicate with the outer world, and to 
attract other humans for social and sexual purposes 1.
The skin is comprised of two main layers, separated by the basement membrane; 
the dermis which originates from the mesoderm, and the epidermis which is 
derived from the ectoderm. The epidermis is further subdivided in the basal 
layer, the spinous layer, the granular layer, and the stratum corneum 2. The skin 
harbours hair follicles, sebaceous, apocrine, and eccrine glands, and on the tips 
of the digits the nails. The epidermis is for 95% composed of keratinocytes that, 
after differentiating to corneocytes, are every day shed from the surface of the 
epidermis. This differentiating compartment of the epidermis is continuously 
replenished from the keratinocytes in the basal layer of the epidermis; the stem 
cells. A sophisticated interplay between these stem cells and its progeny of 
more differentiated cells takes care of the continuous renewal of the epidermis.
A stem cell is defined as a cell which, under normal circumstances, maintains 
its own population, undiminished in function and size and furnishes 
daughters to provide new functional cells of that tissue3;4.  Recent years there 
is a growing interest in stem cells, motivated by an attempt to understand 
ageing and carcinogenesis, as multipotent stem cells are likely to be the main 
target for various types of tumours 5-7. Stem cell research is also focused more 
and more on therapeutic approaches to repair damaged organs and tissues 
by transplantation. Recent advances include the use of stem cells in neural 
degenerative diseases and the use of epidermal stem cells for the repair of 
severed peripheral nerves. Epidermal stem cells have also been used to generate 
reconstitutative skin, after expansion in vitro, for large burn wounds or chronic 
leg ulcers 8-10. Stem cells are thought to reside in niches, which are essential 
in maintaining a balance between stem cell quiescence and activity11. Known 
niches are the bone marrow for hematopoietic stem cells and the intestinal 
crypts for intestinal stem cells. For the human epidermis, the hair follicle 
bulge, and the deep rete ridges of the interfollicular epidermis are considered 
as the niches for skin stem cells 3;12. 
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1.2 Cell populations
1.2.1 Interfollicular epidermis
Bromodeoxyuridine (BrdU) is a synthetic thymidine analog that gets 
incorporated into a cell's DNA when the cell is dividing (during the S-phase 
of the cell cycle). Cells that, once they have incorporated BrdU are quiescent 
and stop dividing, retain their label and are called label retaining cells (LRC’s). 
Stem cells are considered cells which rarely divide, so the stem cells are among 
the LRC’s. Whole mount labelling of murine epidermis with BrdU to generate 
LRC’s visualised interfollicular stem cells dispersed throughout the epidermis 
13. These stem cells are localised at the tips of the deep rete ridges of the basal 
layer, so perhaps it is better to speak of the stem cell niche instead of the stem 
cell compartment in the interfollicular epidermis. In humans, it is very hard to 
identify a single stem cell from its progeny, the transit amplifying cell. A transit 
amplifying cell (TAC) is in its state of differentiation between the stem cell and 
the terminally differentiated cell. Contrary to the stem cell, this type of cell has 
a high proliferative activity and is able to amplify the quantity of cells in the 
epidermis, hence the name 14. Since these cells divide frequently they lose their 
BrdU label.
In vivo labelling with radioactive isotopes or BrdU is considered unethical 
in humans for obvious reasons. Therefore in recent years there has been 
an extensive search for stem cell specific cell surface markers, in order to 
differentiate between epidermal stem cells and their progeny in humans, 
but a definite stem cell marker remains yet to be found. LRC’s have a high 
colonogenic capacity and when these cells are placed in culture, they are 
more likely to produce holoclones with large keratinocyte colonies and with 
the greatest cell regenerative capacity in long term culture 3. These holoclone 
forming cells express high levels of β1 integrin and are also called β1 integrin 
bright cells. Assumed TAC express low levels of β1 integrin and are called β1 
integrin dim cells. The level of β1 integrin expression can be used to separate 
human epidermal stem cells from transit amplifying cells using flow cytometry 
15. The ongoing search for putative stem cell surface markers brought 
researchers to the α6 integrin protein. This protein can be found clustered in the 
hemidesmosome with β6 integrin and plays together with α3β1 integrin, which 
is also found in the basement membrane, an important role in keratinocyte 
survival 6;16. The cells highly expressing α6 integrin (α6 integrin bright cells) 
were found to visualise both the fractions of stem cells and transit amplifying 
cells. When double labelled with the Transferrin receptor (CD71) the cells 
with an α6 integrin bright, CD71 dim profile were shown to be quiescent in 
nature, to have a high overall proliferative capacity, and to reside at the tips of 
the epidermal rete ridges, marking them as putative stem cells 17;18. 
Keratin 15 is an intracellular protein also found in the rete ridges of the 
interfollicular epidermis, but it has been designated as a putative stem cell 
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marker in the bulge of the hair follicle. Its use as being an epidermal stem 
cell marker has been demonstrated by the utilisation of keratin 15 promoters 
to specifically target hair follicular stem cells 19-21. Keratin 15 is only found in 
non activated, non stressed basal keratinocytes, and its expression disappears 
during wound healing, and in the hyperproliferative skin disease psoriasis, 
instances when there is a profound recruitment of transit amplifying cells 22;23. 
Being a marker for epithelial tumours in the 1980’s, keratin 19 was thought 
to be a possible stem cell marker. Cells in the follicular stem cell niche, 
the bulge area of the outer root shaft of the murine hair follicle, that were 
positively labelled with [3H] Thymidine, were also labelled by a synthetic 
antibody to keratin 19. This marked keratin 19 as another hair follicle stem 
cell marker 24. When used in human skin, keratin 19 expressing cells were also 
found in the deep epidermal rete ridges and these cells expressed high levels 
of α3β1 integrin, marking keratin 19 also as a putative stem cell marker in 
interfollicular epidermis 25;26. More recently, keratin 19 was used to isolate and 
identify epidermal stem cells in adult Cashmere goat skin 27.
Concluding, an epidermal stem cell should co-express keratin 15 and 19, have 
an α6 integrin and β1 integrin bright expression profile, while not expressing 
CD71. Of course an epidermal stem cell should also not express markers for 
terminal differentiation as keratin 10.
1.2.2 The epidermal proliferative Unit
The epidermal proliferative unit (EPU) is defined as a hexagonally shaped 
unit of approximately 10 basal cells, consisting of one β1 integrin bright stem 
cell, surrounded in the basal layer by its direct progeny, the TAC that are α6 
integrin bright and β1 integrin dim 25;28-30. These rapidly cycling epidermal cells 
can also be visualized by the expression of the ki-67 protein, which is absent 
in non proliferating cells. The ki-67 protein is expressed during the whole cell 
cycle with the exception of the resting G0 phase and is widely used to visualize 
rapidly proliferating cancer cells in for example squamous cell carcinoma 31;32. 
In the model of the EPU these proliferating TAC give rise to a suprabasal 
column of differentiating epidermal cells which differentially express keratins 
during their differentiation process. In the normal, non hyperproliferative 
epidermis, keratin 10 is expressed in the spinous layer and stratum corneum 
as a marker for terminally differentiated keratinocytes 33-35. Compaction of 
these keratins in the stratum corneum, together with the condensation of the 
keratinocytes, leads to the formation of a dense protective layer on the skin.
In this model there is no direct differentiating progeny from the stem cell, and 
there are no differentiating cells in the basal layer. However, recent years there 
are signs that epidermal stem cells not only divide to form TAC in the basal 
layer of the epidermis, but that also direct asymmetrical division from one 
stem cell into a new stem cell and  a differentiating cell is possible. Extracellular 
matrix (ECM) polymers and growth factors of the basement membrane seem 
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to play an important role in orchestrating this asymmetrical division process 
36. One of the ECM polymers, possibly important in this regulation, is laminin 
5, the ligand for α3β1 integrin, which may explain why epidermal stem cells 
express high levels of β1 integrin 6;15.
1.3 The nail apparatus
1.3.1 Function
Although at first sight the human nail may seem to have limited function in 
daily life, it serves various important functions. The nail not only protects the 
distal part of the finger against trauma, it is also a tool that is used to scratch or 
manipulate little objects. Also does the nail play a role in the sensory function of 
the distal part of the digit because of the fine neurosensoric bodies in the digit 
that are compressed between the nail and the bone. Even more, the extensive 
decorations patient put on their nails is indicative of the major role nails play 
in social interaction. Nail changes are very common. Onychomycosis alone 
has a prevalence of approximately 27% 37. 
1.3.2 Anatomy
The most visual part of the nail apparatus is the nail plate (see figure 1). The 
nail plate is the end product of the nail apparatus and is derived from the nail 
matrix. On the lateral edges the nail plate is bordered by the lateral nail folds. 
On the proximal side the nail plate is attached to the overlying epidermis by 
the cuticulus, a thin ridge of epidermis, providing a protective sheet adhering 
to the proximal part of the nail plate. On the distal side the free edge of the nail 
plate is overlying the hyponychium. The lateral nail folds, the cuticulus, and 
the hyponychium function as a protective border against intrusion of the nail 
apparatus by bacteria and dirt. When we sagitally cut the nail apparatus, we can 
further divide the non visual part of the nail apparatus into the following parts 
(see also figure 1): the epidermis of the dorsal part of the digit is continuous 
with the dorsal and ventral proximal nail fold, of which the latter is continuous 
with the dorsal matrix. The dorsal matrix meets the intermediate matrix at 
the tip of the matrix. The intermediate matrix is parallel with the nail plate and 
continues as the nail bed that ends when the nail leaves the nail bed and the 
hyponychium is formed. At this stage the digit pulp begins which continues 
as the normal epidermis of the tip of the human digit 25;38-40. 
1.3.3 Cell populations in the nail unit
Data on the cell biology of the nail unit is sparse to say at least. The nail plate 
originates from the nail matrix. Lewis divided the nail plate in three layers, 
the most superficial part originating from the dorsal matrix, the intermediate 
part originating from the intermediate matrix, and the ventral part originating 
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from the nail bed (figure 1) 39. In primates and humans labelling of the cells in 
the nail apparatus with radioactive tritiated glycine and thymidine, to follow 
these cells in their distal movement towards the nail plate, showed labelled 
cells in the basal and suprabasal layers of the  intermediate matrix one hour 
after injection. In one to two weeks these cells migrated to the nail plate 41;42. 
Another approach to study the origin of the nail plate is to measure the nail 
plate thickness along the length of the matrix and nail bed. When moving 
along the nail bed, the nail plate increased approximately 20% in thickness, 
indicating a contribution of the nail bed to the nail plate formation 25;43;44. Later 
de Berker showed that the increased thickness of the nail plate did not coincide 
with an increase in the amount of nail plate cells. A probable explanation is 
that there is no contribution of the nail bed in the nail plate formation, but 
that mechanical factors (micro trauma) lead to a compaction of the nail pate 
in the horizontal axis leading to a thickened nail plate 45. Labelling with the 
ki-67 antigen MIB-1, in human nail apparatus sections, indicated a labelling 
index of 22% in the nail matrix and only 0,75% in the nail bed, indicating a 
lot of actively proliferating cells in the intermediate matrix, but nearly no in 
the nail bed 46.  Cultured and in vivo cells of the nail matrix expressed α6 and 
β1 integrin, proteins known as markers for stem cells and transit amplifying 
cells in the interfollicular epidermis. Interestingly, when cultured, these cells 
exhibited a spontaneous migration phenomenon associated with a tendency 
to stratify in a semi lunar area 47;48. All this marks the intermediate matrix as 
the location where actively dividing cells differentiate, compact and eventually 
form the nail plate.
The nail plate consists of compacted corneocytes that have lost their nucleus 
Figure 1: Cross-section through the finger, demonstrating the various compartments of the nail unit.
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and mainly consist of keratins. Twenty percent of the keratins are epidermal 
or soft keratins and 80% are so called “hair type” or hard keratins. The keratin 
fibrils are cross linked with sulfur bridges explaining the solidity of the nail 
plate 49-51. 
Remarkably little is known about the cell populations and the proliferation and 
differentiation processes in the rest of the nail apparatus. We know that the nail 
bed is a thin layer of epithelium that has a very tight contact with the nail plate 
by means of  longitudinal ridges which provide a strong adhesion of the nail 
plate to the nail bed 52. In contrast to the differentiated cells of the interfollicular 
epidermis that have a suprabasal keratin 10 expression, the cells of the nail 
bed exhibit a panepidermal keratin 6 expression, a keratin normally only 
expressed in activated, stressed keratinocytes.  This keratin expression may be 
related to the adherence of the overlying nail plate which serves as some kind 
of suprabasal layer to the nail bed 53. This might explain why in psoriatic nails 
with subungual hyperkeratosis and loss of the overlying nail plate, a granular 
layer in the nail bed develops with a switch from keratin 6 expressing cells to 
keratin 10 expressing cells, resembling the keratin expression and anatomical 
structure of the interfollicular epidermis 54.  
Although the intermediate matrix is designated as the area where actively 
dividing cells give rise to the nail plate, no distinction has been made between 
the supposed stem cell compartment and the transit amplifying compartment 
in this region. So the real origin of the nail, as well as the exact location of 
the transit amplifying compartment, remains to be elucidated. Apart from the 
aberrant keratin 6 expression in the nail bed, one can also wonder why there 
are no actively dividing cells in the nail bed. This indicates that these terminally 
differentiating cells must originate from another part of the nail apparatus. The 
origin of the cells of the nail bed also is in need of clarification.41;46. 
1.4 Psoriasis
1.4.1 Epidemiology 
Psoriasis is a relatively common skin disease with a prevalence varying between 
1 and 2.5% of the population. Caucasian people are more often affected than 
African or Afro-American people 55;56. Although psoriasis may begin at any 
age, two peak incidences have been reported: at 16-22 years of age and at 57-60 
years of age 57. The clinical course of psoriasis is highly unpredictable. It may 
be chronic and may progress with exacerbations and remissions. Some factors 
are known to aggravate psoriasis. The most important are trauma (Koebner 
phenomenon), infections, drugs (e.g. beta-sympaticolytics, lithium and anti-
malarials), and smoking 58-60. 
Although psoriasis for a long time has been considered as a relative harmless 
skin disease, recent research indicates a significant decreased quality of life 
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in patients with psoriasis as compared to patients with no psoriasis. The 
impairment in mental quality of life scores was comparable to patients with 
chronic lung disease or depression, and psoriasis patients scored on the 
physical part of the quality of life tests as high as patients with chronic heart 
failure 61;62. 
Recently the focus on psoriasis related research has shifted to the relationship 
between psoriasis and the metabolic syndrome. Psoriasis is associated with 
obesity, diabetes, hypertension, and increased risk of myocardial infarction. 
Both psoriasis and the metabolic syndrome share the same pathologic changes 
such as chronic inflammation, angiogenesis, and oxidative stress, possibly 
explaining why psoriasis patients with severe psoriasis have a decreased life 
expectancy of average 3.9 years as compared to patients without psoriasis 63-65.
1.4.2 Clinical presentation
Psoriasis is a skin disease with several clinical presentations, all sharing the 
erythemato-squamous appearance. From a morphological point of view these 
presentations should be regarded as different phenotypical expressions of 
one single disease. Different expressions may appear at the same time in one 
person, or one person with psoriasis may have different clinical presentations 
during his life 66. 
The most common form of psoriasis, psoriasis vulgaris, can be found in 
approximately 90% of the patients and is characterised by sharply demarcated 
erythemato-squamous plaques which are red or pink in colour and mostly 
covered with silvery-white scales. The plaques are most commonly located 
on the elbows, knees, scalp, umbilicus, and low lumbar region. The plaques 
Figure 2: Classical presentation of psoriasis vulgaris.
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may be annular, expanding with an active ring and with normal skin in the 
centre, probably reflecting the pathogenic process 67. The flexural psoriasis 
(psoriasis inversa) is located in the intertriginous areas and the plaques are 
typically shiny and red without the typical scaling of psoriasis vulgaris 67;68. 
Guttate psoriasis is a mostly acute form of  psoriasis which is characterised 
by relatively small, round, erythematous, scaling papules that are most often 
spread over the trunk and extremities. Guttate psoriasis is in most patients 
advanced by a β-haemolytic streptococcal infection, such as a tonsillitis or 
pharyngitis. The prognosis is self limiting, but some of the patients develop 
later in life a chronic form of psoriasis 69. Pustular psoriasis is characterised 
by multiple small, sterile pustules that can coalesce to greater “lakes”. Two 
main clinical forms can be distinguished; the localized and the generalized 
Figure 3: Flexural psoriasis
form. The localized form can be subdivided into pustulosis palmoplantaris, 
where pustules can be found on the whole dorsal part of hand and feet and 
the acrodermatitis continua of Hallopeau, where the pustules are located on 
the tips of the digits. In the latter, arthritis of the distal interphalangeal joints 
can be seen (psoriatic arthritis). The acute generalized pustular psoriasis of 
von Zumbusch is the most common form of generalized pustular psoriasis 
and except the sterile pustules covering a great part of the body, patients may 
experience systemic symptoms as fever, nausea, polyarthritis, and cholestasis 
69;70. A rather life threatening situation arises when the psoriasis patient develops 
an erythrodermic psoriasis. This subform of psoriasis is characterised by 
a sudden onset with rapidly progressing lesions that have a predominant 
erythema and limited scaling. Because of the generalized erythroderma, the 
skin loses its barrier function which can result in hypothermia, dehydration, 
hypoalbumineamia, finally resulting in shock and cardiac failure 67;69.
Psoriasis can coincide with psoriatic arthritis, a seronegative inflammatory 
arthritis with a greatly underestimated prevalence. Interestingly in 10% of the 
patients the psoriatic arthritis appears before the skin symptoms 25;67;71.  
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1.4.3 Cell populations in psoriasis
Histopathologically the psoriasis plaque is characterised by a regular elongation 
of the rete ridges with thinning of the suprapapillary plates and absence of 
the granular layer. The epidermis exhibits a focal parakeratosis and formation 
of micropustules of Kogoj and microabcesses of Munro, both containing 
neutrophils. In the dermis there are elongated tortuous capillaries that protrude 
just below the stratum corneum, leaving only a small suprapapillary plate of 
epidermal cells, which is clinically visible as the so called Auspitz phenomenon 
66;72;73. The elongation of the capillaries is accompanied by a mononuclear 
infiltrate, consisting of T lymphocytes, monocytes, macrophages, and mast 
cells, and polymorphonuclear leucocytes, mainly neutrophils 66;74. 
One of the main features of the active psoriatic plaque is a marked epidermal 
hyperproliferation and a disturbed keratinisation, with a decreased 
compartment of normally differentiated keratinocytes 75;76. Although the 
epidermal dynamics in the initiation of the psoriatic plaque are not fully 
understood, the first step in the development of the psoriatic lesion is the 
increased recruitment of basal epidermal cells from the resting G0 phase to 
the G1 phase of the cell cycle 77;78. These actively cycling cells can be visualised 
by counting the number of ki-67 positive cells. This number is increased in the 
psoriatic plaque in comparison with normal epidermis. Ki-67 positive cells, 
normally only residing in the basal layer, are also found in the first suprabasal 
layers in psoriatic epidermis, indicating an enlarged compartment of activated 
keratinocytes 31;32;79.
Whether the increased recruitment of resting cells to active cycling cells is a 
result of the effects of diverse cytokines derived from the dermal mononuclear 
infiltrate is still under debate, as in some mouse models it seems possible to 
develop a psoriatic phenotype without the need for immunocytes 80;81. However, 
the current opinion is that a sophisticated interplay between immunocytes and 
Figure 4: Acrodermatitis continua of Hallopeau.
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the epidermal keratinocytes results in the recruitment of epidermal cells 82-
84. Some believe that the cells recruited from the G0 cell cycle are the basal 
keratinocyte stem cells, as they were β1 integrin positive and keratin 10 
negative 85;86. Nevertheless, this population most likely not only harbours the 
basal epidermal stem cells, but also the transit amplifying cell population 15;25;87. 
With regard to the integrin expression in psoriasis, the basal keratinocytes 
have lost their polarized distribution of α2β1, α3β1, and α6β4 integrins and 
form focal contacts containing β1 and β4 integrins 88. This probably explains 
the expansion of the β1 integrin expressing, suprabasal cell compartment 
in psoriasis. Interestingly, the artificial suprabasal expression of β1 integrin 
in a transgenic mouse model led to an epidermal hyperproliferation and a 
disturbed keratinocyte differentiation, implying a role of this integrin in the 
pathogenesis of psoriasis 89;90.  More recently we found that in analogy with 
the normal epidermis, the psoriatic keratinocytes expressing β1 integrin can 
be split into a β1 integrin bright (stem cells) and β1 integrin dim population 
(transit amplifying cells). These TAC in psoriatic lesions also seemed to 
be more advanced in their life cycle as compared with the TAC of the non 
pathological epidermis 91. 
Keratin 15, a marker for putative stem cells in the bulge of the hair follicle and 
the interfollicular epidermis, is absent in psoriatic epidermis. This is another 
sign that the epidermis of the psoriatic plaque is in a state of activation, as 
keratin 15 is downregulated in activated keratinocytes as in injured skin and 
in hypertrophic scars 21-23. 
Another marker of the recruitment of activated keratinocytes, culminating in 
a hyperproliferative psoriatic epidermis, is keratin 6. This keratin is expressed 
in a hyperproliferative epidermis, but also after wounding and in activated 
keratinocytes in a cultured skin substitute, situations where the keratinocytes 
are under “stress” 92-96. 
Keratin 10 is a well known marker for terminal, epidermal differentiation 
33;34. Its normal suprabasal expression is reduced in psoriatic epidermis while 
the expression of keratin 6 is increased 97;98. Remarkably, in one individual 
keratinocyte the expression of keratin 6 is complementary with the expression 
of keratin 10 99. When studied in the histological context, not only the keratin 
expression of both keratins was complementary, regression of the psoriatic 
lesion during mild treatment also led to a decrease in keratin 6 expression and 
an increase in keratin 10 expression 100;101. 
1.4.4 The margin zone model in psoriasis
Although various animal models for psoriasis exist, none of these models 
mimics the human situation completely 102. As the clinically expanding 
psoriatic plaque is frequently characterised by an active, reddish ring with a 
centre of clinically normal skin, one can assume that histopathologically, the 
changes at a distance from the psoriatic rim are supposed to represent more 
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early changes as compared with changes which are present close to the rim. This 
margin zone model makes it possible to study the various histopathological 
and biochemical changes in the cell populations of the evolving psoriatic 
lesion 79;103.  Studies in the margin zone of the psoriatic plaque revealed that 
changes in the dermal compartment (endothelium and extracellular matrix) 
precede those in the epidermal compartment 104;105. Although most studies 
only studied 6 mm biopsies that were taken across the margin of the psoriatic 
plaque, the most early changes were seen as far as 12 mm from the border of the 
psoriatic plaque 79. More proximally a dermal infiltrate of epidermis invading 
lymphocytes is seen 79;106. This is followed by epidermal hyperproliferation as 
was demonstrated by an increase in the recruitment of ki-67 positive, actively 
cycling cells and the suprabasal expression of keratin 6. The final step in the 
pathogenetic process shows a disturbed suprabasal keratinisation, as visualised 
by a decreased expression of keratin 10 at the edge of the psoriatic plaque 99;105. 
1.4.5 Nail psoriasis
Apart from psoriatic arthritis, psoriasis of the nails is probably one of the most 
overlooked features of psoriasis. There is only sparse data on the prevalence 
of nail changes in psoriasis patients with percentages ranging between 
20% and 80% 107;108. One could argue that most of these patients only have 
minor changes as pitting, longitudinal ridging, and oil spots. But de Jong 
et al found that from the 1728 psoriasis patients that were evaluated, 79.2% 
suffered from nail psoriasis, and 51.8% of these patients complained of pain 
from their nail psoriasis. More than 40% experienced minor restrictions in 
household duties and 93.3% had cosmetic problems with their nails 107. The 
nail changes seen in nail psoriasis can be divided in nail changes resulting 
from nail matrix psoriasis and changes resulting from nail bed psoriasis. 
The changes resulting from nail matrix pathology are: pitting, grooves and 
ridging, onychorrhexis, and the appearance of red spots in the lunula.  When 
the nail bed is involved in the psoriatic process there can be discoloration of 
Figure 5: Nail psoriasis showing pitting (A), dystrophy (B) and onycholysis (C)
A B C
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the nail plate (oildrop phenomena and salmon coloured spots), onycholysis, 
subungual hyperkeratosis, and splinter haemorrhages. Most complaints of 
pain from patients with nail psoriasis are caused by the onycholysis and the 
subungual hyperkeratosis 107;109;110. Psoriatic nails should be distinguished from 
onychomycosis. Some claim that patients with nail psoriasis have a higher 
incidence of onychomycosis than patients without nail psoriasis, although this 
is in dispute. Treatment of the onychomycosis, although difficult, can improve 
the nail symptoms in these patients 111-113.
1.5 Treatments of psoriasis
The main goal when treating psoriasis patients, is not to cure them, as this still 
is not possible, but to treat the symptoms to an extent that the patient is satisfied 
with the end result, and to minimize the impact the psoriasis has on daily life 
114;115. One can imagine that the desired end result can vary per patient. For 
this reason it is very important to tailor the treatment to the specific patient, 
and to guide the patient during the topical or systemic treatment, as patient 
compliance is disappointing, especially with topical treatment 116;117. With the 
recent reports indicating that patients with moderate to severe psoriasis have 
a significantly reduced life expectancy, and also indications of the economic 
burden of psoriasis becoming available, effective systemic treatments become 
more important 64.
1.5.1 Topical treatment
Emollients and Keratolytics
Emollients mostly are fatty ointments, not containing any pharmacologically 
“active” components. They hydrate the dry psoriatic skin, resulting in a 
significant reduction of itching, redness, and pain psoriasis patients experience 
118. Even more, they may reverse the damage in the stratum corneum and more 
recently a significant reduction in epidermal hyperproliferation was seen after 
treatment with emollients alone 101;119. 
Keratolytics, like salic acid, reduce the thick hyperkeratotic scale and thereby 
improve the penetration of the other topically applied therapeutics 120. 
Corticosteroids
Probably the most used topical treatment are the corticosteroids. They are 
classified into four potency classes, of which class IV is the most potent. 
Corticosteroids of class III and IV are highly effective, while corticosteroids of 
lower classes are used in intertriginous areas because other topical therapies 
can induce irritation in these areas 121. Corticosteroids are known to suppress 
the dermal lymphocyte infiltrate, to inhibit the epidermal hyperproliferation 
Chapter 1 - General Introduction
25
of the epidermis, and the fibroblasts proliferation in the dermis. This last effect 
accounts for one of the side effects when corticosteroids are used on the long 
term, namely the dermal atrophy  122-125. 
Dithranol (Anthralin)
Dithranol is mostly used in an inpatient setting. Its precise mode of action is 
still not fully understood, but there are distinct indications that the induction of 
free radicals in the skin is responsible for its therapeutic effect. Unfortunately, 
this mechanism is also responsible for the irritative effect of dithranol, making 
it, together with its powerful staining of clothes, a less suitable therapy for use 
at home 126-128. 
Coal tar
Coal tar preparations have been used for a long time. Its precise mode of action 
is unknown, but it has anti-inflammatory, anti-bacterial, anti-pruritic and anti-
mitotic effects. Clinically it has comparable efficacy as calcipotriol, a vitamin 
D3 analog after 12 weeks of treatment. However, coal tar makes the skin more 
susceptible for UV radiation, limiting its use in the summer time 129;130. 
Calcineurin inhibitors
More recently, calcineurin inhibitors were added to the therapeutic array for 
the treatment of facial and intertriginous areas. Known calcineurin inhibitors 
are tacrolimus ointment (Protopic®), and pimecrolimus cream (Elidel®). The 
mode of action is by blocking calcineurin, an enzyme involved in the activation 
of T-cells and the production of pro-inflammatory cytokines. The most direct 
side effect is a burning and stinging sensation after application. On the long 
term, concern has risen on the possible theoretical risk on the development of 
malignancies 131-133.
Vitamin D3 derivates
Vitamin D3 derivates are considered the first line treatment for mild to 
moderate psoriasis. Two topical vitamin D3 analogues are available in the 
Netherlands: calcipotriol ointment, cream and lotion (50 μg/g) and calcitriol 
ointment (3μg/g). The clinical efficacy of calcipotriol in clearing psoriasis is 
comparable or better than class III topical steroids or dithranol 134;135. At this 
moment topical vitamin D3 derivates have been used for many years as a 
safe treatment for psoriasis. When used with a maximum of 100 g/week for 
calcipotriol ointment and 210 g/week for calcitriol ointment, they have no 
significant effect on calcium metabolism and bone density 136;137. However, 
with respect to the skin, particularly calcipotriol may cause some side effects as 
perilesional erythema and stinging or burning at the applied areas. Calcitriol, 
on the other hand, has these side effects to a lesser extend, at the expense of 
loss of efficacy and for this reason the use calcitriol has been advocated in 
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the sensitive areas of the skin such as the flexural, retro-auricular, and facial 
areas 138;139. Active vitamin D3 binds to the nuclear vitamin D3 receptor, 
thereby modifying the transcription of various target genes 140;141. Vitamin 
D3 analogues are known to reduce epidermal proliferation, induce epidermal 
keratinisation and cornified envelope formation in the psoriatic epidermis 
109;142-144. It seems that the inhibition of the epidermal hyperproliferation in 
psoriasis is mainly due to the direct inhibition of the hyperproliferative basal 
progenitor cells, driving these cells from a hyperproliferative pathway into 
the differentiating compartment 145. Interestingly, the cells that are targeted by 
vitamin D3 analogues are the β1 integrin positive cells in the basal layer, which 
comprise stem cells and transit amplifying cells. This suggests a direct effect 
on the epidermal stem cell, reducing the transit amplifying cell compartment. 
However, further studies are needed to elucidate these hypotheses 146. 
Although the anti-psoriatic effect of vitamin D3 derivates is mainly due to their 
reduction of the hyperproliferative compartment, together with the induction 
of epidermal differentiation, there is also a direct immunosuppressive effect 
on the dermal infiltrate in the psoriatic plaque. Vitamin D3 derivates even 
enhance the immunosuppressive effect of cyclosporine in psoriasis 147-149. 
Because vitamin D3 derivates have a profound effect on epidermal proliferation 
and differentiation combined with a lesser immunosuppressive effect, and 
corticosteroids have a more profound effect on the dermal infiltrate with a 
secondary effect on the keratinocytes, one can imagine that the combination 
of corticosteroids and vitamin D3 derivates have a synergistic therapeutic 
effect on the psoriatic plaque. Various experiments have shown this to be 
the case and a combined formulation of betamethasone diproprionate (class 
III corticosteroid) and calcipotriol has a superior efficacy in psoriasis when 
compared to both formulations alone or combined 150-152. 
1.5.2 Photo(chemo)therapy
Phototherapy can be considered as the next step in the treatment of psoriasis 
when topical treatment fails or when the affected body surface area is too large 
to be treated with topical medications. Photo(chemo)therapy can be divided in 
small spectrum UVB (311-312 nm), broad spectrum UVB (290-320 nm) and 
PUVA (320-400 nm with photosensitizing psoralens) 153-155. Phototherapy has 
shown to reduce lesional T-cells and to induce apoptosis in hyperproliferative 
keratinocytes 156. Although highly effective in treating extensive psoriasis, 
patients have to visit a treatment centre 3 times weekly, and long term treatment 
with PUVA carries an increased risk for the development of skin cancer 157.
1.5.3 Systemic treatment
When both topical and photo(chemo)therapy have failed or are contraindicated, 
for example because of extensive sun damage, systemic treatments can be used 
to treat patients with moderate to severe psoriasis. 
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Methotrexate
Methotrexate is a highly effective and widely used systemic treatment for 
psoriasis 158. It is a folic acid antagonist and competitively inhibits dihydrofolate 
reductase and various other enzymes involved in purine and pyrimidine 
synthesis. Inhibition of these enzymes disturbs cell proliferation in the
epidermis and in the haematopoietic system. This results in a reduction of 
epidermal hyperproliferation and immunosuppression, finally resulting in the 
resolution of the psoriatic plaques 159-161. Although highly effective, methotrexate 
is not without side effects. In the short term nausea, gastrointestinal discomfort, 
and headaches are reported. More serious side effects are leukocytopenia, 
thrombocytopenia, and hepatic impairment. Recent research shows that 
the level of methotrexate related liver injury is less frequent than previously 
thought. Maybe more importantly, diabetes and being obese are significantly 
correlated with liver injury 162;163. For this reason repeated liver biopsies are 
carried out to monitor methotrexate related liver toxicity. Because these 
liver biopsies are not without risk, more and more alternative monitoring 
methods are explored in order to provide an alternative to monitoring for liver 
injury 164;165.
Cyclosporine A
Cyclosporine A is a calcineurin inhibitor that interferes with the signal 
transduction in T-cells, reducing its cytokine production and interfering 
with the immunopathogenesis of psoriasis 166. Cyclosporine is as effective 
as methotrexate in the treatment of moderate to severe psoriasis, but its use 
is limited by organ toxicity 167;168. In the short term, patients can experience 
hypertension, gastro-intestinal complaints, and a burning feeling of the skin. 
Nephrotoxicity and carcinogenicity of mainly skin cancer limits the long term 
use of cyclosporine A 169;170. 
Retinoids
Retinoids are the first systemic treatment of choice for patients with 
erythrodermic or pustular psoriasis but are less effective as compared to 
methotrexate and cyclosporine in treating chronic plaque psoriasis 109;171-
173. Retinoids are natural or synthetic analogues of vitamin A and they bind 
to the nuclear retinoic acid receptor. They have an anti-proliferative effect 
on the psoriatic epidermis, resulting in a normalisation of keratinisation, 
with expression of keratin 13 and 19 109;174;175. The only retinoid used in the 
Netherlands for psoriasis is acitretin. Although very effective in the above 
mentioned forms of psoriasis, their use is hampered by a characteristic 
spectrum of side effects. Almost all patients experience dryness of the mucosa, 
peeling of the palms and soles, and cheilitis. Also hair loss, brittle nails, and 
a feeling of burning of the skin are observed. These short term side effects 
are dose related and vanish following discontinuation of retinoid therapy. On 
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the long term an increase in serum triglycerides and extra-ossal calcification 
may occur and should be monitored. Because retinoids accumulate in the 
fatty tissue for almost 2 years, and because of its teratogenic effects, pregnancy 
within this period is an absolute contraindication and should be avoided at all 
costs 176-178.
Fumarates
Fumarates have shown to be highly effective in the treatment of psoriasis 
and have been used in the German speaking countries for a long time. The 
exact mode of action on psoriasis is unknown, and fumarates have not been 
registered as anti-psoriatic therapy in the Netherlands 179;180. Most of its side 
effects are short term, such as flushing (55%), diarrhoea (42%), nausea (14%), 
tiredness (14%), and stomach complaints (12%). Patients should also be 
monitored for lymphocytopenia 181. 
1.5.4 Treatment with biologials
Until 2004 the treatment of patients with moderate to severe psoriasis was 
restricted to the abovementioned systemic therapies. For those patients not 
responding to these therapies a treatment at an inpatient setting was the sole 
alternative. A not insignificant group had to stop their systemic therapies 
because of side effects, including serious organ toxicity. From 2004 to 2008 
four so called biologicals have been registered for the treatment of  moderate to 
severe plaque psoriasis: efalizumab, infliximab, etanercept, and adalimumab. 
In the USA, alefacept has also been registered for the treatment of psoriasis. 
These biological agents are effective, have less short term side effects, and have 
excellent safety profiles, and so far no organ toxicity is known. However, the 
biologicals are relatively expensive. At this moment there are three major 
targets for biological therapies; the anti T-cell agents, the anti TNF-α agents 
and more recently the anti IL12/IL23 agents. 
1.5.4.1 Anti T-cell agents
Efalizumab (Raptiva®)
Efalizumab is a humanized, recombinant IgG antibody which binds to the 
T-cell surface molecule CD11a. Consequently the interaction between CD11a 
and LFA1 is inhibited, resulting in a blockade of the T-cell activation and 
T-cell trafficking from the circulation into the skin 182;183. Efalizumab is used 
in patients with stable plaque psoriasis and 27% of the patients reach PASI 75 
after 12 weeks, a percentage that has been claimed to increase on the long term 
to 45% 109;184-186. Adverse events are rarely observed and have been reported 
to include flu like symptoms after the first injections, and thrombocytopenia. 
A more serious issue is the observation that the patients may experience a 
rebound of their psoriasis, during or after cessation of treatment 109;186-188. 
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There is no indication of a direct effect of efalizumab on the epidermal cell 
populations.
Alefacept (Amevive®)
Alefacept is a fully human fusion protein, consisting of the first extracellular 
domain of lymphocyte function-associated antigen-3 (LFA-3) fused to IgG1. 
The LFA-3 segment binds CD2 on the surface of T-cells, thereby inhibiting 
T-cell activation and proliferation. Furthermore natural killer cells and 
macrophages  recognize the Fc portion of  alefacept that has bound to CD2+ 
T-cells, and trigger apoptosis of those memory T cells 189-191. Alefacept has a 
comparable efficacy as efalizumab with 30% of the patients reaching PASI-
75 after 12 weeks of treatment. After a second course of 12 weeks alefacept 
therapy this increased, with 40% of the patients reaching PASI 75. Even more 
interestingly, the patients achieving a PASI 75 reduction after one course of 
alefacept, maintained a 50% or greater reduction in PASI for a median duration 
of more than 7 months. Side effects during alefacept therapy were mainly 
headaches, upper respiratory infections, and nasopharyngitis 189;190;192;193. As for 
efalizumab, no direct effect of alefacept on epidermal subpopulations has been 
described.
1.5.4.2 Anti-TNF-α agents
TNF-α
TNF-α is a pro-inflammatory cytokine with a key role in inflammatory 
processes.  An elevated level of TNF-α has been demonstrated in lesional 
psoriatic skin. The TNF-α receptor may be cell surface bound or soluble 194.
Infliximab (Remicade®)
Infliximab is a chimeric (part mouse, part human) monoclonal antibody against 
both membrane bound and soluble TNF-α. It is the most effective biological 
in treating psoriasis with PASI 75 reached by 88% of the patients after 10 
weeks of treatment. Because infliximab has to be administered intravenously, 
the patient cannot treat himself at home 195-197. Because part of this antibody 
is murine, the patient should be monitored for anaphylactic reactions. The 
side effects are mild forms of allergic reactions to the antibody, headaches, 
and upper respiratory infections. One should be alert for the reactivation 
of a latent tuberculosis and the patient should be screened before starting 
infliximab therapy 196-199. Antibody formation against infliximab is found in 
23% of the patients. Continuous treatment with infliximab is accompanied by 
loss of efficacy, due to a decreased availability of this biological, partly due to 
antibody formation 186.
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Adalimumab (Humira®)
Adalimumab is a fully human monoclonal antibody of the IgG1 isotype that 
binds with high affinity and specificity to human TNF-α. Upon binding to 
TNF-α, adalimumab neutralizes the biologic activities of this cytokine by 
blocking its interaction with the p55 and p75 cell surface TNF receptors, 
thereby suppressing TNF-associated biologic responses 200;201. After 16 weeks 
of treatment, adalimumab resulted in 75% PASI reduction in 71-79% of the 
patients and continued to be effective after a year of treatment. In a direct 
comparison between 16 weeks of adalimumab and methotrexate treatment, 
adalimumab was more effective in improving health-related quality of life, 
and symptom scores than methotrexate. Adverse reactions noted were 
upper respiratory infections, and injection site reactions. Antibodies against 
adalimumab were formed in 8.8% of the patients, but had no effect on the 
clinical efficacy 201-203. 
Etanercept (Enbrel ®)
Etanercept is a recombinant human TNF-receptor fusion protein, consisting of 
two identical chains of the recombinant human TNF-receptor p75 monomer 
fused with the Fc domain of human IgG1, that antagonizes the effects of 
endogenous TNF by competitively inhibiting its interaction with cell-surface 
receptors 204. After respectively 12 and 24 weeks of treatment, 34 and 44% of 
the patients reached PASI 75 using 25 mg twice weekly. When the dosage was 
increased to 50 mg biweekly PASI 75 after 12 and 24 weeks increased to 49 and 
59% respectively. These response rates were maintained after longer treatment 
205-207. Treatment with etanercept 50 mg once weekly was as effective as 25 mg 
biweekly 208. Etanercept was effective in clearing psoriasis clinically, and after 
treatment with this biological there was also a significant reduction in fatigue 
and depression scores 209. Injection site reactions are the only side effects that 
were more common in the patients treated with etanercept than in patients 
treated with placebo 210;211.
Effects of TNF-α and anti TNF-α agents on psoriatic epidermal cell 
populations
TNF-α is involved in the psoriatic cascade as a pro-inflammatory cytokine, and 
in psoriatic plaques the level of TNF-α is increased 212. Although the psoriatic 
plaque is characterised by epidermal hyperproliferation and a disturbed 
keratinisation, the literature on the direct effects of TNF-α, and the inhibition 
of TNF-α, on epidermal cell populations and keratinocyte cell dynamics 
remains limited. When psoriatic and normal keratinocytes were co-cultured 
with healthy and psoriatic fibroblasts, the addition of TNF-α had no effect 
on the growth rate of the keratinocytes 213. Nevertheless, keratinocytes grown 
on a dermal equivalent, consisting of fibroblasts in a collagen gel, showed a 
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transient suprabasal β1 integrin expression after exposure to TNF-α, seen also 
in psoriatic epidermis 88;214. Using transcriptional profiling, the transcriptional 
profiles of normal human keratinocytes were compared with or without 
treatment with TNF-α. TNF-α was found to not only regulate immune and 
inflammatory responses, but also tissue remodelling, cell motility, cell cycle, and 
apoptosis. Even more, it also induced actin skeleton regulators and integrins in 
keratinocytes, enhancing their motility and attachment, indicating that TNF-α 
possibly has a direct effect on keratinocytes in psoriasis. Also keratinocytes 
themselves produced TNF-α, creating a positive feedback loop 215. Inhibition 
of TNF-α using blockade by infliximab or etanercept rapidly down regulated 
multiple pro-inflammatory pathways. Also a decrease in epidermal thickness 
and keratin 16 expression was seen, which was preceded by a rapid decrease in 
phosphorylated nuclear factor kappa B (NF-κB). Because in psoriatic plaques 
NF-κB expression is significantly increased, it may play a significant role in 
epidermal psoriatic hyperproliferation 82;83;109;216;217. The exact dynamics in the 
changes in the epidermal cell populations, the role of the stem cell and transit 
amplifying compartment, and the effects of TNF-α and anti TNF-α therapy on 
these compartments, remains to be elucidated.
1.5.4.3 Anti Interleukin 12/23 agents
Very recently a new group of biologicals has emerged, the anti IL12/23 
agents. Interleukins 12 and 23 have an important role in the pathophysiology 
of psoriasis. The p40 subunit of interleukins 12 and 23 is overexpressed in 
psoriasis plaques, and preclinical studies implicate a role for p40 containing 
cytokines in the pathogenesis of psoriasis 109;218;219. 
Ustekinumab (Stelara®)
Ustekinumab is a human monoclonal antibody that binds to the shared 
p40 protein subunit of human interleukins 12 and 23 with high affinity and 
specificity, thereby preventing interaction with their cell surface IL12Rβ1 
receptor. Clinical efficacy with PASI 75 responses of 67 and 71% are seen after 
respectively 12 and 28 weeks of treatment with 45mg ustekinumab. Treatment 
with 90 mg improved the PASI responses to respectively 75 and 78% at week 12 
and 28. The main advantage of treatment with this biological, in comparison 
with other biologicals, besides its efficacy, is the fact that subcutaneous 
injections are given on week 0, 4, 12 and then every 12 weeks, eliminating the 
need for weekly or biweekly injections. The safety profile of ustekinumab looks 
promising, with a rate of  adverse events comparable to the placebo group 
during 76 weeks of treatment 218;220. Nevertheless, long term data are sparse and 
the long term safety profile remains to be established. 
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1.5.5 Treatment of nail psoriasis
As psoriasis of the nails is a frequent phenomenon and causes a lot of pain 
and discomfort in patients, there is a high need for an effective therapy 107. 
The therapeutic arsenal for nail psoriasis is quite extensive, but the evidence 
for therapeutic efficacy of most of these therapeutics is lacking. Nail psoriasis 
tends to be persistent and refractory to treatment, with relatively short lived 
remissions, making long term treatment a necessity, asking for a high degree 
of patient compliance. Topical therapy of nailbed psoriasis is extremely 
challenging because of the very poor permeability of the compact, highly 
keratinised nail plate, with a low drug uptake into the nail apparatus. Various 
approaches, such as improving the permeability with penetration enhancers 
and the use of nail lacquers, containing a depot of drugs, have been proposed 
with promising results 221.
In general, good trials on the treatment of nail psoriasis, with both topical 
and systemic treatments, are scarce and most of the evidence is based on 
case reports or clinical experience. Topical therapies used with varying 
results in the treatment of nail psoriasis include cyclosporine, dithranol 
(anthralin), and 5-fluorouracil 222-224. A double blind comparison of topical 
betamethasone dipropionate with salicylic acid and calcipotriol in 58 patients 
resulted in a reduction of subungual hyperkeratosis of approximately 50% 
in both groups 225. When these two compounds were combined, this result 
improved to a reduction of 77% with respect to subungual hyperkeratosis 
after 9 months of treatment 226. Local photo-chemotherapy was used in a 
limited number of patients also with variable results, possibly because the 
UVA was not able to penetrate deep enough to reach the nail bed and nail 
matrix 227;228. Also radiotherapy demonstrated disappointing results, and when 
the possible carcinogenicity is taken into account, this therapy is not advised 
for the treatment of psoriatic nails 229;230. Probably one of the most effective 
treatments of nail psoriasis resulting from nail matrix involvement are the 
intralesional corticosteroid injections into the matrix, resulting in symptom 
reductions attaining 90% 231-233. The injections are very painful, warranting 
anaesthesia before the injection. Because the injection has to be repeated 
every 6-8 weeks, the burden of treatment is considerable. On the short term 
subungual hematoma is a complication and on the long term, atrophy of the 
distal phalanx has been seen 233.  Of the systemic treatments for psoriasis only 
cyclosporine and etretinate have been investigated. After 22 weeks, there 
was a definite improvement in nail psoriasis symptoms after treatment with 
cyclosporine. Unfortunately treatment with etretinate was stopped after 10 
weeks, so although there was a tendency to improvement of the nail psoriasis 
symptoms, no real conclusion can be drawn 234;235.
With the emerging of biological therapies for the treatment of psoriasis there 
is a promise for long term control of nail psoriasis without major short term 
side effects or organ toxicity. Some improvement in nail symptoms was seen 
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after alefacept treatment in a small group of patients 236. Unfortunately, this 
study was hampered by the fact that most of the patients only had minor 
nail pathology at baseline237. A recent study with 18 patients on the effects of 
prolonged treatment with infliximab on nail psoriatic symptoms, revealed a 
complete resolution of nail symptoms, after 8 infusions of infliximab. A study 
on the efficacy of infliximab in 373 patients, of which 305 patients had nail 
pathology at baseline, revealed that 44.7% had clearance of their nail psoriasis 
after one year of treatment 231;238;239. So far no studies are available on the effects 
of efalizumab, etanercept, and adalimumab on nail psoriasis. With respect to 
alefacept, only studies on patients with minimal nail disease are available. Our 
information on the effects of biologicals on moderate to severe psoriatic nail 
disease is limited.
1.6 Aims of this thesis
This thesis focuses on cell populations, and the differentiation process from 
putative stem cell to the transit amplifying cell, and finally the terminally 
differentiated cell in the human epidermis. This process has been extensively 
studied in the healthy, and psoriatic human epidermis, and the human hair 
follicle. In contrast to the epidermis, the complete process from putative stem 
cell to terminally differentiated cell has not been studied before in the human 
nail apparatus. Many researchers have wondered on the origin of the human 
nail, and various models of nail growth have been proposed. 
Aim I:
To identify cells with stem cell characteristics in the human nail apparatus and 
to visualize their progeny of proliferating and differentiating cells, in order to 
develop a model for proliferation and differentiation of the human nail.
Changes in cell populations, and the process of proliferation and 
differentiation, are present in a multitude of dermatological diseases. One 
of these diseases, psoriasis, is known for epidermal hyperproliferation and 
disturbed differentiation, combined with an inflammation in both the dermis 
and epidermis. One of the models to study the dynamics of the pathogenetic 
process in the psoriatic skin is the margin zone model. Various aspects of 
the process of epidermal proliferation and differentiation have not been fully 
investigated in this model. The combined approach of a newly developed 
technique, the Zenon labelling technique, with computer aided image analysis, 
makes it possible to make a quantitative characterisation of the changes in 
cell populations, proliferation, and differentiation in the developing psoriatic 
lesion.
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Aim II:
To use the dynamic model of the margin zone in psoriasis to visually quantify 
the subpopulations of epidermal cells, with respect to proliferation and 
differentiation, in their evolution from non-lesional skin towards lesional skin.
This quantitative approach to study cell populations can also be used to study 
the effects of various treatments that, directly or indirectly, interfere with the 
various epidermal compartments, in order to find out changes in proliferation 
and differentiation. This makes it possible to describe the changes that occur 
in the various compartments of the epidermis during treatment. Furthermore, 
in addition to the various clinical scoring systems used in dermatology, 
this method provides us with a tool to objectively quantify the effects of the 
treatment on the epidermis, and to follow these effects over time. Also a direct 
comparison between the clinical efficacy and cell biological effects of various 
treatments on epidermal markers can be made.
Aim III:
To quantitatively assess the effects of topical treatment and biologicals on 
clinical scores, epidermal subpopulations, and keratinocyte proliferation 
and differentiation, in patients with moderate to severe plaque psoriasis.
Changes in the cells of the dermis and epidermis represent the micro 
morphological reality of the psoriatic lesion. Up to 70% of the psoriasis patients 
also have aberrations of their nails, representing the hyperproliferation and 
disturbed differentiation in the nail unit. As these nail symptoms can cause 
a lot of discomfort and pain, there is a high need for an efficient treatment. 
Most topical treatments show disappointing results, and traditional systemic 
treatments have a lot of short term side effects and organ toxicity, making them 
less suitable for the treatment of the nail changes. New biological treatments 
have shown promising efficacy, not only on the general psoriatic symptoms, 
but also on nail psoriasis.
Aim IV:
To evaluate the changes in clinical nail pathology, in patients with plaque 
psoriasis and moderate to severe nail involvement, during systemic 
treatment with alefacept.
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ABSTRACT
Background: Stem cells are present in most tissues of our body and are thought 
to reside in niches. It is plausible that there are also stem cells in the human 
nail apparatus. 
Objectives: The aim of this study was to investigate in the human nail apparatus 
the localisation of cells with stem cell characteristics and to further discriminate 
between stem cells and their progeny. 
Results: There was a continuous expression of α6 and β1 integrin through the 
whole nail unit. The root of the nail plate co-expressed keratin 15 and keratin 
19. The nailbed did not express keratin 10, keratin 15, keratin 19 and ki-67 but 
the cells panepidermally expressed keratin 6.
Conclusions: The root of the nail harbours a reservoir of alleged stem cells 
that provide the intermediate matrix with a pool of rapidly dividing transit 
amplifying cells. These cells with high proliferative activity supply the 
intermediate matrix below the nail plate and the nail bed with differentiated 
cells. These cells in the nail bed are pushed between the hard surfaces of the nail 
plate and bone resulting in a stressed cell profile with panepidermal keratin 6 
expression. Eventually these cells form the hyperkeratotic hyponychium which 
expresses keratin 10. Both the nail apparatus and the hair follicle not only seem 
to share a common embryological path, remarkable similarities have been 
shown with respect to integrin and keratin expression, marking the root of the 
nail plate as a possible new niche for stem cells in the human skin.
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INTRODUCTION
Stem cells are considered to be present in almost all tissues in the human 
body.  A stem cell is a cell which under normal circumstances maintains its 
own population, undiminished in function and size and furnishes daughters 
to provide new functional cells of that tissue 1;2. The last decade there has 
been an extensive search for stem cells and a way to distinguish them from 
their progeny. This search has been motivated by the attempts to understand 
ageing and carcinogenesis as multipotent stem cells are likely to be the main 
target for various types of tumours 3;4. Also, stem cell research is focussed 
more and more on therapeutic approaches to repair damaged organs and 
tissues by transplantation. Epidermal stem cells have been used to generate 
reconstitutative skin after expansion in vitro for large burn wounds or chronic 
leg ulcers 5-7.
Stem cells are thought to reside in niches, which are essential in maintaining a 
balance between stem cell quiescence and activity. Known niches are the bone 
marrow for haematopoietic stem cells and the intestinal crypts for intestinal 
stem cells. For the human epidermis the hair follicle bulge and the deep rete 
ridges of the interfollicular epidermis are considered as the niches for stem 
cells 2;8. 
The relatively quiescent stem cells with a high proliferative capacity have to 
be distinguished from their progeny; the transit amplifying cells, which are 
fast cycling and have a high proliferative activity. One of the methods used 
to distinguish these two cell populations is the radioactive [3H] thymidine 
labelling of cells. Infrequently dividing cells retain their label and are called 
label-retaining cells (LRC), in contrast to fast dividing, transit amplifying 
cells who lose their label after a few divisions and are called pulse labelled 
cells 9-12. This technique is useful in animal models, but the use of radioactive 
labelling in humans is considered unethical for obvious reasons. Therefore, 
other methods have been sought to distinguish putative epidermal stem cells 
from their progeny. Several supposed stem cell markers have been found 
using flow cytometry and double labelling of LRC’s with diverse cell surface 
markers. Double labelling of LRC’s with antibodies against keratins revealed 
more putative epidermal stem cell markers, since keratins form the structural 
cytoskeleton of the keratinocyte and are differentially expressed during the 
differentiation process. 
One of the keratinocyte cell surface markers, β1 integrin has shown to have 
a higher expression on epidermal stem cells than on transit amplifying cells, 
revealing the epidermal stem cells to reside at the tips of the dermal papillae 
in the epidermis of several body sites 13-15. α6 Integrin expression is probably 
not limited to the stem cell compartment alone, but combining it with the 
expression of the transferrin receptor (CD71) selects a subpopulation of α6 
integrin bright and CD71 dim cells having stem cell properties 16-18. 
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In both the interfollicular epidermis and in the bulge of the hair follicle, keratin 
15 is highly expressed by those keratinocytes having stem cell properties and 
its use as being an epidermal stem cell marker has been demonstrated by the 
utilisation of keratin 15 promoters to specifically target hair follicle stem cells 
5;19-24. Keratin 19 expressing cells in the hair follicle bulge were not only label 
retaining, but also had a high β1 integrin expression in the deep epidermal rete 
ridges, marking keratin 19 as a possible epidermal stem cell marker in both 
these locations 22;25;26. 
Contrary to the interfollicular epidermis and the hair follicle, little is known 
about the stem cell of the nail apparatus. The nail matrix is the location where 
after [3H] Thymidine labelling the label retaining cells where found in both 
primates and humans and when the intermediate matrix of the nail is spared, 
removal of the nail will result in complete regrowth of the nail. 27;28 These 
two observations make the existence of stem cells in the matrix of the nail 
apparatus very plausible.
The process of nail growth and differentiation has been subject to study by 
various groups in an attempt to elucidate the process of nail growth. Nail 
production has been attributed to the nail matrix by labelling for the ki-67 
antigen. The ki-67 positive cells being cells with a high proliferative activity. 
In the interfollicular epidermis these cells are termed transit amplifying or 
pulse labelled cells 29;30. In vivo and in vitro studies on integrin expression 
showed a very high expression of β1 integrin and α6 integrin in the whole 
nail matrix 31;32. 
An extensive study on the expression of soft keratins in the nail apparatus 
revealed regions of differentiation and a state of minimally developed 
differentiation of the nail bed, probably attributed to the properties of the 
overlying nail 33. 
The current study was undertaken to identify cells with stem cell characteristics in 
the nail apparatus using the putative stem cell markers keratin 15, keratin 19, α6 
integrin and β1 integrin, known from the interfollicular epidermis and the human 
hair follicle. Known markers for epidermal proliferation and differentiation as 
ki-67, keratin 6 and keratin 10 were used to further discriminate between stem 
cells and their progeny and further differentiated cells. The characterisation of 
these cells was done using classic immunohistochemistry and double labelling 
with diverse markers using indirect immunofluorescence. 
MATERIAL AND METHODS
Tissue Samples
Nail specimens were obtained from five toes of four patients after distal limb 
amputations for bone malignancy or trauma. On clinical examination none 
of the toes showed any sign of disease. Three out of five toes were from digit I 
Chapter 2 - Epidermal cell populations in the healthy nail unit
51
and two were from digit III. The nail specimens were prepared by cutting away 
most of the bone and abundant soft tissue, while care was taken not to damage 
the nail apparatus. As controls, abdominal skin from healthy volunteers was 
obtained after reconstructive surgery, lesional psoriatic skin was obtained 
from a psoriatic patient and human foreskin was obtained from a 12-year-old 
boy after circumcision. The specimens were embedded in Tissue-Tek (Sakura 
Finetek, The Netherlands), snap frozen in liquid nitrogen and stored at –80oC 
until further use. 
Immunohistochemistry
Using a cryostat, seven μm sections were cut on superfrost-plus coated slides 
(Menzel, Germany), air dried for 30 minutes and fixed for 10 minutes in cold 
acetone or cold acetone/ether (60%/40%) for ki-67 staining. After blocking 
20  min for endogenous peroxidase, using 3% H2O2 in methanol, the slides 
were washed in phosphate buffered saline (PBS) for 15 minutes. Subsequently, 
sections were incubated with the primary antibodies for 1 h. The following 
primary antibodies (mouse-antihuman) were used, diluted in 1% bovine 
serum albumin (Sigma, St Louis, MO, U.S.A.)/PBS: Antibodies against α6 
integrin (CD49f; Instruchemie, Delfzijl, The Netherlands) (1:100), β1 integrin 
(CD29, clone K20; DakoCytomation, Copenhagen, Denmark) (1:250), Keratin 
6 (LHK6B; Monosan, Uden, The Netherlands) (1:30), Keratin 10 (RKSE60; 
Monosan, Uden, The Netherlands) (1:100), Keratin 15 (LHK15; Neomarkers, 
Fremont, USA) (1:150), Keratin 19 (CK 19, Clone BA 17; DakoCytomation, 
Copenhagen, Denmark) (1:50) and ki-67 antigen (MIB-1; DakoCytomation, 
Denmark) (1:100). 
Sections were washed in PBS for 15  min. Secondary IgG labelled polymer, 
horseradish peroxidase anti-mouse antibody EnVision+ (DAKO, Copenhagen, 
Denmark) was added for 30  min. The sections were washed again for 15 
minutes. To visualize the staining we used aminoethylcarbazole+ high 
sensitivity substrate chromogen for 10 min (DAKO, Copenhagen, Denmark). 
Counterstaining was performed with Mayer's haematoxylin (Sigma). The 
sections were rinsed in tap water, dried and mounted in glycerol gelatin 
(Sigma). For each specimen we performed a haematoxylin and eosin staining 
to verify the histology. After dehydration in alcohol and fixation with Histosafe 
Enhancer (Serotec, Dusseldorf, Germany), these sections were mounted in 
Permount (Biomeda, Foster City, CA, U.S.A.). 
Fluorescent immunohistochemistry and Zenon labelling technique
The used method has been described previously 34;35. Here this technique was 
used to visualize the co-expression of the researched proteins in one cell. In 
brief, seven μm frozen sections of the biopsies were incubated with the labelled 
and/or diluted monoclonal antibodies. Monoclonal antibodies against keratin 
15 (LHK15; Neomarkers, Fremont, USA), keratin 19 (CK 19, Clone BA 17; 
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DakoCytomation, Copenhagen, Denmark), α6 integrin (CD49f; Instruchemie, 
Delfzijl, The Netherlands) and ki-67 antigen (MIB-1; DakoCytomation, 
Denmark) were labelled using the Zenon labelling technique. Monoclonal 
antibodies against β1 integrin (CD29 FITC, clone K20; DakoCytomation, 
Copenhagen, Denmark) were covalently labelled with FITC. 
For the double staining, equal volumes of two antibody dilutions were mixed 
and incubated on the slides. The antibody against Keratin 19 was combined 
with Keratin 15, with α6 integrin and with β1 integrin, while β1 integrin was 
also mixed with ki-67. After incubation the slides were mounted with 20μl 
Vectashield mounting medium with DAPI (diamidino-2-phenylindole, 1,5 
μg/ml) (Vector laboratories, Inc, USA). DAPI was used for counterstaining of 
the cell nuclei.
Microscopy and imaging
The sections and monoclonal antibodies visualised with the Envision technique 
were examined using a light microscope (Axioskop 2 MOT, Zeiss, Germany) 
and a lamp of 100 Watt. 
The sections and monoclonal antibodies visualised with the immunofluorescent 
technique were examined using an immunofluorescence microscope 
(Axioskop 2 MOT, Zeiss, Germany) with a magnification of 100x or 200x and 
a halogen lamp of 100 Watt. The monoclonal antibodies were detected using 
the following filters: for Alexa fluor 594 excitation BP 546/12, FT 580, emission 
LP 590 (red), for FITC and Alexa Fluor 488 excitation BP 485/20, FT 510, 
emission LP 515 (green) and for DAPI excitation BP 365/12, FT 395, emission 
LP 397 (blue). 
Digital images were taken from various parts of the nail apparatus using a 
digital camera with a magnification of respectively 50x, 100x and 200x 
(Axiocam MRc5, Zeiss, Germany) and AxioVision software (Zeiss, Germany). 
The immunofluorescent photos made with the different filters were later 
merged with the AxioVision software to get the triple stained pictures. 
Analysis
Two separate observers analysed the digital pictures and rated the antibody 
expression. This rating was done using a semi quantitative score to estimate 
the intensity of the antibody expression (see legend table 1). Also the location 
of the antibody expression in the nail apparatus and epidermis was scored. For 
ki-67 antibody expression a different scoring method was used. The number of 
ki-67 positive cells was semi-quantitatively rated as compared to the number 
of cells in the basal layer (see legend table 1). The known compartments of 
the nail unit were analysed as the nail apparatus can be divided into various 
compartments depending on which definitions are used. We divide the nail 
apparatus into the following parts (figure 1) 36: the dorsal and ventral proximal 
nail fold, of which the latter is continuous with the dorsal matrix. The dorsal 
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Figure 1: Cross-section through the finger, demonstrating the various compartments of the 
nail unit. The different parts of the nail unit have been given a differential colour.
matrix meets the intermediate matrix at the tip of the matrix. The intermediate 
matrix is parallel with the nail plate and continues as the nail bed that ends 
when the nail leaves the nail bed and the hyponychium is formed. At this stage 
the digit pulp begins which continues as the normal epidermis.
RESULTS
The results of the expression of the various markers in the nail apparatus are 
summarised in table 1.
There was a continuous expression of α6 integrin and β1 integrin along the 
basal membrane and the basal layer of the whole nail apparatus. Remarkable 
was that the expression of both integrins extended up to the 4-5th suprabasal 
layer in the intermediate matrix (fig. 2B & E; fig. 3A-E). The nail bed and digit 
pulp also had a suprabasal positive staining of α6 integrin, but only 2-3 cell 
layers above the basal layer. The expression in the other parts of the nail unit 
was comparable with the healthy interfollicular epidermis.
Keratin 15 had a patchy expression pattern in the dorsal proximal nail fold 
(PNF) and the digit pulp, as in the normal interfollicular epidermis. This patchy 
expression pattern transformed to a continuous expression pattern in the 
ventral PNF, weakened at the border with the dorsal matrix and disappeared 
completely at the most distal part of the dorsal matrix that is continuous with 
the intermediate matrix (fig. 2G & I). In the intermediate matrix there was a 
positive staining for keratin 15 in a few basal cells, but more interestingly in 
the root of the nail, suprabasal in the intermediate matrix. This was also the 
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location with expression of keratin 19, while there was no keratin 19 expression 
in the rest of the nail apparatus (fig. 2C & F). Our immunofluorescent double 
labelling experiments revealed that part of the cells in the root of the nail co-
expressed keratin 15 and keratin 19, visible in fig. 4F as yellow-orange cells. In 
addition to the immuno peroxidase staining, the immunofluorescent staining 
of keratin 19 showed an expression of this keratin high suprabasal in the 
intermediate matrix, continuous with the nail plate (fig. 3A & fig 4). 
The ki-67 antigen was expressed through the whole nail apparatus in the two 
suprabasal layers, except in the intermediate matrix where ki-67 positive cells 
were found in up to the fifth suprabasal layer (fig. 3D & E). The intermediate 
matrix was also the site where the number of ki-67 positive cells was markedly 
increased compared to the rest of the nail apparatus and the healthy skin. A 
slight increase in the number of ki-67 positive cells compared to the healthy 
Antigen
α-6 in-
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β-1 integrin
Keratin 15
Keratin 19
Ki-67
Keratin 6
Keratin 10
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++
B1
++
B
++
B
Patchy
+
B
+ 
SB2 
+
SBSE
++
SBPE
PNF
Dorsal
++
B1
++
B2
++
B 
Patchy
-
++
SB2
-
++
SBPE 
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Ventral
++
B
++
B
++
B
Continuous
-
+
SB2
++
++
SBPE 
Dorsal
Matrix
++
B1
++
B
-
-
+
SB2
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SB4
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SBPE 
Intermediate
Matrix
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B4
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B5
+
Root + some
basal cells
+
SB
Root
+++
SB2
-
-
Nail Bed
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B2
++
B
-
-
-
++
PE
-
Digit Pulp
++
B3
++
B
++
B
Patchy
-
++
SB2
+
SB4 
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++
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Table 1: The expression of the markers at the various sites in the nail unit as compared with the 
controls (respectively: normal epidermis, psoriatic epidermis (keratin 6) and human foreskin 
(keratin 19)). The following semi-quantitative scores were used:
Intensity staining
-
+
++
+++
Ki-67 Staining
-
+
++
+++
Location in epidermis
B:
Bx:
SBx:
PE:
SBPE:
No staining
Light, uneven staining
Moderate staining
Clear staining
No cells stained
1/20 of the cells stained
1/10 of the cells stained
1/5 of the cells stained
Basal staining
Basal staining and staining of x number of cell 
layers above
Suprabasal staining of x number of cell layers
Panepidermal staining, staining of all cell layers
Staining of all cell layers except the basal layer
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interfollicular epidermis was also found in the dorsal PNF and the digit pulp, 
indicating an increased number of cycling cells.
Keratin 6 expression as a marker for activated, stressed keratinocytes is not 
found in the healthy, non-hyperproliferative interfollicular epidermis, the 
dorsal PNF and the intermediate matrix. A suprabasal expression of 4-5 cell 
layers was found in the ventral PNF and continued into the dorsal matrix (fig. 2H). 
Figure 2: Envision horseradish peroxidase staining of the nail apparatus. The antigen stained is 
noted in the diverse pictures. In A the keratin 15 staining in the whole nail apparatus is shown 
(magn: 50x). Pictures B-F show the expression of several markers in the nail matrix. Pictures 
G-I show the expression of keratin 15 at the dorsal PNF (G) and the ventral PNF (H) and the 
expression of keratin 6 at the border of the dorsal and ventral PNF (H). Pictures J & K show 
the expression of keratin 6 (J) and keratin 10 (K) in the nail bed. Picture L shows the keratin 10 
expression which abruptly emerges at the hyponychium in the suprabasal layers. (Pictures B-L: 
magn. 200x).
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Figure 3: Direct and indirect, immunofluorescent triple staining of the matrix of the nail unit. 
The diverse compartments of the nailapparatus are shown in the drawing at the bottom of the 
picture. The diverse parts of the intermediate matrix are colour coded and correspondent with 
the various pictures. The cell nucleoli are stained blue using DAPI (blue). Fig. A shows a double 
labelling of α-6 integrin (green) and keratin 19 (red) (magn: 100x). The expression of keratin 
19 is extending to the more distal part of the intermediate matrix. Fig. B & C exhibit the double
labelling of β1 integrin (green) and keratin 19 (red) in the matrix tip (B) and the more distal part 
of the intermediate matrix (C). There is no co-expression of these proteins. In fig. 3-D & E dou-
ble labelling of β1 integrin (green) with ki-67 (red) is shown. Clearly visual is the higher number 
of ki-67 positive cells in the intermediate matrix as compared to the dorsal matrix (D). The ki-67 
positive cells are not only higher in number in the intermediate matrix; they are also expressed 
in the more suprabasal layers. β1 integrin expression in the more distal part of the intermedi-
ate matrix extends up to the 6th suprabasal cell layer. Note the cells co-expressing ki-67 and β1 
integrin at this site, visual as orangepurple cells with a yellow ring. (Fig. 3 B–E: magn. 200x).
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Interestingly in the nail bed there was a panepidermal expression of keratin 6 
(fig. 2J). A patchy staining of keratin 6 was seen in the digit pulp.
Keratin 10 was expressed in all the suprabasal cell layers in the whole nail 
apparatus except the intermediate matrix and the nail bed, where there was no 
keratin 10 expression at all (fig. 2K). At the border from nail bed to digit pulp, 
at the hyponychium there was an abrupt suprabasal, abundant expression of 
keratin 10 (fig. 2L).
DISCUSSION
From clinical observations we know that removal of the nail matrix, but not 
the removal of the nail bed or proximal nail fold, leads to disturbance of nail 
plate formation. So supposed stem cells should reside within the nail matrix 37. 
Little is known about these cells. The aim of this study was to identify cells with 
stem cell characteristics and their progeny in the human nail apparatus. To 
identify and characterise stem cells and progenitor cells of the nail apparatus, 
markers known from interfollicular epidermis and hair follicle were used.  
After characterisation of cells in the nail matrix the expression patterns of the 
used putative stem cell markers can be divided in two groups; the cells in the 
first group continuously expressed α6 integrin and β1 integrin along the basal 
membrane and basal cells of the intermediate matrix with the exception of a 
more suprabasal expression in the intermediate matrix. This continuous basal 
expression of these two markers was remarkable similar to the expression in 
normal healthy epidermis and hair follicle 38. The expression of these integrins 
in the basal layers is merely a representation of their function as anchoring 
proteins and the suprabasal expression in the intermediate matrix is in 
accordance with the expression pattern in the bulge of the hair follicle 39. It has 
been shown that the β1 integrin bright cell population in the interfollicular 
epidermis contains both stem cells and transit amplifying cells 13;40, this could 
also be the case in the nail matrix.
The second group of expression patterns of cell markers contained the cells 
in the nail apparatus expressing keratin 15 and keratin 19. These two markers 
have shown to be more selective candidate stem cell markers in both the 
hair follicle bulge and the interfollicular epidermis than α6 and β1 integrin 
19;41-44. Keratin 19 expression was detected only in the suprabasal area of the 
intermediate matrix, or more specifically in the root of the nail plate itself. 
Keratin 15 was expressed in the whole nail apparatus, with the exception of 
the matrix and the nail bed and this reflects the patchy, basal expression of this 
keratin in the interfollicular epidermis. In the basal layers of the intermediate 
matrix few clusters of keratin 15 expressing cells are seen. More interestingly 
however, is the co-expression of keratin 15 with keratin 19 in the root of the 
nail plate. This region contains cells with big nuclei and a lot of cytoplasm. 
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Until now this region has always been regarded as a part of the nail apparatus 
where proliferating and differentiating cells of the nail apparatus form the 
terminally differentiated nail plate 28;45. However, proliferation marker ki-67 is 
not expressed in this region, indicating little proliferation in the root of the nail 
plate. The absence of proliferation and the co-expression of stem cell markers 
keratin 15 and keratin 19  indicates that the root of the nail plate is the niche of 
the stem cells of the nail apparatus, comparable to the bulge of the hair follicle. 
Highest expression of ki-67 is found in the first five suprabasal layers of 
the intermediate matrix. The amount of ki-67 positive cells in this region is 
comparable to hyperproliferative psoriatic skin 34;35. 
The ki-67 expression in other parts of the nail apparatus is confined to the 
first 2 basal layers. These findings are in accordance with the literature 29;45. 
This marks the intermediate matrix as the region with the highest proliferative 
activity. Interestingly, this is also the only region with suprabasal expression of 
β1 integrin. In the hair follicle both β1 integrin expression and a marked increase 
in ki-67 positive cells are seen in the hair follicle bulb where transit amplifying 
cells in the hair follicle are located 10;39;46. Which may be an indication that the 
intermediate nail matrix is the section of transit amplifying cells of the nail.
Expression of keratin 6 and some increase in ki-67 positive cells is present in the 
proximal nail fold and the digit pulp. This shows slight increased proliferative 
activity in these areas, which is anatomically reflected by the presence of the 
hyperkeratotic cuticle and the hyponychium.
The nail bed did not express keratin 15, keratin 19 and ki-67, indicating that 
the nail bed is a region of terminal differentiation. This is in agreement with 
Figure 4: Triple staining of keratin 15 (green), keratin 19 (red) and the cell nucleus using DAPI 
(blue) in the intermediate matrix of the nail (A-C). The magnified part of the intermediate ma-
trix shown in E shows a part of the root of the nail in yellow where there is co-expression of 
keratin 15 and keratin 19. These cells are visible as yellow-orange cells in F. (magn. 200x)
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the studies of the Berker, et al, but not with theories on nail formation that 
define the nail bed as the ventral nail matrix and link the formation of the 
ventral nail plate to this region 33;36;47. 
Keratin 6 was expressed in four regions in the nail apparatus. There was a 
panepidermal expression in the nail bed and a suprabasal continuous expression 
in the ventral proximal nail fold, the dorsal matrix and, as mentioned above, 
in the digit pulp. All these regions are liable to physical stress. For a long time 
keratin 6 has been considered a marker for hyperproliferation but research 
indicates that it is mere a marker for activated, “stressed” keratinocytes 35;48. 
The cells of the ventral proximal nail fold are subject to the constant pulling 
force of the growing nail plate and mechanical forces conducted by the nail 
plate after trauma to the tip of the nail. Also the digit pulp is used in daily life 
for diverse tasks as manipulating objects and is subject to mechanical trauma. 
So, both regions are under almost constant physical stress, explaining the 
keratin 6 expression. 
The panepidermal expression of keratin 6 in the nail bed in combination with 
the complete absence of keratin 10 expression confirms earlier results described 
by de Berker et al 33. These cells are being pushed between the hard surfaces of 
the nail plate and the bone of the digit. This physical stress exerted to the nail bed 
by mechanical forces conducted by the nail plate results in a stressed cell profile 
in the nail bed. The absence of keratin 15, keratin 19 and ki-67 expression in the 
nail bed marks this area as more terminally differentiated and it seems more 
logically to assume that these cells originate from the intermediate matrix. 
Figure 5: Picture of the hypothetical model of the proliferation and differentiation process in 
the nail unit. The root of the nail plate incorporates a pool of keratin 15/keratin 19 co-expressing 
cells, a reservoir of alleged stem cells (1) supplying the underlying suprabasal layers of the in-
termediate matrix with cells with a high proliferative activity, the so called transit amplifying 
cells which are β1 integrin and ki-67 positive (2). This pool of transit amplifying cells provides
cells that terminally differentiate to the nail bed and nail plate (3). The stressed cells in the nail 
bed abundantly express keratin 6, while there is no keratin 15, ki-67 or keratin 10 expression (4). 
The keratin 10 expression abruptly returns as the nail leaves the nail bed at the hyperkeratotic 
hyponychium (5).
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The discussed results indicate that the root of the nail is made of a pool of 
relative quiescent stem cells (fig. 4 & fig. 5-1), in analogy with the hair follicle 
bulge. This pool of cells with low proliferation but with a high proliferative 
capacity supplies the intermediate matrix with its progeny, a pool of cells with 
a high proliferative activity, the so called transit amplifying cells (fig. 5-2). 
These cells reside in the suprabasal layers of the intermediate matrix, forming 
the ungular bulge (fig. 3E and fig. 5-2) and can be compared with the bulb of 
the hair follicle. The transit amplifying cells in the intermediate matrix provide 
cells that terminally differentiate in the direction of both the nail plate and nail 
bed. The cells in the layers below the nail plate undergo progressive nuclear 
condensation, after which the nucleus and cells compact to eventually form 
the onychocytes of the nail plate (fig. 5-3) 28;45. The transit amplifying cells in 
the more distal part of the intermediate matrix move towards the nail bed and 
there they further differentiate, expressing keratin 6 (fig. 5-4). Eventually, these 
cells reach the hyponychium and a hyperkeratotic differentiation pattern with 
abundant keratin 10 expression emerges (fig. 2L and fig. 5-5). 
Both the nail apparatus and the hair follicle not only share a common 
embryological path, there are remarkable similarities in integrin and keratin 
expression patterns, marking the root of the nail plate as a possible new niche 
for stem cells in the human skin.
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ABSTRACT
Background: The margin zone in spreading psoriatic lesions has frequently been 
used as a model to study the changes in epidermal proliferation, keratinization 
and inflammation during the transition from symptomless to lesional skin. 
However, the dynamics of the changes in the epidermal subpopulations—basal 
cells, transit amplifying cells and differentiated cells—have not been studied in 
the transition between symptomless and lesional skin.
Objectives: To quantify in a dynamic model of the margin zone in psoriasis the 
characteristics of these subpopulations with respect to epidermal proliferation 
and differentiation.
Methods: From seven patients with active psoriasis, biopsies were taken from the 
distant uninvolved skin, outer margin, inner margin and centre of a spreading 
psoriatic plaque. Frozen sections were labelled immunofluorescently using 
direct immunofluorescence for ki-67 and β1 integrin and the Zenon labelling 
technique for keratin 6, 10 and 15. Digital photographs of the stained sections 
were quantitatively analysed.
Results: In the distant uninvolved skin the expression of β1 integrin was 
decreased and keratin 15 expression was lost. In this area suprabasal cells 
expressed β1 integrin and in the outer margin suprabasal cells expressed ki-67. 
From the outer to the inner margin of the psoriasis plaque, which coincided 
with the appearance of the clinical lesion, there was a significant change in 
the various markers. The patchy expression of keratin 6 in the inner margin 
became homogeneous in the centre of the psoriasis plaque and here was also 
coexpression of keratin 6 and keratin 10 in a single cell.
Conclusions: The present study provides additional evidence that the distant 
uninvolved skin has a prepsoriatic phenotype, which is the first step in a psoriatic 
cascade. The cascade between symptomless and lesional skin comprises first an 
abnormality in inflammation with involvement of β1 integrin-dim cells (transit 
amplifying cells) subsequently eliciting an enlarged germinative compartment 
with increased recruitment of cycling epidermal cells and focal expression of 
proliferation-associated keratins, ultimately culminating in a more-or-less 
homogeneous epidermis with massive recruitment of cycling epidermal cells 
and proliferation-associated keratinization.
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INTRODUCTION
Psoriasis is characterized by inflammation, epidermal hyperproliferation and 
a disturbed keratinization. Although most research over recent years has been 
focused on the immunopathogenesis, there has recently been renewed interest 
in the role of the keratinocyte in the process.1 Various models have been 
postulated to study the pathogenesis of psoriasis. Unfortunately, no animal 
model imitates psoriasis completely.2,3 The margin zone in spreading psoriatic 
lesions has frequently been used as a model to study the changes in epidermal 
proliferation, keratinization and inflammation during the transition from 
symptomless to lesional skin. Changes at a distance from the psoriatic rim are 
supposed to represent more early changes as compared with changes which 
are present close to the rim. Various aspects of epidermal differentiation in 
psoriasis have not yet been fully investigated in this model. The differential 
effect of treatments on epidermal keratinization suggests that abnormal 
keratinization in psoriasis is a complex of different mechanisms which may 
well become involved in different stages of the pathogenesis.4–8 Studies in the 
margin zone revealed that changes in the dermal compartment (endothelium 
and extracellular matrix) precede those in the epidermal compartment.9,10 The 
most early epidermal changes were seen 12 mm from the edge of the psoriatic 
plaque, although most studies only studied 6-mm biopsies across the margin 
of the psoriasis plaque.5 More proximally to the lesion, a dermal infiltration 
of epidermis-invading lymphocytes is seen.5,7 This is followed by epidermal 
hyperproliferation, as was demonstrated by an increase in recruitment of 
cycling epidermal cells (ki-67+ nuclei) and the suprabasal expression of keratin 
6. The clinically involved border represents the final step in the pathogenetic 
process and shows an impaired differentiation.9,11 Although these studies cannot 
be fully compared due to differences in methodology, most studies reveal 
consistent dynamics between the clinically involved and uninvolved skin.5,7,11
Recent studies on changes in the epidermis in psoriasis have shown evidence 
for the presence of three different subpopulations of epidermal cells which 
are relevant to epidermal proliferation: basal cells, transit amplifying cells and 
differentiated cells.12–16 Recruitment of cycling epidermal cells is the mechanism 
of epidermal proliferation, and cycling cells can be visualized by counting 
ki-67+ nuclei.17,18 Basal cells and transit amplifying cells are the cells with 
proliferating capacity. β1 integrin is a marker for germinative cells comprising 
both these populations.12,13 The differentiated cell population expresses keratin 
10,19 and in the hyperproliferative disorder psoriasis it also expresses keratin 
6 protein.20,21 It has been shown in psoriasis that the surface area of the β1 
integrin expressing population is increased with an overpresentation of β1 
integrin-dim cells which are likely to be the transit amplifying cells.22 However, 
due to the thickened, acanthotic epidermis, the relative surface area of cells 
expressing β1 integrin is decreased. The germinative zone in psoriasis has 
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another intriguing characteristic: it does not express keratin 15.23,24 Ki-67+ cells 
are vastly increased, comprising also suprabasal cell layers in psoriasis, whereas 
in normal skin ki-67 is expressed only in the basal cell layer. The suprabasal 
cells in psoriasis express keratin 10 or keratin 6 and some cells express both 
keratins.11,25 So far, the dynamics of the above-mentioned epidermal changes 
in psoriasis have not been studied in the transition between symptomless and 
lesional skin. Now such studies can be carried out by using the Zenon labelling 
technique in combination with image analysis. This permits a very sensitive 
measurement of the changes of pathogenetically relevant aspects in the 
proliferative and differentiating compartments of the epidermis in the psoriatic 
plaque. This technique conjugates primary antibodies quantitatively and the 
labelled antibodies can be used in the same way as covalently labelled primary 
antibodies. Hereby we can not only quantitatively measure the expression of 
different proteins, but can also visualize coexpression of different proteins in 
one individual cell.26
The aim of this study was to quantify, in the dynamic model of the margin 
zone in psoriasis, the characteristics of basal cells, transit amplifying cells and 
differentiated cells with respect to proliferation and differentiation.
MATERIALS AND METHODS
Patients
Seven patients with spreading plaque psoriasis were included. All the patients 
had given informed consent prior to the study. They had psoriatic plaques with 
a diameter of at least 2 cm. For 2 weeks they had not received any topical 
treatment and for 4 weeks they had not received any systemic treatment. They 
had not used medication that could interfere with psoriasis, e.g. systemic 
corticosteroids, β-blockers, lithium carbonate, antimalarial medication or 
immunosuppressants.
Biopsies
Four punch biopsies (3 mm diameter) were taken from each patient with 
psoriasis after local anaesthesia with xylocaine 2%/adrenaline 1 : 100 000. One 
biopsy was taken from the centre of the lesion, one from clinically involved 
skin at the margin, one from symptomless skin at the margin of the lesion 
directly adjacent to the plaque and one from distant uninvolved skin. Distant 
uninvolved skin was defined as clinically normal skin at a distance of at least 2 
cm from the margin of the spreading lesion. 
From healthy skin, 4 mm punch biopsies were obtained from seven different 
people without signs or symptoms of psoriasis. All specimens were embedded 
in Tissue-Tek (Sakura Finetek, Zoeterwoude, the Netherlands), snap frozen in 
liquid nitrogen and stored at -80 0C.
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Fluorescent immunohistochemistry and Zenon labelling technique
Sections were sliced 7 µm thick on slides coated with 3-aminopropyl-
triethoxysilane (Sigma, St Louis, MO, U.S.A.), after which they were air dried 
for 30 min. Then the sections were fixed in cold acetone for 10 min. The 
sections used for ki-67 staining were fixed in acetone/ether 60%/40% for 10 
min, delineated with Dako-pen (DakoCytomation, Glostrup, Denmark) and 
stored in phosphate-buffered saline (PBS).
For analysis of the basal layer of the epidermis monoclonal antibodies against 
β1 integrin [DakoCytomation; CD29 fluorescein isothiocyanate (FITC), 
clone K20] and keratin 15 (Neomarkers, Fremont, CA, U.S.A.; LHK15) were 
used. For analysis of epidermal proliferation a monoclonal antibody against 
the ki-67 antigen (DakoCytomation; MIB-1 FITC) was used. For analysis of 
epidermal differentiation monoclonal antibodies against keratin 6 (Novocastra 
Laboratories, Newcastle-upon-Tyne, U.K.; LHK6B) and keratin 10 (Monosan, 
Uden, the Netherlands; RKSE60) were used.
The monoclonal antibodies against the ki-67 antigen and β1 integrin were 
directly conjugated to FITC and were diluted with 1% bovine serum albumin 
(BSA; Sigma) in PBS at a concentration of 1 : 25 and 1 : 50, respectively.
The Zenon technique was used to couple monoclonal antibodies against 
keratin 6, keratin 10 and keratin 15 with Alexa Fluor 488 (Molecular Probes, 
Eugene, OR, U.S.A.) and Alexa Fluor 594 (Molecular Probes). After incubation 
of the monoclonal antibody with the concomitant Alexa Fluor IgG antibody 
for 5 min, the surplus of fluorochrome was blocked with IgG blocking agent 
for another 5 min. During these steps, the antibodies were kept in the dark. The 
incubation steps were performed in a volume of 20 μl maximum after which 
the solution was further diluted with 1% BSA/PBS to the final concentration.
For keratin 6 (1 : 15), 6 μl of the primary antibody and 2 μl of the Zenon 
IgG2a Alexa Fluor 488 were mixed in 10 μl of 1% BSA/PBS. The mixture 
was incubated for 5 min. Subsequently, 2 μl IgG blocking agent was added 
and the mixture was incubated for an additional 5 min. Finally, 80 μl of 1% 
BSA/PBS was added. For keratin 10 (1 : 15), 4 μl IgG1 Alexa Fluor 594 and 
12 μl of the primary antibody were mixed. The mixture was incubated for 5 
min. Subsequently, 4 μl IgG blocking agent was added and the mixture was 
incubated for 5 min. Finally, 180 μl of 1% BSA/PBS was added. For keratin 15 
(1 : 25), 4 μl of the primary antibody and 2 μl of the Zenon IgG2a Alexa Fluor 
594 were mixed in 12 μl of 1% BSA/PBS. The mixture was incubated for 5 min. 
Subsequently, 2 μl blocking agent was added and the mixture was incubated 
for 5 min. Finally, 80 μl of 1% BSA/PBS was added.
For the double staining procedure, 50 μl antikeratin 6 (1 : 15) and 50 μl antikeratin 
10 (1 : 15) were mixed for double staining of keratin 6 with keratin 10, 50 μl 
antikeratin 15 (1 : 25) and 50 μl anti-β1 integrin (1 : 50) were mixed for double 
staining of β1 integrin with keratin 15, 50 μl antikeratin 10 (1 : 15) and 50 μl anti-β1 
integrin (1 : 50) were mixed for double staining of β1 integrin with keratin 10 and 
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50 μl antikeratin 10 (1 : 15) and 50 μl anti-ki-67 antigen (1 : 25) were mixed for 
double staining of keratin 10 with ki-67. Thereafter the diluted antibodies (100 
μl solution of each antibody) were brought on to the sections and incubated for 
60 min in a humid chamber in the dark. After washing the slides twice for 5 min 
with PBS, the sections were fixed in 3.8% buffered formalin (J.T. Baker, Deventer, 
the Netherlands) for 15 min. After washing again twice for 5 min with PBS, the 
slides were mounted with 20 μl Vectashield mounting medium with diamidino-
2-phenylindole (DAPI) 1.5 μg ml-1 (Vector Laboratories, Burlingame, CA, U.S.A.). 
DAPI was used for counterstaining of the cell nuclei. The mounting medium was 
allowed to harden for 15 min. During the mounting and washing steps the slides 
were kept in the dark. One slide was stained using standard haematoxylin and 
eosin staining to determine the morphology of the sections.
Microscopy and imaging
The sections and monoclonal antibodies were examined using an 
immunofluorescence microscope (Axioskop 2 MOT; Zeiss, Oberkochen, 
Germany) with a magnification of  200x and a halogen lamp of 100 W. The 
monoclonal antibodies were detected using the following filters: for Alexa 
Fluor 594 excitation BP 546/12, FT 580, emission LP 590 (red), for FITC and 
Alexa Fluor 488 excitation BP 485/20, FT 510, emission LP 515 (green) and for 
DAPI excitation BP 365/12, FT 395, emission LP 397 (blue).
Images were photographed using a digital camera (Axiocam MRc5; Zeiss) 
and AxioVision software (Zeiss). For each antibody five different parts of the 
epidermis were photographed. The photographs made with the different filters 
were later merged with the AxioVision software to get the triple-stained pictures.
Image analysis
The images were analysed with IP-lab software (Scanalytics, Billerica, MA, 
U.S.A.) in a standardized manner. For expression of β1 integrin, keratin 6, 10 
and 15 a region of interest (ROI) was drawn in a frame. This ROI contained 
the epidermis without the stratum corneum. In this ROI, the intensity and 
percentage of positive signal in the epidermis was measured. For β1 integrin 
expression this was done by setting the reverse intensity and green signal on 
the median value + 20, whereafter the percentage of ROI and mean intensity 
signal were measured.
For keratin 6, 10 and 15 the reverse intensity was set on the median value + 
15, whereafter the percentage expression in the ROI and the mean intensity 
signal were measured. For ki-67 expression, a different protocol was used. The 
reverse intensity was set on the maximum value. For a cell to be considered 
positive, the segment had to be larger than 40 pixels. The total of positive cell 
nuclei was counted and a line was drawn along the basal layer. The line length 
was measured in pixels and calibrated to micrometres. Thereafter the total 
number of positive cell nuclei per millimetre basal layer was calculated.
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Statistical analysis
Statistical analysis was performed using simple statistics (mean ± SEM) and 
a repeated-measurements analysis of variance. For statistical analysis of the 
differences between the skin of the patients with psoriasis and the skin of the 
healthy volunteers an independent t-test was performed. This was all done 
using Statistica 6 (StatSoft Inc., Tulsa, OK, U.S.A.). P < 0.05 was considered 
statistically significant.
RESULTS
The quantification of various markers for epidermal proliferation and 
differentiation is summarized in Figure 1 (A–F). The qualitative data are shown 
in Figure 2. Immunofluorescent photographs for all the various markers are 
shown from the psoriatic skin and the skin of the healthy persons. 
The number of ki-67+ nuclei, reflecting the number of cycling epidermal cells 
in distant uninvolved skin, showed a tendency to be increased compared with 
the skin of healthy volunteers (27.6 ± 7.4 vs. 19.9 ± 2.3, P = 0.36). Between 
the distant uninvolved skin and the outer margin of the psoriatic plaque no 
significant difference in the number of ki-67+ nuclei was observed. However, 
in the outer margin the ki-67+ nuclei were not restricted to the basal cell layer 
only, as in the distant uninvolved skin, but were also observed in the suprabasal 
cell layers (fig. 3A). The number of ki-67+ nuclei was increased in the inner 
margin of the psoriasis plaque compared with the uninvolved skin (P < 0.05). 
Figure 1: Quantitative results of the various markers measured at respectively the centre, inner 
margin, outer margin, distant uninvolved skin of the psoriatic plaque and the skin of healthy 
persons. Results are expressed as mean ± SEM. * and **P < 0.05. (A) Number of ki-67+ nuclei 
per millimetre basement membrane. (B) Relative surface area of cells expressing keratin 6. (C) 
Intensity of the expressed fluorescence signal of keratin 6. (D) Relative surface area of cells ex-
pressing keratin 10. (E) Relative surface area of cells expressing keratin 15. (F) Relative surface 
area of cells expressing β1 integrin.
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Figure 2: Immunofluorescent photographs of the diverse markers. Shown from left to right is 
the psoriatic skin from the centre of the lesion to the distant uninvolved skin as compared with 
the healthy skin (far right). The lines drawn in the figure represent the regions of interest, con-
taining the whole epidermis. First row shows ki-67 expression (green), with a marked increase 
in expression in the inner margin and centre of the lesion. In the second row the β1 integrin 
expression is shown (green). The third row shows the keratin 6 expression (green), which is vis-
ible in the inner margin (patchy) and the  entre of the psoriatic plaque. Keratin 10 expression 
(red) is shown in the fourth row. The fifth row shows the expression of keratin 15 (red), which is 
only visible in the skin of the healthy controls. Cell nucleolus counterstaining with diamidino-
2-phenylindole is visible in blue. Note that the section of healthy skin expressing ki-67+ cells has 
been cut tangentially through the dermal papillae, resulting in a circular pattern of basal cells, 
some of which express ki-67. (magn. 200x)
Ki-76
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Keratin 6
Keratin 10
Keratin 15
Centre Inner Margin Outer Margin Distant 
Uninvolved
Healthy Skin
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β1 Integrin expression in the distant uninvolved skin of the patients with 
psoriasis was significantly lower compared with the skin of healthy volunteers 
(42.0 ± 4.2 vs. 70.0 ± 6.3, P < 0.01). Between the distant uninvolved skin and 
the outer margin of the psoriatic plaque no statistically significant differences 
were seen. The suprabasal cell layer showed an intriguing phenomenon: on 
top of the bright basal cell layer, cells weakly expressing β1 integrin were 
observed (see fig. 3B). Although the absolute surface of β1 integrin-positive 
cells increased from the outer to the inner margin of the psoriatic lesion, the 
relative surface of β1 integrin-positive cells decreased markedly (from 39.7 
± 4.8 to 28.8 ± 3.9, P < 0.01). This was because the absolute number of cell 
layers with weak β1 integrin expression increased on top of the monolayer of 
β1 integrin-bright cells in the basal layer.
In the skin of the healthy volunteers, the distant uninvolved skin of the patients 
with psoriasis and the outer margin of the psoriatic plaque, there was virtually 
no keratin 6 expression detectable. Both the keratin-expressing surface area 
and the intensity increased significantly from the outer margin to the inner 
margin of the psoriatic plaque (from 6.7 ± 6.6 to 53.0 ± 12.8, P < 0.01 for 
relative surface area and from 10.1 ± 10.0 to 80.5 ± 12.4, P < 0.01 for intensity). 
In the inner margin a patchy expression pattern of keratin 6 was observed 
which became homogeneous in the centre of the psoriatic plaque (fig. 4B,C). 
The expression of keratin 10 in the distant uninvolved skin of the patients 
with psoriasis was not significantly different from that in the skin of healthy 
volunteers. There was a significant decrease in the positive surface area of 
Figure 3: Immunofluorescent photographs showing suprabasal, epidermal expression of ki-
67 and β1 integrin. (A) Suprabasal expression of ki-67+ nuclei (green) in the outer margin of 
the psoriasis plaque. (B) Weak suprabasal expression of β1 integrin on top of a basal cell layer 
expressing β1 integrin brightly in the distant uninvolved skin (green). Note the immunofluores-
cent staining in the dermal compartment of cells expressing β1 integrin, probably infiltrating T 
cells, fibroblasts or endothelia of the vasculature. (magn. 200x)
Fig. 3A Fig. 3B
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keratin 10 in the outer as compared with the inner margin of the psoriatic 
plaque (from 56.2 ± 4.4 to 39.4 ± 11.4, P < 0.05). The centre and the inner 
margin showed comparable keratin 10 expression.
In the skin of the healthy volunteers a patchy, basal expression of keratin 15 was 
found. There was no expression of keratin 15 in the skin of the patients with 
psoriasis, not even in the clinically normal distant uninvolved skin (fig. 1). The 
differences in the positive surface area and intensity of keratin 15 between the 
distant uninvolved skin of the patients with psoriasis and the skin of healthy 
volunteers was highly significant (P < 0.001).
With respect to the double labelling, no cells expressing keratin 6 could be 
detected in the outer margin of the psoriasis plaque. Only keratin 10 was 
expressed here (fig. 4A). In the inner margin we observed a small proportion of 
cells coexpressing keratin 6 and keratin 10. These cells are visualized as yellow 
cells (fig. 4B). Many cells expressed only keratin 10, but no cells expressed 
only keratin 6. Coexpression of both keratin 6 and keratin 10 was seen in a 
large part of the epidermal cells in the centre of the psoriasis plaque. Only a 
small fraction of these cells had single expression of keratin 6 or keratin 10, 
respectively (fig. 4C).
DISCUSSION
In the present study we used the dynamic model of the margin zone to 
investigate the subpopulations of epidermal cells in psoriasis with respect 
to proliferation and differentiation in their evolution from nonlesional skin 
towards lesional skin.
In the distant uninvolved skin (at 2 cm from the border of the psoriatic lesion) 
there was a relative decrease of the surface of the cell layers expressing β1 
Figure 4: Keratin 6 (green) and keratin 10 (red) coexpression in the outer margin, inner mar-
gin and centre of the psoriatic plaque (from left to right). (A) Only keratin 10 expression in the 
outer margin. (B) Both keratin 6 and keratin 10 are expressed in the inner margin of the pso-
riatic plaque. Note the patchy expression of keratin 6 and the cells coexpressing both keratin 6 
and keratin 10 (visualized as the yellow cells). (C) In the centre of the psoriasis plaque most cells 
have coexpression of keratin 6 and keratin 10, visualized as yellow-stained cells. Only a few cells 
have single expression of one of these keratins. (magn. 200x)
Fig. 4A Fig. 4B Fig. 4C
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integrin as a percentage of the total surface of the epidermis, compared with 
the skin of healthy controls. Furthermore, the cell layers just above the basal 
cell layer showed a consistent expression of β1 integrin with a weak intensity 
in this distant uninvolved skin. It is likely that these so-called β1 integrin-dim 
cells comprise transit amplifying cells.14,22 Furthermore, keratin 15 expression 
was lost in the cells in the distant uninvolved skin. Even the number of ki-
67+ nuclei showed a slight increase. However, this was not statistically 
significant. The latter finding is in accordance with previous studies.7,27 The 
early involvement of epidermal cells well before the appearance of T-cell 
subsets and other infiltrating cells in the outer margin7 suggests that psoriasis 
is not merely a disease of the innate and adaptive immune system, the dermal 
compartment or the keratinocytes, but psoriasis appears to be a disease with 
defects in various components of the skin. Interaction of these components 
results in an increased recruitment of transit amplifying cells and development 
of the psoriatic phenotype. This view also explains why treatments which focus 
at any of the components of the skin can result in clinical improvement and 
why histologically detectable changes in the keratinocyte can occur without 
the development of an overt psoriatic lesion.
In the present study no statistically significant changes were observed between 
the distant uninvolved skin and outer margin. Nevertheless, an interesting 
observation in the outer margin was the presence of ki-67+ nuclei in the 
suprabasal cell layers. The relatively early involvement of the suprabasal 
compartment in developing psoriatic lesions has also been shown in a study 
on relapse following corticosteroid treatment. This study also showed that 
the appearance of ki-67+ cells in the suprabasal compartment was the first 
phenotypical change in the epidermis, these cells most probably comprising 
transit amplifying cells.27 Changes in the skin immune system have also been 
reported in the outer margin of the lesion. These changes were accumulation 
of CD8+, CD45RO+ and CD2+ T cells.7 Other studies showed endothelial 
abnormalities (increased alkaline phosphatase and decreased intercellular 
adhesion molecule-1 expression) and abnormalities in the extracellular matrix 
(increased expression of tenascin-X).10,28,29 Therefore early changes in stroma 
and accumulation of some T-cell subsets coincide with an increase in transit 
amplifying cells before statistically significant changes in the proliferating and 
differentiating compartments of the epidermis occur which, according to our 
experiments, concur with the appearance of the overt clinical lesion.
Between the outer (symptomless) and inner (lesional) margin impressive 
epidermal changes were seen: suprabasal expression of keratin 6; a relative 
decrease of the surface of the cell layers expressing β1 integrin as a percentage 
of total surface of the epidermis, with an absolute increase of β1 integrin- 
dim cells (transit amplifying cells); increased number of ki-67+ nuclei and 
decreased number of cells expressing keratin 10. All these changes were 
substantial and statistically significant. The expression of keratin 6 in the 
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suprabasal compartment of the inner margin had a patchy pattern, suggesting 
heterogeneity in this part of the psoriatic cascade. At the inner margin our 
double labelling experiments revealed cells expressing only keratin 10 or cells 
coexpressing both keratin 6 and keratin 10. The cells coexpressing keratin 6 
and keratin 10 had a clustered distribution, with cells expressing keratin 6 
residing at the tips of the dermal papillae. It is interesting that this is also the 
location where in the interfollicular epidermis the stem cells may reside.16,30 It 
is attractive to hypothesize that after these stem cells give rise to an enlarged 
compartment of transit amplifying cells, keratin 6 expression is first locally 
upregulated, indicating a hyperproliferative epidermal state. Thereafter, not 
only do the transit amplifying cells migrate in the direction of the rete ridges, 
but also the cells expressing keratin 6, eventually leading to a homogeneous 
epidermal expression of keratin 6. From the inner margin to the central area 
of the lesion few changes were observed. Perhaps the most important is the 
change of the patchy expression pattern of keratin 6 into a homogeneous 
pattern. In the suprabasal compartment of the central area of the lesion the 
vast majority of keratinocytes coexpressed both keratin 6 and keratin 10. Only 
a few cells expressed only one of these keratins.
The present study provides additional evidence that the distant uninvolved 
skin in psoriasis has a prepsoriatic phenotype. 31 A dysregulation between 
epidermis, the dermal compartment and the innate and adaptive immune 
system might be the first step in a cascade leading to the psoriatic lesion. The 
cascade between symptomless and lesional skin comprises first an abnormality 
in inflammation with involvement of β1 integrin-dim cells (transit amplifying 
cells), subsequently eliciting an enlarged germinative compartment with 
increased recruitment of cycling epidermal cells and focal expression of 
proliferation-associated keratins, ultimately culminating in a more-or-less 
homogeneous epidermis with massive recruitment of cycling epidermal cells 
and proliferation associated keratinization.
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ABSTRACT
Background: Psoriasis is characterised by an activated basal cell layer, an 
expanded transit amplifying compartment, stressed hyperproliferation and a 
disturbed keratinisation. The effects of etanercept treatment on the various 
epidermal cell populations has never been studied. 
Objectives:  We quantitatively assessed the effects of 12 weeks of etanercept 
treatment on the dynamics of epidermal cell populations, and markers for 
proliferation and differentiation in psoriasis.
Patients and methods: From nine patients with moderate to severe psoriasis 
biopsies were taken at baseline and after 4 and 12 weeks of treatment with 
etanercept. Frozen sections were immunofluorescently labelled using direct 
immunofluorescence for ki-67 and β1 integrin and the Zenon labelling 
technique for keratin 6, 10 and 15. Digital photographs of the stained sections 
were quantitatively analysed. 
Results: Four out of 9 patients reached PASI 75 after 24 weeks of treatment and 
these patients showed a reappearance of keratin 15 after 4 weeks of treatment. 
Simultaneously an increase in the relative surface area expressing β1 integrin 
was seen with a decrease in the cell layers with β1 integrin dim expression. 
These changes were followed by normalisation of  suprabasal keratin 6 and 10 
expression after 12 weeks of treatment. 
Conclusions: TNF-α blockade by etanercept directly and indirectly resulted in 
an early de-activation of the basal progenitor cells, combined or followed by 
a decrease in the TAC compartment. The early re-appearance of basal keratin 
15 expression in only those patients responding to therapy marks keratin 15 as 
a putative predictive marker for long term response to etanercept treatment. 
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INTRODUCTION
Psoriasis is a relatively common skin disease with a varying prevalence of 1 to 
2.5% of the population. Especially in patients with moderate to severe psoriasis 
the burden of disease is comparable to that of patients with severe depression 
or severe heart disease 1-4. 
Clinically visible as an erythematosquamous plaque, one of the main cellular 
features of the active psoriatic plaque is a marked epidermal hyperproliferation 
and a disturbed keratinisation with a decreased compartment of normally 
differentiated keratinocytes 5;6. Although the precise interaction between 
immunocytes and keratinocytes in the initiation of the psoriatic plaque is not 
fully understood, the first step in the development of the psoriatic plaque is 
the increased recruitment of basal epidermal progenitor cells from the resting 
G0 phase to the G1 phase of the cell cycle 7;8. This activation is visualised by 
the downregulation of the putative stem cell marker keratin 15 and an increase 
in the transit amplifying compartment in the epidermis 9-12. The number of 
transit amplifying cells in the suprabasal layer can be visualised by an increase 
in the β1 integrin dim cells and an increased number of actively cycling ki-
67 positive cells 10;13-15. Another marker for the recruitment of activated 
keratinocytes culminating in a hyperproliferative psoriatic epidermis is 
keratin 6. This keratin is expressed in a hyperproliferative epidermis where 
it replaces keratin 10 as a marker for normal terminal differentiation. Keratin 
6 is also expressed in the suprabasal layers of the epidermis after wounding 
and in activated keratinocytes in a cultured skin substitute; in these situations 
keratinocytes are under “stress” 16-20. 
The last decade it has become evident that the development of the psoriatic 
lesion is merely a result of the sophisticated interplay of T-cells, dendritic 
cells and keratinocytes with a major role for cytokines as IL-23, IFN-γ and 
TNF-α 21;22. TNF-α is involved in the psoriatic cascade as a pro-inflammatory 
cytokine and in psoriatic plaques the level of TNF-α is increased 23. Blocking 
inflammatory pathways as TNF-α or IL-23 results in the resolution of the 
psoriatic plaque 21;22. These recent insights in the pathogenesis of psoriasis 
has led to the development of “tailored” antipsoriatic treatments that directly 
target this part of the psoriatic cascade, the so called biologicals 24. One of these 
biologicals is etanercept, a recombinant human TNF-receptor fusion protein 
consisting of two identical chains of the recombinant human TNF-receptor 
p75 monomer fused with the Fc domain of human IgG1 that antagonizes the 
effects of endogenous TNF by competitively inhibiting its interaction with 
cell-surface receptors 25.           
Etanercept has proven to be a highly effective treatment for psoriasis and 
psoriatic arthritis with relatively little side effects 26;27. Etanercept reduces 
multiple inflammatory pathways eventually leading to a reduction in the 
keratinocyte stress response and reduced hyperproliferation as visualised by 
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a decreased keratin 16 expression. Finally resulting in the normalisation of 
epidermal keratinisation 21;28. 
Although etanercept therapy has been shown to reduce keratinocyte 
hyperproliferation and keratin 16 expression, little is known about its effects 
on the various epidermal subpopulations in the psoriatic epidermis. In this 
light it would be of interest to see how TNF-α inhibitors would influence the 
activated basal and transit amplifying compartment in the psoriatic epidermis 
and how the changes in epidermal cell populations correlate with clinical 
improvement. Our aim is to assess quantitatively the effects of a 12 week 
course of etanercept therapy on the dynamics of epidermal subpopulations, 
keratinocyte proliferation and differentiation in patients with moderate to 
severe plaque psoriasis. 
MATERIALS AND METHODS
Patients and biopsies
Nine patients (six males and three females, aged 53 ± 2.1 years), with moderate 
to severe plaque psoriasis were included in this study. All had a PASI score of at 
least 10, had been treated previously with methotrexate, photo(chemo) therapy 
and cyclosporine and/or had contraindications for one of these treatments. 
Patients were included for treatment with etanercept, 50 mg twice weekly, 
subcutaneously for 12 weeks. After these 12 weeks a PASI improvement of 50% 
was needed in order to get the permit to continue treatment according to the 
Dutch guidelines for treatment of psoriasis with biologicals. After obtaining 
informed consent, 4 mm punch biopsies were taken from representative 
lesions on the lower back after local anaesthesia with lidocaїne 2%/adrenaline 
1:100 000 (AstraZeneca BV, Zoetermeer, the Netherlands). These biopsies were 
taken before treatment, after four weeks and after twelve weeks of treatment. All 
specimens were embedded in Tissue-Tek (Sakura Finetek, The Netherlands), 
snap frozen in liquid nitrogen and stored at -800C.
Before and during treatment the patients did not use systemic medications 
that could interfere with psoriasis, e.g. corticosteroids, β-blockers, lithium 
carbonate, antimalaria medication or immunosuppressants. As the patients 
were treated at the routine biological unit, other topical antipsoriatic treatments 
were allowed, except on the lesions targeted for biopsy. Interestingly, only few 
patients actually used topical medications while on etanercept therapy.  Clinical 
efficacy of both treatments was evaluated using the PASI score. Furthermore, 
a SUM score was performed of the target lesion to assess the clinical efficacy 
of the treatment on that lesion. This SUM score was calculated by using a five-
point scale ranging from 0 to 4 for erythema, induration and desquamation, 
resulting in a SUM score with a maximum of 12 points. 
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Fluorescent immunohistochemistry and Zenon labelling technique
This method has been described previously 10;29. In brief, monoclonal 
antibodies were labelled and/or diluted and incubated on 7 μm frozen sections 
of the biopsies. Monoclonal antibodies against keratin 10 (Monosan, Uden, 
The Netherlands, RKSE60) and keratin 6 (Novocastra Laboratories, Newcastle 
upon Tyne, UK, LHK6B) were labeled using the Zenon labeling technique 
and were used for assessment of epidermal differentiation. For examination 
of epidermal proliferation, ki-67 antigen (DakoCytomation, Copenhagen, 
Denmark, MIB-1 FITC), covalently FITC-labeled, was used. Monoclonal 
antibodies against β1 integrin (DakoCytomation, Copenhagen, Denmark, 
CD29 FITC, clone K20) and keratin 15 (Neomarkers, Fremont, USA, LHK15) 
were used for analysis of the basal layer of the epidermis. Keratin 15 was 
labeled using the Zenon labeling technique whereas β1 integrin was covalently 
labeled with FITC. 
For the double staining, equal volumes of two antibody dilutions were mixed 
and incubated on the slides. Keratin 10 was combined with ki-67, with β1 
integrin and with keratin 6, while β1 integrin was also mixed with keratin 15. 
The cell nuclei were counterstained with diamidino-2-phenylindole (DAPI).
The sections and monoclonal antibodies were examined using an 
immunofluorescence microscope (Axioskop 2 MOT, Zeiss, Germany) with 
a magnification of 200x and a halogen lamp of 100 Watt. The monoclonal 
antibodies were detected using the following filters: for Alexa fluor 594 
excitation BP 565/30, FT 585, emission BP620/60 (red), for FITC and Alexa 
Fluor 488 excitation BP 470/40, FT 495, emission BP 525/50 (green) and for 
DAPI excitation BP 365/12, FT 395, emission LP 397 (blue). 
Images were photographed using a digital camera (Axiocam MRc5, Zeiss, 
Germany) and AxioVision software (Zeiss, Germany). For each antibody 5 
different parts of the epidermis were photographed. The photos made with the 
different filters were later merged with the AxioVision software to get the triple 
stained pictures. 
Image analysis
The images were analysed with IP-lab software (Scanalytics, USA) in a 
standardized manner. For expression of β1 integrin, keratin 6, 10 and 15 a 
region of interest (ROI) was drawn in a frame. This ROI contained the 
epidermis without the stratum corneum. In this ROI the intensity and 
percentage of positive signal in the epidermis was measured. For β1 integrin 
expression this was done by setting the reverse intensity and green-signal on 
the median value +20, whereafter the percentage of ROI and mean intensity 
signal were measured. 
For keratin 10 and 15 the reverse intensity was set on the median value + 15 and 
for keratin 6 the reverse intensity was set on the median value + 25, where after the 
percentage expression in the ROI and the mean intensity signal were measured.
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For ki-67 expression, a different protocol was used. The reverse intensity was 
set on the maximum value. For a cell to be considered positive, the segment had 
to be larger than 50 pixels. The total number of positive cell nuclei was counted 
and a line was drawn along the basal layer. The line length was measured in 
pixels and calibrated to µm. Hereafter the total number of ki-67 positive cell 
nuclei per mm basal layer was calculated.
Statistical analysis
Statistical analysis was performed using simple statistics (Mean, SEM). For 
statistical analysis of the differences between the various treatment time points, 
a repeated measurements analysis of variance (ANOVA) was performed. This 
was all done using Statistica 6 (Statsoft Inc, Tulsa, OK, U.S.A.). P-values < 0.05 
were considered statistically significant.
RESULTS
The results for the clinical scores and for the biomarkers are summarised 
in figure 1 and figure 2 respectively. These results are subdivided into three 
groups, the results from all patients (A), the responders (B) and the patients 
not responding to etanercept therapy (C). A responder was defined as a 
patient with a PASI improvement of 75% or more after 24 weeks of etanercept 
treatment. Four out of 9 patients (44%) reached this PASI 75. One patient did 
not reach PASI 50 at week 12 and had to discontinue therapy. The PASI score 
of this patient at week 12 was carried forward to week 24. In figures 1 and 2 
significant changes (p<0.005) are indicated by an asterisk. 
There was a significant decrease in PASI scores after 4 and 12 weeks of treatment 
in the complete group which was due to the rapid clinical response in the 
responder group. In the group not responding to etanercept treatment there 
was no significant improvement in PASI scores. The SUM score improved in 
both the responder and non responder group The decrease in SUM score in 
the responder group, although larger than in the non responder group did not 
reach significance after 4 weeks of treatment. This was caused by the larger 
SEM in this group originating from the bigger variance in SUM scores in this 
group and the smaller group size of the responder group.
Basal keratin 15 expression increased after 4 and 12 weeks of treatment 
exclusively in the responder group, an increase already significant after 4 weeks 
of treatment. This increase was the result of the return of keratin 15 expression 
in the responder group. No keratin 15 expression was seen in this group at 
baseline (see fig. 2 & 4B). In the non responder group there was a consistant 
expression of keratin 15 in the basal layer of one patient that did not change 
during therapy. The rest of the non responders did lack keratin 15 expression 
during the whole treatment period.
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In the responder group there was a significant increase in the relative surface 
area of the cell layers expressing β1 integrin as compared to the cell surface of 
the total epidermis after 4 and 12 weeks. A qualitative analysis revealed that 
this was due to a decrease in the suprabasal cell layers with low β1 integrin 
expression (β1 integrin dim cells) combined with a decrease in thickness of 
the epidermis (see fig. 2 & 4). In the non-responder group there was no such 
change in β1 integrin expression (see fig. 2C).
In both groups there was a significant decrease in the number of actively cycling 
ki-67 positive cells after 12 weeks of treatment. But as with the SUM score, 
this decrease was not significant after 4 weeks of treatment in the responder 
group, probably due to the smaller group size. Although the number of ki-67 
positive cells decreased in both groups, the ki-67 positive cells in the responder 
group were more confined to the basal layers after 4 and 12 weeks of treatment 
as compared to the non-responders (fig. 3B). The decrease in ki-67 positive 
Figure 1: Clinical scores at baseline, after 4, 12 and 24 weeks of treatment. Results are expressed 
as mean +/- SEM, * p<0.05. The results are presented for the complete treatment group (A), the 
patients responding to treatment (B) and the patients not responding to treatment (C). From left 
to right the overall clinical score, expressed as the PASI is seen, followed by the PASI improve-
ment, in percentages as compared to baseline and finally the clinical score of the target lesions, 
expressed as SUM score (no data at 24 weeks).
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Figure 2: Quantitative results for the diverse biomarkers at baseline, after 4 and after 12 weeks 
of treatment. Results are expressed as mean +/- SEM, * p<0.05. The results are presented for the 
complete treatment group (A), the patients responding to treatment (B) and the patients not re-
sponding to treatment (C). Displayed from top to bottom are the relative surface area of keratin 
15 and β1 integrin as compared to the total surface area of the epidermis. Next are displayed the 
number of ki-67 positive nuclei per mm basement membrane. Finally the relative surface area 
of keratin 6 and keratin 10 as compared to the total surface area of the epidermis is displayed.
A) Complete Group B) Responders C) Non Responders
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cells continued in the responder group between 4 and 12 weeks of treatment 
whereas the number of ki-67 positive cells in the non responder group stayed 
the same (fig. 2B & C & fig. 3B).
There was a significant decrease in the relative surface area of the cell layers 
expressing keratin 6 as compared to the total cell surface of the epidermis in 
the responder group after 12 weeks of treatment. This was not the case in the 
non-responder group. Simultaneously there was a significant increase in the 
Figure 3: Qualitative changes in the expression of the various markers at baseline, after 4 and 
after 12 weeks of treatment and subdivided between the responder and non responder group.
Visible in (A) is the double labeling of keratin 6 (green) with keratin 10 (red). In this figure the 
shift from cells expressing keratin 6 towards cells expressing keratin 10 is seen. At baseline there 
are primarily cells with single expression of keratin 6 and a few cells co-expressing both keratins, 
visible as yellow-orange cells. After 4 weeks of treatment, in the responder group, there is a shift 
towards the cell population co-expressing keratin 6 and keratin 10 (yellow), also few cells with 
single expression of keratin 10 can be seen. Eventually after 12 weeks of treatment virtually all 
cells show single expression of keratin 10 (red). In the non responder group no such shift in 
keratin 6 and keratin 10 expressing cells is seen. 
In (B) the double labeling of ki-67 (green) and keratin 10 (red) is shown. Visible is that in the 
responder group the ki-67 positive cells are more confined to the basal layer after 4 and 12 
weeks of treatment. In the non responder group there are still ki-67 positive cells in the supra-
basal layers after 4 and 12 weeks of etanercept treatment. Counterstaining of the cell nuclei with 
diamidino-2-phenylindole (DAPI; blue). (magn. 200x)
Responders
Non responders
(A)
Responders
Non responders
(B)
Baseline t = 4 weeks t = 12 weeks
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relative cell layers expressing keratin 10 in the responder group that reached 
significance after 12 weeks of treatment (fig. 2 & 3A). 
A qualitative analysis of the responders showed a shift in keratin 6 and keratin 
10 co-expressing cells. At baseline most suprabasal keratinocytes had either 
single expression of keratin 6 or co-expression of keratin 6 and keratin 10. 
After 4 weeks of treatment there was a shift visible towards the cell population 
co-expressing keratin 6 and keratin 10. Also some keratinocytes with single 
expression of keratin 10 were seen. After 12 weeks of treatment the balance of 
expression shifted further with most cells having single expression of keratin 
10 (see fig. 3A).
Figure 4: Qualitative changes in the expression of the various markers at baseline, after 4 and 
after 12 weeks of treatment and subdivided between the responder and non responder group. 
Visible in (A) is the double labeling of β1 integrin (green) with keratin 10 (red). Visible is that in 
the responder group, after 4, but even more after 12 weeks of treatment the β1 integrin expres-
sion is more confined to the basal layer as compared with the non responder group. Although 
not easily visible, after 12 weeks of treatment still suprabasal cells co-expressing β1 integrin and 
keratin 10 can be seen (red cells with a green border). This expression is not seen in the respond-
er group. In (B) single staining of basal keratin 15 expression is shown (red). Clearly visible is 
the return of keratin 15 expression after 4 and even more after 12 weeks of etanercept treatment 
in the responder group. No return of keratin 15 expression is seen in the non responder group. 
Counterstaining of the cell nuclei with diamidino-2-phenylindole (DAPI; blue). (magn. 200x)
Responders
Non responders
(A)
Responders
Non responders
(B)
Baseline t = 4 weeks t = 12 weeks
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DISCUSSION
TNF-α is involved in the psoriatic cascade as a pro-inflammatory cytokine and 
in psoriatic plaques the level of TNF-α is increased 23. Although the evidence 
on the direct effect of TNF-α on epidermal keratinocytes is limited, there have 
been reports that a direct effect of TNF-α exists 12;30-32. In the present study we 
investigated the effects of etanercept on epidermal cell population dynamics, 
proliferation and differentiation.
Etanercept improved the mean PASI score in our total group of patients by 
57%. Although there are indications that in a real life treatment situation the 
treatment response to etanercept may be different, our results are in accordance 
with literature 26;27;33. 
The first change seen in the epidermis after 4 weeks of treatment was the 
reappearance of keratin 15 expression in the basal layer of all patients that 
reached PASI 75 at 24 weeks of treatment (the responders). This is in sharp 
contrast with the reappearance of keratin 15 expression during treatment 
with either vitamin D3 derivates or alefacept which was a relatively late event, 
emerging after normalisation of the hyperproliferative suprabasal epidermal 
cell layers 34;35. Treatment with the vitamin D3 derivates resulted in a switch of 
the early progenitor transit amplifying cells (TAC) from the hyperproliferative 
into the differentiating compartment, finally resulting in the de-activation 
of the basal progenitor cells as visualised by keratin 15 reappearance. After 
treatment with alefacept keratin 15 reappearance was seen only in the patients 
with an almost resolution of their psoriasis and in these patients long term 
remissions of more than 10 months were seen. This denoted keratin 15 as a 
possible marker for the prediction of long term remission in psoriasis after 
alefacept treatment 34;35. 
Only one patient in the non-responder group had basal keratin 15 expression, 
but this expression was constant and already present at baseline, which may 
have been the result of previous anti-psoriatic treatments.  
In vitro TNF-α has been known to directly activate basal progenitor cells, as 
visualised by the disappearance of keratin 15 expression. In vivo this can be 
seen after wounding of the skin or in psoriatic skin with keratin 15 expression 
disappearing at the tips of the epidermal rete ridges 9;11;12. Macrophages and 
dendritic cells are the main producers of TNF-α in the skin 36. Beside the direct 
inhibition of TNF-α on cell surface receptors, etanercept also has been known 
to induce apoptosis in infiltrating CD11+ dendritic cells (DC) after 4 weeks of 
treatment. This happened only in patients achieving PASI 75 after 24 weeks of 
treatment. The reduction in DC was followed by a decrease in IL23 and TNF-α 
production and preceded the normalisation of histological parameters37. 
Another study showed also a decrease in epidermal and dermal CD3+ T-cells 
after 4 weeks of etanercept treatment, resulting in a direct interruption in 
interferon-γ, TNF-α and IL12/IL23 mediated inflammatory cascades. This 
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interruption probably was mediated by the decrease of phosphorylated NF-
κB. Active, phosphorylated NF-κB promotes transcription of diverse pro-
inflammatory cytokines and NF-κB is known to be increased in lesional and 
non-lesional psoriatic skin 9;21;28. Upregulation of NF-κB is also associated with 
keratinocyte hyperproliferation 28. In summary it is likely that the reappearance 
of keratin 15 after 4 weeks of treatment with etanercept was the result of a direct 
and indirect downregulation of TNF-α. With the indirect downregulation 
being the result of the rapid decrease in DC and CD3+ T-cells. 
After 4 weeks of treatment with etanercept also a decrease in the TAC 
compartment was seen in the responder group. This was visualised by 
a decrease in the cell layers with β1 integrin dim expression, a decrease in 
actively dividing ki-67 positive cells and an increase in the relative cell surface 
area expressing β1 integrin as a percentage of the total cell surface of the 
epidermis. Although it is possible that this decrease in TAC’s is the result 
of the de-activation of the basal progenitor cells, there is also the possibility 
that this decrease is the result of a direct effect of the TNF-α reduction on the 
TAC compartment. There is limited literature on the direct effects of TNF-α 
and TNF-α blockade on the TAC’s. Most studies used the normalisation of 
the hyperproliferation associated keratin 16 or its keratin partner keratin 6 
to evaluate the effects of etanercept treatment on the normalisation of the 
psoriatic epidermis 21;28;38. In vitro studies show a transient induction of a 
suprabasal expression of  β1 integrin after exposure to TNF-α 31. TNF-α also 
has shown to induce hyperproliferation in β1 integrin positive, keratin 10 
negative keratinocytes, probably early TAC’s 39.  Because the reduction of the 
TAC compartment happened after 4 weeks of etanercept treatment and in light 
of the above mentioned literature it is definitely possible that the reduction of 
TNF-α levels had a direct effect on the TAC. 
A significant reduction in hyperproliferation associated keratin 6 expression 
combined with an increase in keratin 10 expression was seen after 12 weeks 
of etanercept treatment in only the responder group. These changes marked a 
relatively late shift in the suprabasal stressed hyperproliferative compartment 
towards normal terminal keratinisation. 
Our results indicate that TNF-α blockade by etanercept directly and indirectly 
results in an early de-activation of the basal progenitor cells, combined or 
followed by a decrease in the TAC compartment. These changes are probably 
further amplified by the reduction in dermal and epidermal DC and CD3+ 
T-cells resulting in a further downregulation of TNF-α production. Activated 
keratinocytes are known to produce TNF-α themselves 30.  The reduction of 
the amount of activated keratinocytes, together with the reduction in dermal 
and epidermal T-cells and DC’s probably results in a further reduction of 
TNF-α production, in turn breaking the psoriatic cascade 21;28;30. The early de-
activation of the basal progenitor cells as visualised by the reappearance of basal 
keratin 15 expression precedes the interruption of this psoriatic cascade. This 
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targets keratin 15 return as an early putative predictor of  long term response 
to etanercept treatment. Further studies are needed to define the potential of 
keratin 15 as a prognostic marker for anti TNF-α treatment.
Until now most studies on the effects of treatment on epidermal subpopulations 
used the decrease of keratin 6 or 16 expression to assess epidermal response 
to treatment.  Our results from earlier studies show keratin 6 expression to be 
a relatively late phenomenon occurring after the activation of the basal layer 
and the expansion of the TAC compartment has taken place 10. The current 
study reveals that the decrease in keratin 6 expression occurred after the de-
activation of the basal layer and a decrease in the TAC compartment. We 
conclude that for the investigation of the epidermal response to treatment 
in psoriasis patients a more diverse set of markers can be more appropriate 
in order to fully understand the cell population dynamics during and after 
treatment. 
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ABSTRACT
Background: Calcitriol and calcipotriol are widely used in the topical treatment 
of psoriasis. However, studies comparing both treatment modalities are scarce. 
Especially, there are almost no studies comparing the effects on epidermal cell 
populations in a quantitative manner.
Objectives: The aim of this study was to quantitatively compare the effects of 
topical calcitriol and topical calcipotriol on clinical scores and epidermal sub-
populations.
Patients and methods: From five patients with stable plaque psoriasis, skin 
biopsies were taken from two symmetrical regions on the trunk or extremities 
before and after treatment with either calcitriol or calcipotriol. Frozen sections 
were labelled immunofluorescently using direct immunofluorescence for β1 
integrin and the Zenon labelling technique for keratin (K) 6, K10 and K15. The 
digital photographs of the stained sections were quantitatively analysed and 
the results of both treatments were compared.
Results: The clinical SUM-score improved significantly for both the calcitri-
ol- and the calcipotriol-treated lesions. In the calcipotriol-treated group the 
expression of K10 and K15 increased and the expression of K6 decreased sig-
nificantly. No changes were seen for the marker β1 integrin. In the calcitriol-
treated group none of the markers changed significantly. A tendency towards 
significance was seen for the changes in the expression of K6 and K15 in favour 
of calcipotriol.
Conclusions: Both calcitriol and calcipotriol gave a significant improvement in 
clinical scores. However, treatment with calcipotriol resulted in a normaliza-
tion of K6, K10 and K15, whereas treatment with calcitriol did not. Compari-
son of both treatments showed a tendency towards significance for the above-
mentioned markers for calcipotriol only.
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INTRODUCTION
Vitamin D3 derivatives are used over many years as a safe and effective topical 
treatment for psoriasis. When used with a maximum of 100 g week-1 for cal-
cipotriol ointment (50 μg ml-1) and 210 g week-1 for calcitriol ointment (3 μg 
ml-1) they also have little effect on calcium metabolism or bone density.1,2 The 
clinical efficacy of one of the most used vitamin D analogues, calcipotriol, in 
clearing psoriasis is comparable or better than topical steroids or dithranol.3,4 
Whereas calcipotriol is effective, it also has some dermatological side-effects 
such as perilesional erythema and stinging or burning at the applied areas. 
Calcitriol has these side-effects at a lower frequency5 and therefore the use of 
calcitriol has been advocated in sensitive areas of the skin, such as the flexural, 
retro-auricular and facial areas.6
Whether calcitriol has as strong antipsoriatic properties as calcipotriol is 
unclear. Comparative clinical studies between calcitriol and calcipotriol are 
scarce and individual study results are difficult to compare because of differ-
ences in study design. Most importantly, various scoring systems have been 
used to compare the clinical improvements after treatment with either calci-
triol or calcipotriol. Bourke et al.1 found an improvement in PASI of 32% in 
the group of patients treated with calcitriol and 68% in the group of patients 
treated with calcipotriol. The difference between these therapies was statisti-
cally significant. In another trial, Franssen et al.7 found an improvement of 
65% and 74% in the SUM scores of selected lesions on nonflexural areas for 
calcitriol and calcipotriol, respectively. However, the difference between the 
improvements of these two therapies was not significant.7 Using a global non-
quantitative scoring system Ortonne et al.6 showed that calcitriol gave better 
results in flexural areas compared with calcipotriol.
Psoriatic lesions are characterized by inflammation, an increased epidermal 
proliferation, and a disturbed keratinization with a decreased compartment of 
normally differentiated keratinocytes. Vitamin D derivatives are known to in-
hibit keratinocyte proliferation, induce keratinization and cornified envelope 
formation in psoriasis.8–10 The inhibition of the epidermal hyperproliferation 
seems to be mainly due to the direct inhibition of the hyperproliferative basal 
keratinocytes.11 According to Gniadecki this is ascribed to the induction of 
the differentiative pathway in the hyperproliferative epidermal progenitor cells 
residing in the basal cell layer.12
Only three cell biological studies have compared the effects of calcitriol and 
calcipotriol on the various components of the human skin. One study focusing 
on the effects of both topical vitamin D derivatives on cultured keratinocytes 
showed that both calcitriol and calcipotriol inhibited the keratinocyte prolif-
eration, induced the cornified envelope formation and had no effect on kera-
tin (K) 5 and K1 expression.9 Another study reported a significant reduction 
in factor XIII expressing dermal dendritic cells after treatment with calcitriol, 
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but not after treatment with calcipotriol.13 Finally, a flow cytometric study on 
keratinocytes by Franssen et al.7 discovered a significant increase in K10+/
K6- subpopulations, K6 and K10 double negative subpopulations and in over-
all K10 expression after treatment with calcipotriol. A similar tendency was 
found for calcitriol, but this was not significant.7 Overall, the data comparing 
the clinical and cell biological effects of calcitriol and calcipotriol are not only 
scarce, but also incongruous with each other.
Because the affinity for the vitamin D receptor and the pharmacokinetics of 
calcitriol and calcipotriol differ, a disparity in clinical efficacy and cell biologi-
cal effects might be expected.14 Therefore, the aim of our study was to quan-
titatively compare the effects of topical calcipotriol and topical calcitriol on 
clinical scores, epidermal subpopulations and keratinocyte proliferation and 
differentiation in patients with stable plaque psoriasis.
PATIENTS AND METHODS
Patients and biopsies
Five patients with stable plaque psoriasis were included in this study, after giv-
ing informed consent. Patients were diagnosed with stable and mild to moder-
ate plaque psoriasis. They all had symmetrical lesions on their trunk and/or 
extremities. Patients had not received any topical treatment for 2 weeks and 
no systemic treatment for 4 weeks. They had not used medication that could 
interfere with psoriasis, e.g. systemic corticosteroids, β-blockers, lithium car-
bonate, antimalaria medication or immunosuppressants. Patients with known 
or suspected abnormality of calcium metabolism were excluded. Exposure to 
sun or ultraviolet radiation was prohibited during the course of the study. 
Patients were double-blind randomized to treat all psoriatic lesions on either 
the left or the right side of their body with calcitriol ointment or calcipotriol 
ointment. Patients were instructed to wash their hands between applications 
and after the applications. During the study no other topical or systemic antip-
soriatic treatments were allowed.
Clinical efficacy of both treatments was evaluated by selecting a target lesion 
on each of the body parts treated with either calcitriol or calcipotriol. Of this 
target lesion a SUM-score was performed. This SUM-score was calculated by 
using a five-point scale ranging from 0 to 4 for erythema, induration and desq-
uamation, resulting in a SUM-score with a maximum of 12 points. Care was 
taken to ensure that both target lesions on each of the body parts had the same 
SUM-score at baseline. The target lesions were located symmetrically on the 
trunk or extremities.
At baseline and after 6 weeks of treatment 4 mm punch biopsies were taken from 
both target lesions on the trunk or extremities after local anaesthesia with lido-
caine 2%/adrenaline 1 : 10 0000 (AstraZeneca BV, Zoetermeer, the Netherlands). 
Chapter 4 - Treatment effects on psoriatic epidermal cell populations
99
All specimens were embedded in Tissue-Tek (Sakura Finetek, Zoeterwoude, the 
Netherlands), snap frozen in liquid nitrogen and stored at -80 oC.
Fluorescent immunohistochemistry and Zenon labelling technique
This method has been described previously.15,16 In brief, monoclonal antibod-
ies (mAbs) were labelled and/or diluted. Frozen sections (7 μm) of the biopsies 
were incubated with the labelled antibodies. A mAb against K10 (RKSE60; 
Monosan, Uden, the Netherlands) was labelled using the Zenon labelling tech-
nique and was used for the assessment of epidermal differentiation. For ex-
amination of epidermal hyperproliferation, K6 antibody (LHK6B; Novocastra 
Laboratories, Newcastle upon Tyne, U.K.) was labelled using the Zenon label-
ling technique. mAbs against β1 integrin (CD29 FITC, clone K20; DakoCy-
tomation, Copenhagen, Denmark) and K15 (LHK15; Neomarkers, Fremont, 
CA, U.S.A.) were used for analysis of the basal layer of the epidermis. K15 was 
labelled using the Zenon labelling technique whereas β1 integrin was cova-
lently labelled with fluorescein–isothiocyanate (FITC). 
For the double staining, equal volumes of two antibody dilutions were mixed 
and incubated on the slides. K10 was combined with β1 integrin and with K6, 
while β1 integrin was also mixed with K15.
The sections and mAbs were examined using an immunofluorescence micro-
scope (Axioskop 2 MOT; Zeiss, Oberkochen, Germany) with a magnification 
of 200x and a halogen lamp of 100 W. The mAbs were detected using the fol-
lowing filters: for Alexa fluor 594 excitation BP 546/12, FT 580, emission LP 
590 (red), for FITC and Alexa Fluor 488 excitation BP 485/20, FT 510, emis-
sion LP 515 (green) and for DAPI excitation BP 365/12, FT 395, emission LP 
397 (blue).
Images were photographed using a digital camera (Axiocam MRc5; Zeiss) 
and AxioVision software (Zeiss). For each antibody five different parts of the 
epidermis were photographed. The photos made with the different filters were 
later merged with the AxioVision software to get the triple stained pictures.
Image analysis
The images were analysed with IP-lab software (Scanalytics, Rockville, MD, 
U.S.A.) in a standardized manner.15,16 For expression of β1 integrin, K6, K10 
and K15 a region of interest (ROI) was drawn in a frame. This ROI contained 
the epidermis without the stratum corneum. In this ROI the intensity and per-
centage of positive signal in the epidermis was measured. For β1 integrin ex-
pression this was done by setting the reverse intensity and green signal on the 
median value +20, after which the percentage of ROI and mean intensity signal 
were measured.
For K6, K10 and K15 the reverse intensity was set on the median value +15, 
after which the percentage expression in the ROI and the mean intensity signal 
were measured.
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Statistical analysis
Statistical analysis was performed using simple statistics (mean, SEM). A t-
test for dependent samples was done for the separate analysis of the effects of 
both ointments. For statistical analysis of the differences between calcitriol and 
calcipotriol a repeated measurements analysis of variance (ANOVA) was per-
formed. This was all done using Statistica 6 (StatSoft Inc, Tulsa, OK, U.S.A.). 
P-values < 0.05 were considered statistically significant.
RESULTS
The quantification of the various markers and scores have been summarized 
in Figure 1.
A statistically significant reduction of the SUM scores was seen in both the 
calcitriol- and calcipotriol-treated lesions (from 7.0 to 3.8; P < 0.05 for calcipo-
triol and from 7.0 to 5.0; P < 0.05 for calcitriol). However, the decline in the 
calcipotriol- treated lesions was more pronounced (-46%) than in the calcitriol 
treated lesions (-29%).
The K6 expression in the calcipotriol-treated lesions decreased significantly (from 
54.0 to 9.98; P < 0.001). The K6 expression in the calcitriol-treated lesions also de-
creased, but this decrease was not significant (from 46.6 to 35.72; P = 0.46).
In the calcipotriol-treated lesions the K10 expression increased significantly 
(from 49.3 to 62.6; P < 0.05). The K10 expression in the calcitriol-treated le-
sions did not change significantly (from 48.1 to 50.1; P = 0.78).
Before treatment no K15 expression could be detected in either treatment 
Figure 1: Quantitative results of the diverse markers for both calcipotriol and calcitriol at base-
line and after 6 weeks of treatment. Results are expressed as mean ± SEM, *P < 0.05. (A) Clini-
cal score of the target lesions, expressed as SUM score. (B) Relative surface area of keratin (K) 
6-expressing cells. (C) Relative surface area of K10-expressing cells. (D) Relative surface area of 
K15-expressing cells. (E) Relative surface area of β1 integrin-expressing cells.
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group (fig. 2). After 6 weeks of treatment the K15 expression in the lesions 
treated with calcipotriol increased significantly (from 0 to 1.19; P < 0.05). In 
contrast, the K15 expression in the lesions treated with calcitriol did not in-
crease significantly (from 0 to 0.13; P = 0.88).
In both the calcipotriol- and the calcitriol-treated lesions the β1 integrin ex-
pression did not change.
When the effects of treatment with calcipotriol and calcitriol were compared 
using a repeated measurement ANOVA, for the SUM score, K10 expression 
and β1 integrin expression, no statistically significant differences between 
both treatments were found. However, for K6 and K15 expression, there was 
a tendency towards significance (P = 0.06 for both markers) in favour of the 
calcipotriol-treated lesions.
When comparing the double labelling of K6 and K10 (fig. 3) we found three 
different subpopulations of cells in the epidermis. Before treatment the major-
ity of the epidermal cells in the lesions in both treatment groups co-expressed 
K6 and K10. A small percentage of the cells showed an expression of only K6, 
whereas single expression of K10 within one cell was hardly seen. After treat-
ment with calcipotriol there was a shift in cell populations in the lesions. In 
Figure 2: The expression of 
keratin (K) 15 (red) before and 
after treatment with calcipot-
riol (A,B) and calcitriol (C,D). 
Note the reappearance of basal 
K15 (visible as a patchy, basal 
red fluorescent staining) after 
treatment with calcipotriol. 
(magn. 200x)
C D
A B
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these lesions all cells showed a single expression of K10 and there were no cells 
co-expressing K6 and K10 (fig. 3B). In the lesions treated with calcitriol this 
shift in the cell populations expressing K6 and K10 was not seen.
With respect to the double labelling of β1 integrin and K10 three different cell 
populations were also found (fig. 4). The cells in the suprabasal compartment 
below the stratum corneum showed single expression of K10. The basal cell 
layers showed single expression of β1 integrin. Nevertheless, before treatment 
a population of two to three cell layers coexpressing β1 integrin dim cells and 
K10 was seen just above the basal cell layer (fig. 4A,C). After treatment with 
either calcipotriol or calcitriol this cell population disappeared or was reduced 
to one cell layer only (fig. 4B,D).
DISCUSSION
Vitamin D3 derivatives are a cornerstone in the topical treatment of psoriasis. 
Both calcipotriol and calcitriol are approved and have been shown to be effec-
tive in several studies.4,17–19 Comparative studies between calcipotriol and cal-
citriol are scarce but calcipotriol appears to be the more powerful antipsoriatic 
Figure 3: Double labelling of 
keratin (K) 6 (green) and K10 
(red), before and after treat-
ment with calcipotriol (A,B) 
and calcitriol (C,D). Co-ex-
pressing cells are visible as yel-
low or orange cells. Clearly vis-
ible is the disappearance of K6 
expression after treatment with 
calcipotriol (B). (magn. 200x)
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compound in chronic plaque psoriasis on nonflexural, nonfacial sites.1,4,7 Al-
though these studies used a variety of clinical scoring systems, our clinical data 
confirms that calcipotriol appears to be the most potent vitamin D3 derivative.
After 6 weeks of treatment with calcipotriol the clinical SUM scores in our 
study were reduced by 46%, whereas treatment with calcitriol reduced the 
SUM scores by 29%.
Vitamin D3 derivatives are known to inhibit hyperproliferation and to pro-
mote keratinocyte differentiation in the psoriatic epidermis.9,11,20,21 In this study 
we investigated the effects of topical calcipotriol and topical calcitriol on epi-
dermal subpopulations and keratinocyte proliferation and differentiation in 
psoriasis patients. We used the marker K6, a keratin upregulated in hyper-
proliferative epidermal keratinocytes, to assess the effects of both vitamin D3 
derivatives on hyperproliferation. 22,23
Only one study has been published investigating the effect of vitamin D de-
rivatives on K6 expression.7 In this comparative, flow cytometric study on K6/
K10 subpopulations, no change in overall K6 expression was seen. However, 
studies on K16, a keratin co-expressed with K6, which also has an increased 
expression in hyperproliferative skin such as in psoriasis, show a decreased 
expression after treatment with calcipotriol or calcitriol.7,24–28 This is in ac-
Figure 4: Double labelling of 
β1 integrin (green) and kera-
tin (K) 10 (red), before and 
after treatment with calcipot-
riol (A,B) and calcitriol (C,D). 
Just above the basal cell layer 
a population of two to three 
cell layers coexpressing β1 in-
tegrin and K10 is seen, visible 
as cells with a red cytoplasm 
surrounded by a green cell 
membrane. These cell layers 
disappear after treatment with 
either calcipotriol or calcitri-
ol. The cells coexpressing β1 
integrin and K10 can be seen 
even more clearly in the mag-
nified inlays. Note the dermal 
immunofluorescent staining 
of β1 integrin on fibroblasts 
and the endothelium of the 
vasculature. (magn. 200x)
C D
A B
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cordance with our quantitative experiments that show a definite inhibition of 
hyperproliferation as was measured by a decreased K6 expression. This inhi-
bition of hyperproliferation after treatment with calcipotriol was statistically 
significant. After treatment with calcitriol the inhibition of hyperproliferation, 
although qualitatively visible as a diminished expression of K6, did not reach 
statistical significance. This was even more visible in a qualitative way in our 
pictures showing the almost complete disappearance of K6 expression after 
calcipotriol treatment, whereas after calcitriol treatment only a slight shift in 
the cell populations expressing K6 and K10 was seen, with a slight increase in 
cells showing single K10 expression.
The different results of the study from Franssen et al.7 can perhaps be explained 
by the difference in methodology used. Franssen et al. used flow cytometry to 
quantitatively measure cell populations co-expressing K6 and K10. This was 
done by measuring co-expression in single cells, out of their histological con-
text. In our experiments we also qualitatively visualized these cell populations, 
but they were still in their histological context. After treatment with calcipotri-
ol, a significant increase in the expression of the differentiation-related marker 
K10 was seen. The expression of K10 in psoriatic lesions treated with calci-
triol did not change at all, and was not even visible in a qualitative way. This 
difference between calcipotriol and calcitriol was even more obvious in our 
double-labelling experiments with K6 and K10. After treatment with calcipot-
riol there was a decrease of the cell population co-expressing K6 and K10 and 
a concomitant increase of the keratinocyte population expressing only K10, 
thus showing a shift from the hyperproliferative cell compartment towards the 
differentiating cell compartment. This shift was not seen in the group of pso-
riatic lesions treated with calcitriol. Although there is scant literature on the 
changes in K10 expression after treatment with calcitriol, all the literature on 
the K10 changes after treatment with calcipotriol shows a marked increase in 
K10 expression, confirming our results.21,29,30 Franssen et al.7 also found that 
calcipotriol significantly increased the K10 expression whereas calcitriol did 
not. This is in accordance with literature showing that treatment with vitamin 
D derivatives also tends to normalize other differentiation-related markers as 
involucrin.9,20
The relative surface area of β1 integrin compared with the total epidermal 
surface area did not show any statistical changes in both the calcitriol- and 
calcipotriol-treated lesions. This is also in agreement with the aforementioned 
study in which the epidermal cell population not co-expressing K6 and K10 
represents for the most part the β1 integrin-positive population.7 However, 
in our double-labelling experiments of β1 integrin with K10 we observed a 
definite reduction in the number of basal cell layers expressing β1 integrin. 
Interestingly this reduction was mainly due to a reduction in the number β1 
integrin dim cells. These cells also co-expressed K10 before treatment and are 
thought to represent the transit amplifying cells that are the direct descend-
Chapter 4 - Treatment effects on psoriatic epidermal cell populations
105
ants of the epidermal stem cell and have a very high proliferative activity.31,32 
Furthermore, the number of cell layers containing the β1 integrin dim cells is 
increased in the psoriatic lesion, giving rise to the thickening of the epider-
mis.16,31 It is conceivable that vitamin D derivatives inhibit hyperproliferation 
in the psoriatic epidermis by controlling the epidermal progenitor cell into a 
differentiating pathway rather than a hyperproliferative pathway.12 
The reappearance of K15 in the basal cell layers after treatment with calcipotri-
ol further strengthens this hypothesis because K15 is known to be downregu-
lated in activated basal epidermal cells.33 Treatment with calcipotriol switches 
the basal progenitor cell towards a differentiating pathway, resulting in differ-
entiation instead of a pathway resulting in the typical hyperproliferation seen 
in psoriasis. In this differentiating pathway the basal keratinocytes become less 
activated and basal K15 expression returns. The diminishment of the transit-
amplifying cell compartment and increase of the differentiative cell compart-
ment results in normalization of the structure of the psoriatic epidermis.
Calcitriol showed the same tendency to do this; a slight increase in K15 was 
visible with a diminishment of the transit-amplifying cell compartment which 
was qualitatively visible. However, the tendency to increase the differentiated 
cell compartment was not even qualitatively visible (as our double-labelling 
experiments show). This indicates that after treatment with calcitriol there is 
an induction of the progenitor cells in the basal layer from a hyperprolifera-
tive state into a differentiative state, leading to a qualitatively visible decrease 
in the transit-amplifying cell compartment. However, this effect is not strong 
enough to influence the suprabasal cells; therefore, this does not lead to an 
increase in suprabasal epidermal differentiation as measured by an increase in 
K10 expression.
Both calcitriol and calcipotriol are vitamin D derivatives with comparable af-
finity for the vitamin D receptor. Perhaps an even lower affinity for the vitamin 
D receptor is found for calcipotriol compared with calcitriol.14 Nevertheless, 
the concentration of the active compound in calcitriol ointment is not only 
more than 10 times lower than that of calcipotriol, it also has a 30 times high-
er affinity for vitamin D-binding protein in the blood.34 In vitro experiments 
show that due to this higher affinity of calcitriol for the vitamin D-binding 
protein, combined with the higher concentration of the active compound in 
calcipotriol ointment, the local biological activity of calcitriol in the psori-
atic epidermis is probably markedly decreased compared with calcipotriol.14 
Although calcitriol is as capable as calcipotriol in inducing differentiation in 
hyperproliferative progenitor epidermal cells in vitro, the above-mentioned 
mechanisms can be the reason why calcipotriol is the clinically more powerful 
compound.12 Our experiments show that calcitriol is probably capable of in-
ducing the same route into differentiation in psoriatic epidermal cells, but does 
this less insistently. For calcitriol to be able to achieve similar clinical improve-
ment, it requires more time for the psoriatic lesion to return to a nonactivated, 
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normally differentiated state.
This may also explain the difference in the potential of calcipotriol and calci-
triol to re-induce the marker for nonactivated basal keratinocytes, K15. This 
has been demonstrated in another study from our group, which found the re-
appearance of K15 to be a relatively late phenomenon in the normalization of 
the psoriatic epidermis, occurring even after normalization of differentiation-
related markers had taken place. Interestingly, K15 reappearance also seemed 
to be a possible predictor for the disease remission period.35 The pharmacoki-
netic differences between calcitriol and calcipotriol might also explain why 
calcipotriol has a higher incidence of side-effects such as skin irritation and 
erythema than calcitriol.
Both calcipotriol and calcitriol are vitamin D derivatives which are able to in-
hibit proliferation and induce differentiation in the psoriatic plaque in vitro; in 
vivo, calcipotriol seems to be more potent in doing so than calcitriol. After 6 
weeks of treatment calcipotriol is able to switch the activated basal cells from 
a hyperproliferative state into a differentiating state, leading to a decrease in 
the transit-amplifying cell compartment and finally giving rise to an almost 
normally differentiated suprabasal cell population and a definite reduction in 
epidermal thickness. Calcitriol probably is also able to do this, but needs more 
time to do so.
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ABSTRACT
Background and objectives: The effect of the established antipsoriatic treat-
ment with topical calcipotriol (with a maximum of 100 g per week) in addi-
tion to systemic treatment with alefacept, a new biological agent for psoriasis, 
on epidermal cell populations in the psoriatic lesion was investigated using a 
combination of the Zenon labelling technique and microscopic image analysis. 
Epidermal cell populations were measured quantitatively with this sensitive 
method.
Patients/methods: Frozen sections of non-treated psoriatic epidermis and pso-
riatic epidermis treated with either alefacept intramuscular or alefacept intra-
muscular in combination with topical calcipotriol for 12 weeks were compared 
immunohistochemically. Antibodies against keratin 6, 10 and 15 were labelled 
with the Zenon technique, whereas antibodies against the ki-67 antigen and 
β1 integrin were covalently Fluorescein Isothiocyanate (FITC)-labelled. Using 
image analysis, these markers were measured in the epidermis in a standard-
ized manner.
Results and conclusions: Treatment of psoriasis with alefacept resulted in a 
good clinical response in several patients and in a normalization of epidermal 
expression of the immunohistochemical parameters for differentiation and 
proliferation. The addition of topical calcipotriol resulted in a faster clinical 
improvement with a similar overall clinical response and a similar response 
of epidermal cell populations as compared to treatment with alefacept mono-
therapy after 12 weeks of treatment. This study also suggests that the appear-
ance of keratin 15 has a predictive value for the duration of remission. It can 
be concluded that the addition of a low-dose calcipotriol treatment does not 
contribute to the clinical efficacy of alefacept, both at the clinical level and with 
respect to markers for epidermal proliferation and differentiation.
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INTRODUCTION
Specific anti-T-cell treatments have a substantial therapeutic efficacy in psoria-
sis.1 One of these anti-T-cell treatments is alefacept, which is a recombinant, 
fully human fusion protein, with a selective therapeutic action. Krueger et al. 
showed in a placebo-controlled trial that the mean psoriasis area severity in-
dex (PASI) decreases progressively in patients receiving alefacept during a 12-
week treatment period and continues to decrease after the last dose. A second 
course of 12 weeks had an additional benefit, further reducing the mean PASI.2
Alefacept is able to give long off-treatment disease remissions.3–6
Established antipsoriatic treatments have broader effects on the pathogenesis 
of psoriasis. For instance, topical vitamin D analogues, such as calcipotriol, 
inhibit the proliferation of the epidermal keratinocytes and enhance the corni-
fied envelope formation, indicating an effect on keratinocyte differentiation in 
psoriasis.7
In view of the different modes of action of alefacept vs. calcipotriol, it is at-
tractive to speculate that the combination of both treatments might have a 
synergistic effect. In the present study the effect of the combination of alefacept 
and calcipotriol vs. alefacept monotherapy was monitored by markers for epi-
dermal proliferation and differentiation that allow a quantitative and sensitive 
assessment of the severity of the psoriatic lesion.
Recruitment of cycling epidermal cells can be assessed by the number of ki-67 
positive nuclei, which is increased in the psoriatic lesion.8,11–15 Furthermore, β1 
integrin is an important marker as stem cells reside in the β1 integrin positive 
cell compartment.9,16–19 Keratin 15 is also expressed in the basal layer and it 
has been suggested that keratin 15 may be a marker for stem cells in the hair 
follicle.20 It is intriguing that in a hyperproliferative state such as psoriasis, ex-
pression of keratin 15 disappears.21,22 The altered differentiation in psoriasis is 
also shown by the replacement of keratin 10 by keratin 6.23–28 Major differences 
in expression of the above-mentioned epidermal cell markers between normal 
and psoriatic epidermis were shown with fluorescent immunohistochemistry 
using the Zenon technique, which can detect even small changes in epidermal 
cell populations after mild treatment of psoriasis.29
MATERIALS AND METHODS
Patients and biopsies
After obtaining informed consent, skin punch biopsy specimens were collected 
from seven patients (five males and two females, aged 54.9 ± 10.7 years) with 
moderate to severe plaque psoriasis. They did not receive any topical treatment 
for at least 2 weeks or systemic therapy for at least 4 weeks before specimens 
were obtained. The alefacept treatment was given in courses. In the first 12 
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weeks, 15 mg of alefacept was administered as intramuscular injections once 
weekly. After these 12 weeks, there was a follow-up period of at least 12 weeks 
in which no alefacept was administered. A second and a third course were ad-
ministered after completion of the 12-week followup period and when psoria-
sis had progressed to require systemic therapy. During the first course, a 4 mm 
punch biopsy was taken from two representative lesions after local anaesthesia 
with xylocain 1%/adrenaline (1 : 100 000) (AstraZeneca BV, Zoetermeer, the 
Netherlands). After obtaining the punch biopsies, patients were given 15 mg 
of alefacept (Amevive®, Biogen Idec, Cambridge, MA, USA) with intramuscu-
lar injections once a week. The plaques were treated with calcipotriol cream 
(Daivonex®, 50 μg/g cream, Leo Pharmaceutical Products, Denmark), once 
daily every other day except for one of the representative lesions, which was 
not treated. Treatment with calcipotriol cream was restricted to a maximum 
weekly dose of 100 g to maintain calcium homeostasis. In view of the extensive 
distribution of psoriatic lesions, a reduced frequency of applications had to be 
adopted. After 12 weeks of treatment, another 4 mm punch biopsy was taken 
from both representative plaques. All specimens were embedded in Tissue-
Tek (Sakura Finetek, Zoeterwoude, the Netherlands), snap-frozen in liquid 
nitrogen and stored at − 80 °C.
Erythema, infiltration and scaling of the lesions were recorded using a five-
point scale from 0 = ‘none’ to 4 = ‘extremely severe’ before (week 0) and after 
treatment (week 12). The SUM-score was calculated.
Fluorescent immunohistochemistry and Zenon labelling technique
This method has been described previously.30 In brief, monoclonal antibod-
ies were labelled and/or diluted and incubated on 6 μm frozen sections of the 
biopsies. Monoclonal antibodies against keratin 10 (RKSE60, Monosan, Uden, 
the Netherlands) and keratin 6 (LHK6B, Novocastra Laboratories, Newcastle 
upon Tyne, UK) were labelled using the Zenon labelling technique and were 
used for assessment of epidermal differentiation. For examination of epider-
mal proliferation, ki-67 antigen (MIB-1 FITC, DakoCytomation, Copenha-
gen, Denmark), covalently FITC-labelled, was used. Monoclonal antibodies 
against β1 integrin (CD29 FITC, clone K20, DakoCytomation, Copenhagen, 
Denmark) and keratin 15 (LHK15, Neomarkers, Fremont, USA) were used for 
analysis of the basal layer of the epidermis. Keratin 15 was labelled using the 
Zenon labelling technique whereas β1 integrin was covalently labelled with 
FITC.
For the double staining, equal volumes of two antibodies dilutions were mixed 
and incubated on the slides. Keratin 10 was combined with ki-67, with β1 in-
tegrin and with keratin 6, while β1 integrin was also mixed with keratin 15.
The sections and monoclonal antibodies were examined using an immunoflu-
orescence microscope (Axioskop 2 MOT, Zeiss, Sliedrecht, the Netherlands) 
and images were photographed using a digital camera (Sony, DXC-390P 3 
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CCD) and ‘Image J’ software (Scanalytics, Fairfax, USA). For each antibody, 
10 different parts of the epidermis were photographed. These images were 
analysed with IP-lab software (Scanalytics) in a standard manner. For dou-
ble staining and co-expression, photographs of the same part of the epidermis 
were taken for each antibody and these pictures were merged using IP-lab. 
Values are given as mean ± SEM.
Statistical analysis
Statistical analysis was performed using a t -test: twosample assuming unequal 
variances. P-values of less than 0.05 were considered statistically significant.
RESULTS
The clinical SUM-scores revealed a statistically significant decrease in ery-
thema, induration and scaling for the alefacept-treated lesions as well as for 
the alefacept-calcipotriol treated lesions (from 5.3 ± 0.7 to 1.9 ± 1.1 and from 
5.3 ± 0.7 to 1.4 ± 0.8, respectively). The decrease was statistically significant 
and equal in both groups (P < 0.05) (fig. 1). However, the plaques treated with 
calcipotriol responded faster than the non-calcipotriol-treated lesions.
The number of ki-67 antigen-positive nuclei per mm basal membrane was di-
minished in the lesions treated with alefacept monotherapy as well as in the le-
sions treated with the combination of alefacept and calcipotriol. This decrease 
was statistically significant (from 38 ± 2.2 to 11 ± 3.6 and from 44 ± 4.4 to 12 
± 2.1, respectively; P <0.05). These decreases could not be compared with each 
other because of the statistically significant different number of ki-67 positive 
nuclei between both untreated lesions (fig. 2A).
β1 integrin has a suprabasal expression pattern in untreated psoriatic skin that 
changes to a more basal expression after treatment with both alefacept mono-
therapy and after treatment with the combination of alefacept with calcipotriol. 
The positive surface area of β1 integrin was increased in the alefacept-treated 
lesion (from 10.5 ± 1.8% to 20.8 ± 4.0%; P <0.05) as well as in the alefacept/
calcipotriol-treated lesion (from 14.8 ± 3.7% to 19.4 ± 2.2%; P <0.05). Because 
Figure 1: SUM-scores of 
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of statistically unequal positive surface areas for β1 integrin between both un-
treated plaques, the differences in increase could not be compared. For β1 in-
tegrin intensity a statistically significant increase within the same range was 
found after treatment with alefacept in combination with calcipotriol and with 
alefacept monotherapy (from 75.2 ± 4.1 to 80.8 ± 4.0 FU and from 72.5 ± 1.5 
to 77.9 ± 3.5 FU, respectively; P < 0.05) (fig. 2B,C).
Keratin 10 has a suprabasal expression pattern that is heterogeneous in the 
untreated psoriatic lesion. After treatment, it becomes more homogeneous. 
The positive surface area of keratin 10 shows a statistically significant increase 
within the same range after both alefacept treatment and combination treat-
ment of alefacept with calcipotriol (from 43.9 ± 3.6% to 54.9 ± 3.6% and from 
35.6 ± 3.5% to 53.7 ± 3.1%; P <0.05). The intensity of keratin 10 only shows a 
tendency to improve after treatment with alefacept and alefacept/calcipotriol 
(fig. 3A,B).
Keratin 6 is also expressed in the suprabasal layers of the epidermis in psoriatic 
lesions. In the untreated lesions a more homogeneous pattern of expression 
was seen, while after 12 weeks of treatment the pattern was more heterogene-
ous. A significant decrease in the positive surface area of keratin 6 was found 
in both treatment groups (from 39.1 ± 3.1% to 19.9 ± 4.4% for the alefacept 
monotherapy treatment and from 58.5 ± 2.3 to 23.0 ± 4.5% for the combina-
tion of alefacept and calciptriol; P <0.05). Keratin 6 intensity also revealed a 
statistically significant decrease in the alefacept treatment group (from 163.8 ± 
4.5 to139.4± 7.2 FU; P <0.05) as well as for treatment with alefacept in combi-
nation with calcipotriol (from 179.1 ± 4.4 to 145.4 ± 8.9 FU; P <0.05). Because 
of statistically significant differences in positive surface area and intensity of 
Figure 2: Ki-67-positive cells: (A) number 
of ki-67-positive nuclei per millimetre 
length of basement membrane before (black 
bars) and after (grey bars) treatment (*P < 
0.05). β1 integrin expression: (B) β1 integrin 
positive surface area as a percentage of epi-
dermis before (black bars) and after (grey 
bars) treatment (*P < 0.05). (C) Intensity of 
β1 integrin expression assessed as units of 
fluorescence before (black bars) and after 
(grey bars) treatment (*P < 0.05).
Alefacept Alefacept + Calcipotriol Alefacept Alefacept + Calcipotriol
Alefacept Alefacept + Calcipotriol
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keratin 6 between both untreated plaques, the decreases could not be com-
pared (fig. 3C,D).
Keratin 15 has an alternate expression pattern in the basal layer of the epi-
dermis that does not occur in the psoriatic epidermis before treatment. How-
ever, after 12 weeks of treatment, keratin 15 was expressed in the alefacept 
treated epidermis and in the alefacept/calcipotriol-treated lesion in the epi-
dermis of two patients (fig. 4). Of all the participating patients, these two had 
the best clinical response to alefacept in combination with calcipotriol (data 
not shown). After 12 weeks of treatment, the psoriatic lesions in these patients 
were almost cleared, and 11 months after the last alefacept injection, the dis-
ease is still in remission in these two patients. The other five participating pa-
tients have already received a second course of alefacept.
Double staining of ki-67 with keratin 10 visualizes an overlap in expression in 
the untreated epidermis. Some ki-67-positive nuclei reside in keratin 10-posi-
tive cells. ki-67-positive nuclei are also present in suprabasal layers. After 12 
weeks of treatment with either alefacept monotherapy or alefacept in combi-
nation with calcipotriol, ki-67-positive nuclei are more confined to the basal 
layer (fig. 5A-C).
In the double staining of β1 integrin with keratin 10, β1 integrin-positive cells 
are found in the basal layer after treatment with alefacept and with the combi-
Figure 3: Keratin 10 expression. (A) Keratin 10 positive surface area as a percentage of epider-
mis before (black bars) and after (grey bars) treatment (*P < 0.05). (B) Intensity of keratin 10 ex-
pression assessed as units of fluorescence before (black bars) and after (grey bars) treatment (*P 
< 0.05). Keratin 6 expression. (C) Keratin 6 positive surface area as a percentage of epidermis be-
fore (black bars) and after (grey bars) treatment (*P < 0.05). (D) Intensity of keratin 6 expression 
assessed as units of fluorescence before (black bars) and after (grey bars) treatment (*P < 0.05).
Alefacept Alefacept + Calcipotriol Alefacept Alefacept + Calcipotriol
Alefacept Alefacept + Calcipotriol Alefacept Alefacept + Calcipotriol
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nation alefacept/calcipotriol. No co-expression of β1 integrin and keratin 10 
was found in the untreated epidermis. In the treated epidermis, a few cells that 
express both β1 integrin and keratin 10 are seen (fig. 5D–F ).
Double staining of keratin 6 with keratin 10 in the untreated epidermis shows 
keratinocytes expressing both keratin 6 and keratin 10 (yellow/orange cells) 
and keratinocytes only expressing keratin 6 (green cells). These double-posi-
tive cells are localized throughout the epidermis. Cells that were only positive 
for keratin 10 were not seen in the untreated epidermis. However, after treat-
ment with alefacept and alefacept-calcipotriol, expression of keratin 6 drasti-
cally decreased, whereas most cells express keratin 10. Co-expression of kera-
tin 6 with keratin 10 is hardly seen (fig. 5G–I).
DISCUSSION
To study a possible additional effect of a topical calcipotriol treatment to sys-
temic treatment with alefacept, epidermal cell populations in alefacept-treated 
psoriatic lesions were compared with those of psoriatic lesions treated with 
both alefacept and calcipotriol. Alefacept is an antipsoriatic treatment with 
a specific targeting against the T cell, while calcipotriol clearly has effects on 
psoriatic hyperproliferation and disturbed differentiation. With the combina-
tion of these two treatments, all the above-mentioned characteristics of the 
psoriatic epidermis are being treated, while alefacept monotherapy only in-
terferes with the communication between the antigen-presenting cells and the 
T cells in the epidermis.3–5,7 Alefacept treatment was given in patients with 
moderate to severe psoriasis and the percentage body surface involved with 
psoriasis was more than 30% in most of our patients. As the maximum weekly 
quantity of calcipotriol cream was 100 g, an intermittent application schedule 
for once daily treatment was chosen.
After 12 weeks of treatment, the clinical SUM-scores of psoriatic plaques in pa-
Figure 4: Keratin 15 staining pattern before treatment (A) and after treatment with alefacept (B). 
(magn. 200x)
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tients treated with alefacept monotherapy and in those treated with both ale-
facept and calcipotriol were equally diminished. However, the plaques treated 
with calcipotriol responded faster than the non-calcipotriol-treated lesions. 
The faster response of the intermittent application schedule of calcipotriol as 
observed by the investigator was well appreciated by the patients.
Hyperproliferation, measured through the number of ki-67-positive nuclei 
and the positive surface area and intensity of β1 integrin, is diminished to the 
same extent in both treatment groups. The differentiation markers keratin 6, 
which is only expressed in hyperproliferative skin diseases, and keratin 10 also 
show a change towards normalization to the same extent with both treatments. 
Treatment with calcipotriol in patients with mild to moderate psoriasis has 
been reported to be clinically as effective as a potent topical corticosteroid af-
ter 8 weeks of treatment31, while alefacept reaches its optimal efficacy after 16 
weeks of treatment.4 It is also known that the calcium homeostasis can be af-
fected by calcipotriol, even when used in recommended doses. This indicates 
that calcipotriol may have systemic effects on psoriasis.32 Further research, 
with biopsies collected at time intervals of 4, 8 and 16 weeks after initiation of 
treatment, is needed to investigate the additional effect of calcipotriol to treat-
Figure 5: Double staining of ki-67 with keratin 10 before treatment (A), after treatment with 
alefacept (B) and after treatment with alefacept/calcipotriol (C). Double staining of β1 integrin 
with keratin 10 before treatment (D), after treatment with alefacept (E) and after treatment with 
alefacept/calcipotriol (F ). Double staining of keratin 6 with keratin 10 before treatment (G), af-
ter treatment with alefacept (H) and after treatment with alefacept/calcipotriol (I). (magn. 200x)
H
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ment with alefacept at different points during treatment. This may also show 
that the faster clinical improvement with the combination treatment of ale-
facept with calcipotriol is reflected by faster changes in epidermal parameters.
Keratin 15, which is presumed to be a stem cell marker, is not present in the 
untreated psoriatic epidermis. In the normal epidermis, a patchy expression 
pattern is seen in the basal layer. After mild treatment no reoccurrence of this 
protein is shown29, and after treatment with alefacept in combination with top-
ical calcipotriol, keratin 15 appeared in the epidermis of two patients. These 
two patients were the best responders of all the patients studied. After 12 weeks 
of treatment, the psoriatic lesions in these patients were almost cleared. Eleven 
months after the last alefacept injection, the disease is still in remission in these 
patients, while the other five patients have already received a second course 
of alefacept. Therefore, keratin 15 could be a promising marker to predict the 
duration of remission.
The effect of alefacept and of alefacept/calcipotriol on the suprabasal compart-
ment is evident. After treatment, ki-67-positive nuclei are more confined to 
the basal layer, the suprabasal expression of β1 integrin disappears and keratin 
10 expression occurs just above the basal layer. An effect on differentiation is 
indicated in the double staining of keratin 6 and keratin 10. Keratin 6, only 
present in hyperproliferative skin disorders, is almost completely replaced by 
keratin 10 after 12 weeks of treatment. Therefore, double stainings clearly show 
the effect of this treatment on the transit amplifying cells (TAC) as target cells 
for pharmacological intervention.
In conclusion, treatment of psoriasis with alefacept resulted in a good clinical 
response, and normalization of several immunohistochemical parameters for 
epidermal differentiation and proliferation was shown with this sensitive im-
munofluorescent technique. The addition of topical calcipotriol resulted in a 
faster clinical improvement, but did not result in a better clinical response or in 
a better response of epidermal cell populations in comparison with treatment 
with alefacept monotherapy after 12 weeks. This improvement indicates the 
need for further studies with several time intervals to investigate the additional 
effect of calcipotriol to alefacept. Furthermore, studies on the combination of 
alefacept and twice daily application of calcipotriol are worthwhile to find out 
whether selected recalcitrant lesions may benefit. Keratin 15 expression ap-
peared after treatment in the epidermis of two patients who had long-lasting 
clinical responses to the alefacept treatment. Follow-up suggests that keratin 
15 is a possible marker for the duration of remission.
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Effects of alefacept treatment on
nail psoriasis
This chapter is based on the following publication:
Therapeutic effects of a 12-week course of alefacept on nail psoriasis.
J.E.M. Körver, A.M.G. Langewouters, P.C.M. van de Kerkhof, M.C. Pasch.
J Eur Acad Dermatol Venereol. 2006 Nov;20(10):1252-5.
Therapeutic effects of a 12-week course of alefacept on nail 
psoriasis.
J.E.M. Körver, A.M.G. Langewouters, P.C.M. van de Kerkhof, M.C. Pasch.
J Eur Acad Dermatol Venereol. 2006 Nov;20(10):1252-5.
ABSTRACT
Background and objectives: Nail psoriasis is a common finding in psoriatic pa-
tients and it affects the quality of life in a great proportion of patients. Topical
or systemic treatments have limited effectiveness or have a serious toxicity po-
tential. Biologicals such as alefacept are the most recent treatment modalities 
for psoriasis. In the present study we evaluated changes in nail pathology in 
patients with plaque psoriasis and nail involvement during treatment with ale-
facept.
Patients and methods: Digital photographs from eight patients were produced, 
which were analysed using the nail psoriasis severity index (NAPSI). A mini-
mal NAPSI of 15 was chosen to divide patients into a moderate to very severe 
nail psoriasis group and a group with no or mild nail psoriasis. A decrease in 
NAPSI of at least 25% was considered a significant response to therapy.
Results: In the group with at least moderate nail psoriasis, two patients im-
proved, in two patients the nail changes remained unchanged and in one pa-
tient the nail pathology was aggravated. The group with no or mild nail pso-
riasis showed variable results.
Conclusions: Although alefacept showed some results in treating nail pathol-
ogy in psoriasis, a more extensive study is required, covering both more pa-
tients and a more extensive time period. Furthermore, it would also be clini-
cally relevant to compare the effects of alefacept on nail psoriasis with other 
biologicals.
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INTRODUCTION
Nail psoriasis is a common finding in psoriatic patients with the frequency of 
patients being affected reaching up to 79%.1,2 These nail changes affect quality 
of life in a great proportion of the patients. More than half of the patients with 
psoriatic nail changes suffer from pain and are restricted in their daily activities 
because of these changes.2 Topical treatments include topical steroids, vitamin 
D derivates, topical cyclosporin, 5-fluorouracil and anthralin. However, the ef-
fectiveness of these therapies is limited, mainly because of the impermeability 
of the nail plate, leading to poor drug uptake in the nail apparatus.3 The appli-
cation of topical therapies is often difficult and the use of high potency topical 
steroids such as clobetasol propionate for more than 3 to 4 months can lead to 
skin atrophy. Tapering of the digits can eventually occur when high potency 
steroids are used continuously for years, leading to a ‘disappearing digit.’4 Lo-
cal injection of steroids showed a 45 and 91% improvement in ridges and pits, 
respectively, but onycholysis improved only in 19 to 50% of the patients. This 
method can be painful and complications such as haematoma formation, re-
versible nail fold atrophy and puncture of the nail plate have been observed.4,5 
Systemic treatments such as acitretin and cyclosporin have shown a better re-
sult, yielding an improvement in nail lesions of, respectively, 34 and 48%.6,7
The most recent treatment modalities for psoriasis are the biologicals. Inf-
liximab, a chimeric monoclonal IgG1 antibody to TNF-α, which has shown 
impressive results in the treatment of psoriasis vulgaris, demonstrated a 50% 
reduction in nail psoriasis severity index (NAPSI) at 14 weeks and a complete 
remission of psoriatic nail pathology in all treated subjects at week 22.8 Ale-
facept is a completely human fusion protein of the receptor LFA3 and human
IgG1. It binds to CD2 on T cells leading to inhibition of T-cell costimulation 
and a reversible reduction of memoryeffector T cells. It has proven to be effec-
tive in the treatment of moderate to severe plaque psoriasis.9,10 However, the 
effect of alefacept on nail psoriasis is not well established. A previous report 
on six patients suggested that alefacept had a rather modest effect on nail pso-
riasis.11 In these patients the NAPSI before treatment was relatively low (5/6 
patients had a NAPSI below 13). In the present study we evaluated changes in 
nail pathology in patients with plaque psoriasis and nail involvement (NAPSI 
> 15) during treatment with alefacept.
MATERIALS AND METHODS
We performed an open prospective study with eight patients who received ale-
facept in a dose of 15 mg/week, i.m., for treatment of moderate to severe plaque 
psoriasis. The total course of alefacept treatment was 12 weeks. At baseline and 
after 12 weeks of treatment digital, highresolution photographs were taken, 
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which were analysed using the NAPSI. The NAPSI is a numeric, objective and
reproducible scoring system for psoriatic nail changes and is used to evaluate 
and quantify the severity of psoriasis of the nail bed and nail matrix.12 NAPSI 
scoring was performed on randomized photographs by an examiner other than 
the treating physician. During the course of alefacept the patients’ skin psoria-
sis was regularly assessed using the psoriasis area and severity index (PASI).
Theoretically the NAPSI score may vary between 0 and 80. For pragmatic rea-
sons patients having a NAPSI between 0 and 15 were designated as having mild 
nail psoriasis, between 16 and 30 as moderate, between 31 and 50 as severe, 
and between 51 and 80 as having very severe psoriatic nail disease. Therefore, 
a NAPSI score higher than 15 was taken as a cut off point to select the patients 
with a clinically relevant degree of nail psoriasis (group I). In our clinical expe-
rience some patients with only mild involvement of the nails had aggravation 
of their psoriatic nail disease after starting alefacept therapy. Therefore, we also 
followed patients with a NAPSI below or equal to 15, considered to have no or 
mild psoriatic nail disease (group II). A decrease in NAPSI of at least 25% was 
considered a significant response to therapy.13
RESULTS
The overall group consisted of two women and six men with a mean age of 44.9 
years. Group I with a NAPSI > 15 comprised five patients: one woman and four 
men with a mean age of 43.4 years. Group II with a NAPSI ≤ 15 comprised 
three patients: one woman and two men with a mean age of 47.3 years. The 
results are summarized in Table 1.
In group I, considered as having moderate to very severe nail psoriasis (with 
a NAPSI > 15), two patients showed improvement, in two patients the nail 
changes remained unchanged and in one patient nail pathology was aggra-
vated (see fig. 1).
In the group considered as having only mild nail psoriasis (with a NAPSI ≤ 15, 
group II), one patient improved, in one patient no changes were seen, and in 
Table 1: Changes in NAPSI and PASI scores at baseline and after 12 weeks of alefacept treat-
ment. Negative numbers represent worsening of nail psoriasis.
Patient
1
2
3
4
5
6
7
8
Baseline
14.3
8.1
24.6
23.7
13.8
21.7
16.3
28.6
PASI
12 weeks
10.6
3.2
12.9
42.2
5.9
7.6
13.3
18.4
% change
26
60
48
-78
57
65
18
36
Baseline
33
48
33
50
21
11
6
5
NAPSI
12 weeks
31
28
23
56
37
20
5
2
% change
6
42
30
-12
-76
-82
17
60
Group I
Group II
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one patient the nail changes worsened. All but one patient showed an improve-
ment in the activity of the skin psoriasis as measured with the PASI score; 
however, in none of our patients was PASI 75 reached.
DISCUSSION
Nail pathology in psoriasis is difficult to treat with either topical or systemic 
therapies.5,14 Recently, in a small series of patients infliximab showed promis-
ing results in the treatment of nail changes in psoriatic patients.8 Of the eight 
patients in this study, five showed improvement in nail pathology, but only 
three showed a relevant improvement in NAPSI score (> 25%). Two patients 
showed a definite aggravation in nail psoriasis symptoms, with one patient con-
sidered as having only mild involvement of the nails before treatment meeting 
the criteria for having moderate nail psoriasis after alefacept treatment. The 
skin symptoms of psoriasis improved in 3/8 patients (PASI reduction > 50%). 
These patients did not respond better with respect to their nail psoriasis than 
the other patients did (Table 1). The results observed on psoriasis activity of 
the nails following alefacept treatment are worse than seen after infliximab 
therapy, which is in line with the more modest therapeutic efficacy of alefacept 
when compared to infliximab with respect to psoriatic plaques.9,15 However, 
alefacept did have a therapeutic action on nail psoriasis in 3/8 patients in our 
Figure 1: Clinical picture of a nail of patient no. 2 at (A) baseline, and (B) after 12 weeks of 
alefacept treatment.
A B
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study. In most studies significant results with treatment of nail psoriasis were 
seen after 12 weeks of treatment, especially with systemic treatments.4,6,7,13,16–18 
These 12 weeks were also used in the literature to evaluate the effectiveness of 
alefacept therapy on skin psoriasis.9,10 However, because of the relatively slow 
growth of the human nail and the slow onset of effect of alefacept therapy the 
effectiveness of this biological on nail psoriasis should possibly also be meas-
ured after a more prolonged period of time.
Although alefacept showed some results in treating nail pathology in psoriasis, 
a more extensive study is required, covering both more patients and a more 
extensive period of time. Furthermore, it would also be clinically relevant to 
compare the effects of alefacept on nail psoriasis with the effects of other bio-
logicals.
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6.1 Introduction
The present thesis aims to elucidate the dynamics of epidermal cell populations 
in healthy and diseased skin. Innovative techniques have permitted to identify 
changes in epidermal cell populations by quantitative multi parameter imaging 
techniques. The aims of this thesis have been noted in the introduction. In the 
general discussion we will summarise the major conclusions of aim I to IV. 
Finally, the observed changes in cell populations in the epidermis, proliferation 
and differentiation in the nail apparatus, the margin zone of the psoriatic lesion, 
and the psoriatic lesion during treatment, will be integrated into a model to 
understand the dynamics of epidermal cell populations in health and disease. 
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6.2  
Aim I:
To identify cells with stem cell characteristics in the human nail 
apparatus and to visualize their progeny of proliferating and 
differentiating cells, in order to develop a model for proliferation 
and differentiation of the human nail.
In chapter 2 we characterised the expression patterns of the cells of the nail 
apparatus, using both classic immunohistochemistry and the innovative 
Zenon labelling technique, in order to visualise the diverse cell populations 
and to differentiate between quiescent, proliferating, and differentiating cells.
Most interestingly, we found keratin 15 and keratin 19, two putative stem cell 
markers from the interfollicular epidermis and hair follicle, to colocalize in 
the root of the nail apparatus. It is the classical view that the root of the nail 
apparatus harbours the more terminally differentiated cells. The cells forming 
the nail plate were thought to originate from the intermediate matrix, the 
dorsal matrix and the nail bed 1-3. Although more recent studies confined the 
origin of the nail plate to the intermediate matrix, still the more basal layers 
of the intermediate matrix were thought to harbour the progenitor cells of 
the nail plate, with a suprabasal terminal differentiation of the onychocytes 4-7. 
In contrast to the cells in the basal and suprabasal layers of the intermediate 
matrix, the cells in the root of the nail plate have big nuclei and a lot of 
cytoplasm, do not express the proliferation marker ki-67 and markers of more 
terminal differentiation, as keratin 6 and keratin 10. This marks the root of the 
nail plate as a region containing relatively quiescent cells, probably being stem 
cells. 
The basal and suprabasal layers of the intermediate matrix express α6 and 
β1 integrin. The basal expression of these two markers can be found in the 
basal layer of the whole nail apparatus, and probably reflects their function as 
anchoring proteins in the normal epidermis. As discussed in the introduction, 
both SC and TAC express β1 integrin. These cells also highly express α6 integrin, 
and are called α6 integrin bright cells. Cells with low expression of  β1 integrin 
(β1 integrin dim cells), represent the TAC compartment 4;8-10. The suprabasal 
expression of both integrins, with a marked dim expression of β1 integrin, 
together with an increased number of actively cycling cells as visualised by an 
increased number of ki-67 positive cells, marks this part of the intermediate 
matrix as the region with the highest proliferative activity, comparable to 
the suprabasal layers of psoriatic epidermis 11-13. We can conclude that the 
suprabasal layers of the intermediate matrix harbour the TAC compartment 
in the human nail apparatus. 
Until recently the expression of keratin 6 was thought to represent the 
hyperproliferative status of epidermal differentiation as in the psoriatic 
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skin14;15. Recently, keratin 6 expression was also found in non hyperproliferative 
situations, as in wounding of the skin, and in cultured skin equivalents. In 
these situations the expression of keratin 6 is a mere representation of the 
“stress” exerted to the keratinocytes 16-18. Keratin 6 was expressed in four 
regions of the nail apparatus that are under constant stress; the ventral 
proximal nail fold, the dorsal nail matrix, the digit pulp, and the nail bed. 
Both the nail fold and the dorsal matrix are subject to the pulling force of the 
growing nail plate and trauma transmitted by the nail plate. The digit pulp is 
the object of constant trauma as it is used in the diverse tasks of the digit. The 
panepidermal keratin 6 expression in the nail bed, in combination with the 
absence of the expression of the putative stem cell markers α6 and β1 integrin 
and the proliferation marker ki-67, marks the nail bed as more terminally 
differentiated. The suprabasal keratin 10 expression, in normal epidermis 
marking terminal differentiation, is replaced by the expression of keratin 6, 
without evident hyperproliferation in the nail bed. Interestingly, in psoriatic 
nails, when there is onycholysis as a result of subungual hyperkeratosis, 
keratin 10 expression returns in the nail bed 19. 
There are two explanations for this phenomenon, although both mechanisms 
might be responsible. First, the nail bed is subject to the constant trauma 
exerted to the nail plate, as there is a very tight adhesion of the nail plate 
to the nail bed. However, this does not explain why the onychocytes in the 
hyponychium, at the most distal part of the nail, regain keratin 10 expression 
as this region of the nail apparatus is under as much stress. More likely, 
the cells of the nail bed are derived from the actively dividing intermediate 
matrix. The constant division of cells pushing the onychocytes of the nail 
between the hard surfaces of the nail plate and the bone of the digit, resulting 
in a stressed cell profile. 
Based on the results described in chapter 2, and in analogy with the 
interfollicular epidermis, we can synthesise a model for onychocyte 
proliferation and differentiation in the human nail apparatus (see figure 
1). The root of the nail apparatus harbours a pool of relatively quiescent 
stem cells, with a relatively low proliferation activity, and high proliferative 
capacity, comparable with the pool of stem cells in the tips of the epidermal 
rete ridges and the bulge of the hair follicle (fig. 1-1) 4;10;20;21. This niche with 
stem cells furnishes the ungular bulge with cells having a high proliferative 
activity, the TAC. The ungular bulge resides in the suprabasal layers of the 
intermediate matrix and can be compared with the suprabasal β1 integrin 
dim cell population in the interfollicular epidermis and the hair follicle bulb 
(fig. 1-2). The TAC in the ungular bulge provide terminally differentiating cells 
to two other compartments. First, the nail plate is formed by compaction of the 
onychocytes after progressive nuclear condensation has occurred (fig. 1-3) 2;22. 
Second, the TAC in the intermediate matrix are the source of the cells of 
the nailbed. The TAC divide, thereby pushing the cells of the more distal 
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part of the intermediate matrix towards the nail bed. There they further 
differentiate, expressing the “stress” keratin 6 (fig. 1-4). Once they reach the 
hyponychium, a hyperkeratotic differentiation pattern with excessive keratin 
10 expression develops (fig. 1-5). 
According to the above mentioned model, the cell population dynamics 
of the human nail apparatus closely resemble the dynamics of the human 
interfollicular epidermis, and the human hair follicle. While the direction of 
proliferation and differentiation in the interfollicular epidermis is vertical, the 
overlying properties of the human nailplate forces the nail cells in a horizontal 
growth pattern. So, the cell population dynamics, and characteristics of 
proliferation and differentiation in the interfollicular epidermis and the nail 
unit are similar. Therefore, the question arises whether the clinical signs of 
psoriatic nails, in particular nail pitting and subungual hyperkeratosis, are 
compatible with changes in epidermal cell populations, as observed in the 
lesional skin of psoriasis patients.
Figure 1: Picture of the hypothetical model of the proliferation and differentiation process in 
the nail unit. The root of the nail plate incorporates a pool of keratin 15/keratin 19 co-express-
ing cells, a reservoir of alleged stem cells (1) supplying the underlying suprabasal layers of the 
intermediate matrix with cells with a high proliferative activity, the so called transit amplifying 
cells which are β1 integrin and ki-67 positive (2). This pool of transit amplifying cells provides
cells that terminally differentiate to the nail bed and nail plate (3). The stressed cells in the nail 
bed abundantly express keratin 6, while there is no keratin 15, ki-67 or keratin 10 expression (4). 
The keratin 10 expression abruptly returns as the nail leaves the nail bed at the hyperkeratotic 
hyponychium (5).
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6.3 
Aim II:
To use the dynamic model of the margin zone in psoriasis to visually 
quantify the subpopulations of epidermal cells, with respect to 
proliferation and differentiation, in their evolution from non-
lesional skin towards lesional skin.
In chapter 3 we used the model of the margin zone in psoriasis to examine 
epidermal cell population dynamics, proliferation, and differentiation in the 
diseased skin. The margin of spreading psoriatic plaques comprises the evolution 
of the psoriatic lesion from distant symptomless skin, representing more early 
changes, as lesional skin presenting more the mature psoriatic lesion. The first 
changes seen, as compared to normal healthy skin, was the disappearance 
of keratin 15 expression in the distant uninvolved skin, 2 centimetres from 
the border of the psoriatic lesion. Keratin 15 is a putative keratinocyte stem 
cell marker, visualising the stem cells at the tips of the epidermal rete ridges 
10;21. Keratin 15 is known to be down regulated in activated keratinocytes, and 
its expression in cultured keratinocytes is directly suppressed by TNF-α, a 
cytokine playing a major role in the pathogenesis of psoriasis 4;23;24. 
Together with this disappearance of keratin 15, a decrease in the relative surface 
of the cell layers expressing β1 integrin was seen in the distant uninvolved 
skin, as compared to the healthy controls. This decrease coincided with the 
expression of one suprabasal layer of β1 integrin dim cells, indicating an 
onset of an increase in the TAC compartment 4;8;9;25. These epidermal changes, 
occurring in the distant uninvolved skin, precede the appearance of T-cell 
subsets, and early changes in stroma and endothelium that occur in the outer 
margin of the psoriatic plaque 26-28.These epidermal changes, occurring before 
the influx of a T-cell infiltrate, shed some doubts on the paradigm of the T-cell 
as the driving force for the development of the psoriatic plaque. These results 
suggest that psoriasis is not only a disease of the immune system or the dermal 
compartment, but that in an early phase of the lesion, keratinocytes show an 
abnormality before the influx of T-cells occurs. The activation of the epidermal 
basal progenitor cells is in part regulated by TNF-α 24.
However, TNF-α levels have not been measured in the distant uninvolved skin, 
but have been shown to be increased in the psoriatic plaque. So, no direct effect 
of this cytokine on the epidermal changes seen in chapter 3 can be proven 29. 
Nevertheless, a direct effect of upregulated TNF-α in the distant uninvolved 
skin could be an explanation for the early epidermal changes we found.
In the transition from the distant uninvolved skin to the outer margin no 
significant changes in the epidermal cell populations were seen. The increase 
in the TAC compartment in the distant uninvolved skin is followed by the 
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appearance of ki-67 positive cells in the suprabasal layers in the outer margin 
of the psoriatic plaque. This indicates further activation of these suprabasal 
layers of the pre-psoriatic epidermis, with actively cycling cells ascending to 
the suprabasal layers, even before overt clinical changes in the skin can be seen. 
The passage from the outer margin to the inner margin of the psoriatic 
plaque coincides with a further significant decrease in the relative cell layers 
expressing β1 integrin. This marks a further increase in the TAC compartment, 
as visualised by an increase in the suprabasal cell layers of β1 integrin dim cells. 
This suprabasal compartment harbours actively cycling cells, as there is also a 
significant increase in ki-67 positive cells in these suprabasal layers of the inner 
margin. The expression of keratin 10, as a marker for normal keratinisation, 
decreases in the inner margin and concurs with a significant increase in 
keratin 6 expressing cells, as could be expected since the expression of the 
“stress” marker keratin 6 is complementary with keratin 10 expression in one 
individual cell 30. In the inner margin cells co-expressing keratin 6 and keratin 
10 can be found at the tips of the dermal papillae. 
In the EPU model, the SC divide and give rise to an immediate progeny of 
TAC, surrounding the SC in the basal layer. Not only cell division in vertical 
direction occurs, but also cell division in horizontal direction occurs, giving 
Figure 2: The margin zone model
A. - Keratin 15 expression in basal cell-layers.
 - Normal suprabasal keratinisation with keratin 10 expression.
 - No keratin 6 expression.
B. - Activation of basal cells.
 - Disappearance of keratin 15 expression.
 - Beginning of the expansion of the transit amplifying compartment.
C. - Suprabasal, actively cycling ki-67+ cells.
 - Further expansion of the transit amplifying compartment.
D. - Further expansion of the transit amplifying compartment.
 - Increased number of suprabasal actively cycling ki-67+ cells.
 - “Patchy” localisation of “stressed” keratin 6 expressing cells.
 - Decreased normal keratinisation.
E. - Further expansion of suprabasal keratin 6 expression.
 - Full blown psoriatic histology.
A B C D E
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rise to TAC in the first suprabasal epidermal layer 4;8;31;32. After the activation 
of the basal progenitor cells, there is an expansion of the TAC compartment in 
the basal and suprabasal cell layers. In the suprapapillary plates a preferential 
expression of keratin 6 and keratin16 is seen as a consistent and classical feature 
of psoriasis 13;33-35. The expression of keratin 6, seen on the suprapapillary plates, 
may be the result of mechanical compression by the expansion of the TAC 
compartment in the epidermal rete ridges, resulting in this stressed phenotype. 
Further in the psoriatic cascade, at the centre of the psoriatic plaque, these 
hyperproliferative “stressed” keratinocytes have migrated suprabasally from 
the tips of the dermal papillae to the rest of the epidermis. Finally, leading to a 
homogeneous epidermal expression of keratin 6. At the centre of the psoriatic 
plaque, cells with single expression of keratin 10 are virtually absent, and the 
whole epidermis is occupied by cells with a single expression of keratin 6, 
and cells co-expressing keratin 6 and keratin 10. At this stage of the psoriatic 
cascade, the whole epidermis is in an activated “stressed” state, clinically visible 
as a full blown psoriatic plaque, and histologically as keratin 6 expression 
throughout the epidermis.
Using the data described in chapter 3, a model can be drawn explaining the 
dynamics of changes in the epidermal cell populations in the pathogenesis of the 
psoriatic plaque (see figure 2). The pre-psoriatic epidermis is first distinguished 
from the normal healthy epidermis by the activation of the basal keratinocytes, 
visualised by an absence of keratin 15 expression. This activation of the basal 
cells coincides with an increase in the TAC compartment, visualised by a 
relative increase in the β1 integrin dim cells (fig. 2B). This TAC compartment 
further increases with a distinct suprabasal cell population with low β1 integrin 
expression. These TAC divide in horizontal and vertical direction (fig. 2C). At 
the inner margin of the psoriatic plaque, this expansion leads to the patchy 
expression of keratin 6 at the dermal papillae, indicating a hyperproliferative, 
“stressed” suprabasal cell population (see fig 2D). In the centre of the psoriatic 
plaque, the whole epidermis is in an activated state, as visualised by a complete 
suprabasal compartment co-expressing keratin 6 and keratin 10 (see fig 2E). 
Whether the initiator of the activation of the basal layer resides in the diverse 
cytokines, as for example TNF-α, the invading T-cells and dendritic cells, or an 
inborn error in the keratinocyte itself remains to be elucidated. 
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6.4 
Aim III:
To quantitatively assess the effects of topical treatment and biologicals 
on clinical scores, epidermal subpopulations, and keratinocyte 
proliferation and differentiation, in patients with moderate to severe 
plaque psoriasis.
In paragraph 6.2 we developed a model to understand the epidermal cell 
population dynamics in the diseased psoriatic skin. In chapter 4 we assessed 
the effects of various treatments on these different epidermal compartments, 
proliferation, and differentiation in psoriasis. Most interestingly, we investigated 
treatments that are supposed to have different modes of action. 
Vitamin D3 derivates, as calcipotriol and calcitriol, are known to reduce 
epidermal hyperproliferation, and to induce epidermal keratinisation in 
psoriasis 36-38. Although probably less pronounced, also an immunosuppressive 
effect of vitamin D3 derivates has been noted 39;40. 
Alefacept inhibits T-cell activation and proliferation, and induces apoptosis 
in memory T-cells 41;42. Because there are no known direct effects of alefacept 
on epidermal keratinocytes, the evaluation of the changes in epidermal cell 
populations after treatment with this biological is extremely suited to assess 
the indirect effects of this treatment on the psoriatic epidermis. 
Etanercept inhibits the pro-inflammatory cytokine TNF-α, a major player 
in the psoriatic cascade. TNF-α is upregulated in psoriasis and is known to 
regulate immune and inflammatory responses 43;44. Although literature is less 
clear on the direct effects of TNF-α on epidermal keratinocytes, there are 
distinct clues that a direct effect of TNF-α exists 24;45;46. 
We wondered if the supposed different anti psoriatic modes of action are 
reflected in different effects on epidermal cell populations, or that a common 
anti psoriatic principle exists. 
Before treatment with any of the four compounds mentioned above, the 
psoriatic plaques of the treated patients exhibited a full blown psoriatic 
histology. There was an absence in keratin 15 expression, a relative decreased β1 
integrin cell compartment with an increased TAC compartment, as visualised 
by the increase of suprabasal β1 integrin dim cells. Suprabasally, an abundant 
co-expression of keratin 6 and keratin 10 was seen, with a marked decrease 
in keratin 10 expression. We treated the various patients in different studies, 
with either a 12 weeks course of etanercept, with 6 weeks of topically applied 
calcipotriol and calcitriol, or 12 weeks with alefacept, partially combined with 
topical calcipotriol. 
In all these patients successful treatment resulted in a decrease in the TAC 
compartment, as visualised by a decrease in the suprabasal layers expressing 
a low level of β1 integrin and a relative increase in the surface area of the cell 
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layers with β1 integrin expression as a percentage of the total surface area of 
the epidermis. This decrease in the TAC compartment was further visualised 
by a decrease in suprabasal, actively dividing ki-67 positive cells. Furthermore, 
there was a shift in the suprabasal compartment, from “stressed” keratin 6 
expressing cells, towards normally differentiated cells expressing keratin 10. In 
patients with an excellent response to treatment also a reappearance in basal 
keratin 15 expression was seen, as a marker for the deactivation of the basal 
progenitor cells. However, there was a difference between the several therapies 
in the timing and extend of these changes. 
Treatment with etanercept resulted first in a fast and impressive re-
appearance of keratin 15 expression in the basal layer, combined with a 
decrease in the TAC compartment. Keratin 15, a putative stem cell marker 
in the interfollicular epidermis and hair follicle bulge, is known to be directly 
suppressed by TNF-α in vitro24. Keratin 15 suppression is also seen in vivo, in 
situations where the epidermis is in a state of activation, as in wounding or 
in the culture of reconstitutative skin 16;23;47. So it is likely that the blockade of 
TNF-α by etanercept deactivates the basal stem cells at the rete ridges of the 
psoriatic epidermis. Our experiment showed this deactivation to be followed 
by a decrease in the actively cycling TAC. Consequently, there was a further 
normalisation of the psoriatic epidermis, with a further decrease of keratin 6 
expressing cells, and an increase in keratin 10 expressing cells. Interestingly, the 
percentage of cells expressing keratin 6 as a marker of “stressed” keratinocytes 
after 6 weeks of topical treatment with calcipotriol decreased more than after 
12 weeks of etanercept treatment, perhaps reflecting the direct effect of vitamin 
D3 derivates on the TAC compartment. 
In the experiment comparing calcipotriol with calcitriol, the latter had a less 
pronounced effect on epidermal cell populations. This difference in effect can 
be explained by the fact that the concentration of the active compound in 
calcitriol ointment is 10 times lower than that of calcipotriol. Also, calcitriol 
has a 30 times higher affinity for the vitamin D binding protein in the blood. 
The biological activity of calcitriol is due to these mechanisms markedly 
decreased, which explains our results 48;49. The mode of action of both vitamin 
D3 derivates is nevertheless the same, and they have a comparable affinity 
for the vitamin D3 receptor. Therefore, in analogy with the margin zone 
model, and because the therapeutic effects of calcipotriol on the dynamics 
of the epidermal cell populations are more pronounced, the changes seen 
after calcitriol treatment, during the same time frame, may represent more 
early changes in epidermal proliferation and differentiation 48. After 6 weeks 
of treatment with calcitriol no quantitative changes in the cell population 
markers mentioned above were seen. However, there was a decrease in the 
TAC compartment, as visualised by a decrease in suprabasal β1 integrin dim 
expressing cells. Furthermore, there was a qualitative shift visible in the keratin 
6 and keratin 10 co-expressing cells towards the cell population with single 
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keratin 10 expression. Six weeks of treatment with the more potent vitamin 
D3 derivate calcipotriol resulted in the almost normalisation of epidermal cell 
populations as described above. This experiment showed vitamin D3 derivates 
to have a preferential effect on the TAC compartment, followed by a reduction 
in stressed suprabasal hyperproliferative keratinocytes, and a trend toward 
normalisation of the terminal differentiation of the suprabasal compartment. 
Our observations are confirmed by an in vitro experiment showing vitamin 
D3 derivates to actively inhibit the formation of holoclones by stimulating 
the progenitor cells into cells with a differentiating phenotype 50. Franssen et 
al also showed, in a flow-cytometric study, a reduction in the cell population 
without keratin 10 or keratin 6 expression after treatment with vitamin D3 
derivates. This population contains SC and TAC. Because SC are quiescent, the 
progenitor cells targeted in both experiments probably are early TAC 51. 
In normal, healthy epidermis the percentage of the cell surface expressing 
keratin 15 as compared to the cell surface of the complete epidermis, reaches 
20% (see chapter 3). After treatment with the biological etanercept, the relative 
cell surface expressing keratin 15 extends to 7%. The relative cell surface of 
keratin 15 reappearing after treatment with calcipotriol reaches 1.7%, which is 
a relatively small increase compared to the healthy situation and after treatment 
with etanercept. The reappearance of keratin 15 after treatment appears to be a 
relatively late effect, occurring after a decrease in the TAC compartment and a 
virtual normalisation of the hyperproliferative, suprabasal compartment. 
A 12 week treatment with alefacept showed an improvement in clinical SUM-
scores. This clinical response was again reflected by a decrease in the TAC 
compartment and the hyperproliferative suprabasal compartment expressing 
keratin 6. Also a normalisation of keratinisation was seen, visible by an increase 
in keratin 10 expression. Interestingly, this trend towards normalisation 
of the suprabasal layers of the psoriatic epidermis was not followed by the 
reappearance of keratin 15 expression, as indication of the deactivation of 
the basal stem cells. Only the two patients with an almost clearance of their 
psoriasis regained keratin 15 expression. 
Alefacept preferentially targets CD45RO+ memory effector T-cells in the 
dermis and epidermis of the psoriatic plaque. This results in the decrease of 
the CD4+ and CD8+ memory effector T-cells in respectively the dermis and 
epidermis and this decrease is correlated with clinical response52. The memory 
effector T-cells in the epidermis are already significantly decreased in number 
after 8 days of treatment 53. Bovenschen et al showed the epidermal response, 
as visualised by a decline in the number of ki-67 positive cells and an increase 
in keratin 10 expression, to occur somewhat later and only to be significant 
after 12 weeks of alefacept treatment 54. This is in accordance with our results.
It is difficult to draw conclusions on the sequence in which the various epidermal 
compartments respond to alefacept therapy, as in our study only biopsies before 
and after 12 weeks of treatment were taken. Because only the patients with virtual 
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clearance of their clinical psoriasis, coinciding with a virtual normalisation of 
their epidermis, regained keratin 15 expression, it seems safe to assume keratin 
15 return to be a relative late phenomenon after the treatment with alefacept. This 
means that during alefacept treatment the reduction in the TAC compartment, 
and a normalisation of the stressed suprabasal compartment, precedes the 
deactivation of the basal progenitor cells. 
To date there is no known evidence on the cell to cell interaction of CD4+ or 
CD8+ T-cells and epidermal keratinocytes 55. The pathogenesis of psoriasis is 
a sophisticated interplay between the keratinocyte, T-cells and an extensive 
array of cytokines. In one study, the addition of CD4+ T-lymphocytes 
induced keratinocyte proliferation in β1 integrin positive and keratin 10 
negative psoriatic keratinocytes. This induction of proliferation in TAC and 
SC keratinocytes was mediated by soluble cytokines as Interferon γ (IFN-γ), 
IL-3, and TNF-α 56. A recent study showed induction of actively cycling ki-
67 positive cells in human foreskin keratinocytes after 72 hours of incubation 
with CD4+ and CD8+ T-cells. This induction was mediated by IFN-γ, IL-4, 
and IL-8, with IFN-γ and IL-8 produced by CD8+ T-cells resulting in a much 
higher number of ki-67 positive cells 57. It is therefore remotely possible that the 
reduction in the subpopulation of epidermal CD8+ memory effector T-cells, 
induced by alefacept, has an effect on the actively cycling TAC population, 
mediated by Th1 cytokines as IFN-γ. 
Macrophages are the main source of TNF-α in the skin. In psoriasis these 
macrophages reside in the papillary dermis 58. Two studies using a mouse 
model showed macrophages to be essential in the development of psoriasis. 
The mice in these studies developed a psoriatic phenotype, without the need 
for T-cells, indicating an IFN-γ independent pathway in the development 
of the psoriatic phenotype. Inhibition of TNF-α in this model led to the 
reduction of the psoriatic phenotype 59;60. Although macrophages are the main 
source of TNF-α in the psoriatic skin, activated keratinocytes are also known 
to produce TNF-α, as are CD4+ dermal and epidermal T-cells 43-45;56. After 
treatment with alefacept a definite reduction in dermal and epidermal CD4+ 
and CD8+ T-cells is seen 53;54. This reduction, combined with the reduction in 
the TAC and suprabasal keratinocytes, leads to a definite reduction in TNF-α 
production in the psoriatic skin, breaking the self sustaining psoriatic cascade. 
This may be a possible explanation for the relatively late reappearance of basal 
keratin 15 expression after alefacept treatment, as TNF-α is known to activate 
the basal progenitor cells, resulting in a suppression of keratin 15 23;24. 
It is attractive to hypothesize that the long term remission in patients responding 
to alefacept therapy and having returning keratin 15 expression is due to the 
deactivation of the basal stem cells. It can be proposed that in patients with 
an activated basal cell compartment, and in the absence of treatment, this 
activation again results in an expansion of the TAC compartment. The cytokines 
produced by these TAC further activate the psoriatic cascade, resulting in a 
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renewed influx of T-cells and a further activation of the psoriatic epidermis. 
This hypothesis would explain why the two patients with a re-appearance of 
keratin 15 were still in remission after 11 months of alefacept therapy.
To summarise the findings, we may conclude that the margin zone model, 
as postulated in paragraph 6.2, is further validated by the results in chapter 
4. Successful treatment with either topical vitamin D3 derivates, alefacept, 
or etanercept reverses the psoriatic phenotype. The various treatments, with 
their specific modes of action, also directly or indirectly affect different cell 
compartments in the psoriatic skin (see figure 3). Etanercept blocks TNF-α, 
thereby indirectly deactivating the basal stem cell population (fig 3-I). The 
vitamin D3 derivates calcitriol and calcipotriol directly affect the early TAC 
population, redirecting these cells directly from a hyperproliferative “stressed” 
state into the terminally differentiating cell compartment (fig 3-II). With the 
less potent vitamin D3 derivate calcitriol resulting in less impressive changes 
in cell population dynamics in the same time frame. Finally, treatment with 
alefacept is known to mainly affect the dermal and epidermal memory-
effector T-cells. This probably results in a decrease in Th1 cytokines as IFN-γ 
and TNF-α. This results in a somewhat slower normalisation of the TAC and 
suprabasal hyperproliferative cell compartment, and later in the deactivation 
of the basal stem cell compartment (fig 3-III). Reappearance of keratin 15 
seems to predict clinical response during etanercept treatment and possibly 
predicts long term remission after alefacept treatment.
Figure 3: Sites of action of different treatments of psoriasis.
Chapter 6 - General Discussion
144
6.5 
Aim IV:
To evaluate the changes in clinical nail pathology, in patients with 
plaque psoriasis and moderate to severe nail involvement, during 
systemic treatment with alefacept.
The in paragraph 6.1 proposed model of the dynamics in the diverse cell 
populations in the nail apparatus parallels the cell population dynamics in the 
interfollicular epidermis. In this model a compartment of quiescent progenitor 
stem cells gives rise to a population of more rapidly dividing TAC, which in 
turn terminally differentiate to form the stratum corneum in the interfollicular 
epidermis, and the nail plate in the nail unit. In paragraph 6.2 we used the 
quantitative Zenon labelling technique to visualise the changes in the diverse 
epidermal cell populations in the initiation from normal to full blown psoriatic 
epidermis. 
The frequency in which patients with skin psoriasis also have nail symptoms 
is estimated to reach 80% 61-63. Although the literature on the normal healthy 
development of the nail is rather scarce, the literature on the disturbances in 
the various cell compartments of the nail apparatus is almost non-existent. 
In 1969 Zaias performed a clinical pathologic study on psoriatic nails 64. In 
that time it was believed that the nail bed had a significant contribution to the 
nail plate formation 2. As a result, traditionally the clinical nail aberrations in 
nail psoriasis are divided in changes derived from nail bed and nail matrix 
psoriasis.
In analogy with both models, as proposed in chapter I and II, it would be 
attractive to speculate that in nail psoriasis also an activation of the stem cells 
in the nail root leads to an enlarged, rapidly dividing TAC compartment in the 
intermediate matrix, resulting in a disturbed terminal differentiation in the 
nail plate and nail bed. Such a model could provide a better understanding in 
the pathogenetic process of nail psoriasis. 
Nail psoriasis is difficult to treat, and in paragraph 6.3 we have shown two 
biologicals to normalise the epidermal cell characteristics in skin psoriasis. 
Although it would be more interesting to access the effects of this treatment 
on the diverse cell populations in the nail unit, the removal of a part of the 
nail apparatus is considered unethical as it requires a rather painful procedure 
and carries the risk of permanent nail dystrophy 65;66. Therefore in chapter 5 
we investigated the effect of a 12 weeks course of alefacept on the clinical nail 
psoriasis scores as a representation of histological changes. 
In this study 40% of the patients had 25% or more improvement in their 
nail psoriasis symptoms, while 40% of the patients in our treatment group 
reached a PASI improvement of 50% (PASI 50). We can conclude that both 
the nail psoriasis symptoms and the skin psoriasis symptoms improve, but 
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that the improvement of the skin symptoms is more pronouced. The response 
of alefacept therapy on the skin symptoms was somewhat less compared to 
literature, although the small size of our treatment group make the results 
difficult to compare 42;67. Only one case serie on the effect of alefacept treatment 
on nail psoriasis has been published. In this report similar results were found. 
However, 4 out of the 6 patients treated in this experiment had only minimal 
nail psoriasis as reflected by a NAPSI of maximal 12 (out of maximal 80) 68. 
This raises the question whether there was treatable nail psoriasis in this study 
to begin with 69. Our study was confined to a relatively small group of patients 
having significant nail psoriasis, as defined by a minimum NAPSI of 15. As 
shown in the general introduction, there are relative little studies on the effects 
of systemic treatment on nail psoriasis. When comparing our result from 
alefacept treatment with the two trials assessing the effects of cyclosporine 
and etretinate on nail psoriasis, we can draw 2 conclusions. First, the clinical 
effect of alefacept treatment is comparable with the treatment of cyclosporine 
or etretinate, with nail psoriasis improving in about 40-50% of the patients. 
Secondly, as after treatment with cyclosporine, the skin symptoms improved 
more than the nail symptoms 70;71.
Because nails roughly grow 3 mm/month, and although psoriatic nails grow 
faster, the 12 weeks of treatment in both our study and the other mentioned 
studies probably is too short to access the final effects of these treatments 72-74. 
Possibly a treatment period with alefacept of 24 weeks would result in a more 
extensive improvement in nail pathology. Also the diverse treatment outcomes 
are difficult to compare, as until recently a good instrument to measure changes 
in psoriatic nail pathology was not available. This made the comparison of 
the outcomes of the diverse treatments difficult 75. Recently, in analogy with 
the PASI, the Nail Psoriasis Severity Index was introduced as a reproducible, 
objective, and relatively simple tool for the evaluation of nail psoriasis. This not 
only makes the comparison of the diverse treatment outcomes possible, but 
also gives insight in the seriousness of pre-treatment nail psoriasis76;77. 
Recently, infliximab has shown to be quite effective in the treatment of nail 
psoriasis with almost 45% of the patients reaching clearance of their nail 
psoriasis after 50 weeks of treatment 62. This response was reflected by an 
enormous improvement in quality of life, reflecting the underestimated burden 
a lot of patients experience from their nail psoriasis 61;78.
In the light of these recent advances the biological therapies provide us with 
new, effective, and simple means to treat nail psoriasis, while avoiding the short 
and long term side effects of, for example, cyclosporine. Alefacept seems to be 
less promising for the treatment of both nail and skin psoriasis, although no 
studies accessing the long term effects of alefacept in nail psoriasis have been 
performed. This is for alefacept even more important, because alefacept has 
been shown to have a relatively late effect on psoriasis and its strength lies in 
the possible long term remissions that have been achieved 67. More studies on 
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the effects of potent biologicals as etanercept, adalimumab, and more recently, 
ustekinumab on nail psoriasis are needed. Furthermore, we can imagine the 
treatment with biologicals being reserved for severe cases of nail psoriasis or 
when there is an indication because of moderate to severe skin psoriasis or 
psoriatic arthritis. 
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6.6 Conclusion and future suggestions
In the recent years a lot of progress has been made that increased the knowledge 
on the immunopathogenesis of psoriasis. The induction and propagation 
of the psoriatic cascade is a complex interplay of keratinocytes, diverse 
immunocytes, and a multitude of cytokines, resulting in a full blown psoriatic 
plaque. A recent article places the cytokine network, and its interactions with 
the diverse cell types, in the most complex category, only being matched by 
social networks and the world-wide-web 79.  
In this thesis the novel Zenon labelling technique has been used to develop and 
validate two models explaining the cell population dynamics in the healthy 
nail apparatus, and the margin zone model in psoriasis. Both models share 
the same cell compartments, and although the direction of proliferation and 
differentiation differs, there are many similarities in cell population dynamics, 
proliferation, and differentiation. We have shown that various treatments, each 
with their own mode of action, target different parts of the psoriatic cascade, 
but share the reversal of the cell population dynamics as seen in the margin 
zone model (see fig 3). Finally, we have shown one of these treatments to 
be effective on nail psoriasis and on the skin symptoms in psoriasis, which 
possibly can be explained by the models proposed earlier in this thesis.
The histology and the dynamics of the diverse cell populations in the nail 
apparatus have not been subject to ample study. After marking the root of the 
nail as a possible stem cell niche, research is needed to further characterise this 
population of cells. Various putative stem cell markers have been proposed, 
for example CD34 and MTS24 80;81. It would be very interesting to see whether 
these putative stem cell markers are also expressed in the root of the nail 
apparatus, confirming our results. The next step in the identification and 
characterisation of the stem cells in the root of the nail apparatus is to isolate 
these cells and grow them in culture. One of the characteristics of stem cells is 
their ability to form holoclones. The attempts to isolate and grow these cells in 
culture could be hampered, first by the difficulty to obtain viable root cells. It is 
also the question if these cells, when placed outside their niche, still behave as 
stem cells. Because of the location at the most proximal part of the nail plate, 
it is conceivable that root stem cells can be found at the most proximal part of 
an extracted nail plate, providing easy access to these cells. 
At this moment the knowledge of the pathogenetic process involved in psoriatic 
nails, and the cell population dynamics in the diseased nail is virtually absent. 
It would be interesting to test the hypothesis that the psoriatic nail is the result 
of an activated stem cell compartment resulting in the expansion of the TAC 
population and finally in a disturbed terminal differentiation. It would be 
rather simple to test this hypothesis using the quantitative Zenon labelling 
technique, in combination with multiparameter imaging techniques as used 
in this thesis. This attempt would probably be hampered by the difficulty to 
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obtain material from psoriatic patients. 
When investigating the effects of treatment with the relatively new and 
innovative biological therapies, the focus has been on the effects of the 
treatment on cytokine production and T-cell subsets. When the effects on 
epidermal proliferation and differentiation was evaluated this was done by 
looking at keratin 6/16 expression, as a marker of epidermal hyperproliferation. 
Our research indicates that the main target of the three treatments is not the 
suprabasal cell compartment, but the activated basal stem cell compartment, 
and the TAC compartment. It seems therefore logical to use markers, visualising 
the dynamics in these compartments at various time points, to appraise the 
effects of these treatments on the epidermis in further studies. At this moment 
it remains the question which compartment directly or indirectly is targeted 
by more or less recently developed biologicals as infliximab, adalimumab, and 
ustekinumab. Elucidation of this question also would shed more light on the 
role of the keratinocyte in the development and maintenance of the psoriatic 
phenotype. 
As more information on the economic and psychosocial burden of psoriasis 
becomes available, more and more patients are treated with expensive, 
innovative biological treatments. Because psoriasis is a heterogenetic skin 
disease and a definite cure still has to be found, not all patients respond to a 
treatment. Sometimes various biologicals have to be tried before an effective 
treatment has been found. In the line of the increasing costs and to minimise 
treatment failure it would be great to have a method to predict treatment 
outcome in an early stage of the treatment. We showed the reappearance 
of keratin 15 to be a potential marker, predicting treatment success at the 
longer term, and possibly even foresee long term remission. It would be very 
interesting to see whether this is also true in large patient groups being treated 
with anti TNF-α therapy and the newer IL12/23 blocking agents. If this is the 
case, a relative inexpensive and rapid method to predict treatment success 
would become available, making it possible to efficiently tailor the treatment 
to the individual psoriasis patient. 
To date no effective topical or systemic treatment for nail psoriasis exists, while 
nail psoriasis definitely has a profound effect on quality of life, and effective 
treatments are urgently needed. In the light of the recent remissions in nail 
psoriasis induced by infliximab, further investigation on the effects of the 
other biologicals on nail psoriasis is required. Especially as the new biologicals 
adalimumab and ustekinumab theoretically should be effective in treating 
nail psoriasis, as their efficacy on skin psoriasis approaches infliximab. These 
biologicals are much easier to administer, and hold a much more reduced 
risk of allergic reactions than infliximab. Possibly, these treatments hold the 
promise of a safe long term treatment in patients experiencing an extensive 
reduction in their quality of life because of their nail psoriasis.
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7.1 Summary
The growth and maintenance of the human skin and its appendages is 
warranted by the constant, dynamic changes in epidermal cell populations, 
epidermal proliferation, and differentiation. In normal, healthy epidermis 
there is a delicate balance between the production of young basal cells, and 
the shedding of terminally differentiated epidermal scales at the surface of 
the skin. In skin diseases like psoriasis, this balance is disturbed, resulting in 
changes in the various epidermal cell compartments. 
In this thesis we investigated the dynamics of epidermal cell populations in 
healthy, diseased skin, and its appendages using a novel quantitative imaging 
technique. Furthermore, we assessed the effects of various treatments on the 
changes in these cell compartments. Four major aims were dealt with in the 
various chapters in this thesis:
I  To identify cells with stem cell characteristics in the human nail apparatus 
and to visualize their progeny of proliferating and differentiating cells, 
in order to develop a model for proliferation and differentiation of the 
human nail.
II To use the dynamic model of the margin zone in psoriasis to visually 
quantify the subpopulations of epidermal cells, with respect to 
proliferation and differentiation, in their evolution from non-lesional 
skin towards lesional skin.
III To quantitatively assess the effects of topical treatment and biologicals on 
clinical scores, epidermal subpopulations, and keratinocyte proliferation 
and differentiation, in patients with moderate to severe plaque psoriasis.
IV To evaluate the changes in clinical nail pathology, in patients with plaque 
psoriasis and moderate to severe nail involvement, during systemic 
treatment with alefacept.
In chapter 1 a general introduction is given on the human skin and the cell 
populations in the epidermis. This is followed by a description of the nail 
apparatus and the current knowledge on the cell populations in the nail unit. 
In addition, a comprehensive overview is given on psoriasis, and the influence 
of this skin disease on the epidermal cell populations, proliferation, and 
differentiation. Finally the various treatments for psoriasis, and where relevant 
for this thesis, their influence on the epidermal cell population dynamics is 
presented.
In chapter 2 we used classic immunohistochemistry and the Zenon labelling 
technique to visualise the various cell populations in the human nail apparatus. 
We found the root of the nail apparatus to harbour cells co-expressing the 
putative stem cell markers keratin 15 and keratin 19. These putative stem cells 
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gave rise to a compartment of transit amplifying cells in the intermediate matrix, 
the ungular bulge. These cells were visualised by the suprabasal expression of 
α6 and β1 integrin, and an increased number of actively cycling ki-67 positive 
cells. These transit amplifying cells in the ungular bulge of the intermediate 
matrix provide terminally differentiated cells to both the nail plate and the nail 
bed. The nail plate is formed by compaction of these onychocytes. The cells in 
the ungular bulge divide in the direction of the nail bed, thereby pushing the 
cells between the hard surfaces of the bone and the nail plate, resulting in a 
stressed cell profile with abundant keratin 6 expression. We proposed a model 
of proliferation from stem cell to terminal differentiated cell in the nail unit.
In chapter 3 we studied the epidermal cell population dynamics, proliferation, 
and differentiation in the margin zone model, to assess the changes in these 
epidermal cell populations, in the evolution from distant symptomless skin 
towards the mature psoriatic plaque. We found the first step in the development 
of the psoriatic plaque to be the activation of the basal progenitor cells, as 
visualised by the disappearance of keratin 15 expression at the tips of the 
epidermal rete ridges. This activation was followed and coincided with an 
expansion of the TAC compartment. This expansion was characterised by a 
suprabasal expression of β1 integrin dim cells and a relative decrease in the 
cell surface area expressing β1 integrin. Also an increased number of actively 
cycling, ki-67 positive cells was seen in these suprabasal epidermal cell layers. 
The rapid extension of these TAC exerted pressure to the suprabasal cells in 
the thin suprapapillary plates, resulting in a local, patchy expression of the 
stress related keratin 6. Finally, the expression of keratin 10, as a marker for 
normal terminal differentiation, was replaced by keratin 6 expression in the 
entire epidermis, culminating in a full blown psoriatic plaque.
In chapter 4 we investigated the effects of three different anti-psoriatic 
treatments, each having its own mode of action on epidermal cell populations 
in the psoriatic epidermis. We wondered whether these different modes of 
action were reflected in different effects on the epidermal cell populations 
or that they relied on a common anti-psoriatic principle. We found that 
successful treatment with all these medications resulted in the de-activation of 
the basal layer, as visualised by the reappearance of basal keratin 15 expression. 
This coincided with a decrease in the TAC compartment, visualised by a 
decrease in the suprabasal cell layers having low β1 integrin expression, and 
a decreased number of suprabasal ki-67 positive nuclei. Also a normalisation 
of the suprabasal compartment was seen with replacement of keratin 6 
expression by keratin 10 expression. The various treatments differed in the cell 
compartment targeted. Etanercept targeted the basal progenitor cells, resulting 
in a rapid return of keratin 15 expression, followed by a decrease in the TAC 
compartment, and eventually the suprabasal compartment. The vitamin 
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D3 derivates had a preferential effect on the early TAC, resulting first in a 
decrease of this compartment, and followed by the de-activation of the basal 
compartment and a normalisation of the suprabasal cell compartment. Which 
cell compartment was targeted by alefacept was not fully clear, but alefacept 
treatment resulted first in a normalisation of the TAC and the suprabasal 
compartment, which was followed by the deactivation of the basal progenitor 
cells. Keratin 15 has shown to reappear only in those patients responding to 
alefacept or etanercept treatment. After alefacept treatment this reappearance 
predicted long term remission. The reappearance of keratin 15 expression after 
4 weeks of etanercept treatment proved to predict good clinical response in 
these patients after 24 weeks of treatment.
In chapter 5 we evaluated the response of clinical nail psoriasis to systemic 
treatment with alefacept. We concluded that the improvement of clinical nail 
psoriasis symptoms after treatment with alefacept was less pronounced than 
the improvements seen in skin psoriasis symptoms. Also the improvements 
in nail psoriasis symptoms were comparable with the improvements in 
clinical nail psoriasis seen after treatment with cyclosporine or etretinate. We 
concluded that long-term studies on the effects of the diverse biologicals are 
needed, as they hold the promise for a safe, and possibly non-toxic treatment 
of nail psoriasis.
In chapter 6 the general discussion is presented, in which the observations 
from chapters 2-5 are integrated and positioned in the context of recent 
literature. We recapitulated the model proposed in chapter 3 and integrated 
the results of chapter 4 in this model, thereby offering insight in the different 
modes of action of the various treatments. At last, final conclusions are drawn 
and some suggestions for future investigation are made. 
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7.2  Samenvatting
De groei en herstel van de menselijke huid en zijn adnexen vindt plaats door 
constante veranderingen in epidermale celpopulaties, epidermale proliferatie 
en differentiatie. In de normale, gezonde epidermis bestaat een delicate balans 
tussen de productie van jonge basale cellen en het afschilferen van terminaal 
gedifferentieerde epidermale cellen aan het oppervlak van de huid. Bij hu-
idziekten zoals psoriasis is deze balans verstoord, hetgeen resulteert in veran-
deringen in de diverse epidermale celcompartimenten.
In dit proefschrift onderzochten we de dynamische veranderingen in epider-
male celpopulaties in gezonde en zieke huid en zijn adnexen. We gebruikten 
hiervoor een nieuwe visualisatie techniek waarmee kwantitatieve veranderin-
gen kunnen worden gemeten. Verder gebruikten we deze techniek om de ef-
fecten van verschillende behandelingen op de veranderingen in deze diverse 
celcompartimenten te onderzoeken. In de verschillende hoofdstukken in dit 
proefschrift werden de volgende vier doelen behandeld:
I Het identificeren van cellen met stamcel eigenschappen in het humane
  nagelapparaat, waarbij we tevens het nageslacht van prolifererende en 
 differentiërende cellen in beeld brengen. Dit teneinde een model te 
 ontwikkelen waarmee we het proces van proliferatie en differentiatie 
 in de humane nagel kunnen beschrijven.
II Het visueel kwantificeren van de subpopulaties van de epidermale 
 cellen, met de nadruk op proliferatie en differentiatie, in hun ontwikkeling
 van niet lesionale naar lesionale psoriasis huid, gebruik makend van 
 het dynamische model van de randzone in psoriasis.
III Het kwantitatief bepalen van de effecten van topicale behandelingen 
 en behandelingen met biologicals, op klinische scores, epidermale
 subpopulaties en proliferatie en differentiatie van keratinocyten
 bij patiënten met matige tot ernstige plakpsoriasis.
IV Het evalueren van de veranderingen in nagelpathologie, tijdens de
 behandeling met alefacept, bij patiënten met plakpsoriasis en matige
 tot ernstige aantasting van de nagels.
In hoofdstuk 1 geven we een algemene introductie over de humane huid en 
de celpopulaties in de epidermis. Vervolgens beschrijven we het nagelapparaat 
en de huidige stand van zaken met betrekking tot celpopulaties in het nagelap-
paraat. Verder presenteren we een kort overzicht over psoriasis en de invloed 
van deze huidziekte op epidermale celpopulaties, proliferatie en differentiatie. 
Tenslotte worden de diverse behandelingen voor psoriasis en, waar relevant 
voor dit proefschrift, hun invloed op de diverse epidermale celpopulaties be-
schreven.
Chapter 7 - Summary & Samenvatting
162
In hoofdstuk 2 hebben we klassieke immunohistochemische technieken en 
de Zenon labelling techniek gebruikt om de verschillende celpopulaties in 
het human nagelapparaat te visualiseren. In de wortel van het nagelapparaat 
vonden we cellen die zowel keratine 15 als keratine 19 in één cel tot expressie 
brachten (zogenaamde co-expressie). Deze mogelijke stamcellen verzorgden 
een compartiment met zogenaamde “transit amplifying cellen” (TAC) in de 
intermediaire nagelmatrix, de “ungular bulge.” Deze “transit amplifying cellen” 
werden gevisualiseerd door hun suprabasale expressie van α6 en β1 integrine 
en een toegenomen aantal actief delende, ki-67 positieve cellen. De nagelplaat 
en het nagelbed worden beide gevoed door de cellen uit de “ungular bulge.” De 
nagelplaat wordt gevormd door het samendrukken van deze cellen. De cellen 
in de “ungular bulge” delen in de richting van het nagelbed. Hierdoor worden 
de cellen tussen de harde oppervlakken van de nagelplaat en het bot geperst, 
wat resulteert in een gestrest celprofiel, met overvloedige keratine 6 expressie. 
Tenslotte ontwikkelden we een model om de proliferatie van stamcel tot termi-
naal gedifferentieerde cel in het nagelapparaat te verklaren.
In hoofdstuk 3 bestudeerden we de dynamiek in epidermale celpopulaties en 
de proliferatie en differentiatie in het randzone model teneinde de verander-
ingen in deze celpopulaties te meten, in de overgang van niet aangedane huid 
op afstand van de psoriasis plak naar de volwaardige psoriasisplak. We vonden 
dat de eerste stap in de ontwikkeling van de psoriasis plak de activatie van de 
basale voorloper cellen was, welke zichtbaar was als het verdwijnen van de 
basale keratine 15 expressie op de toppen van de epidermale retelijsten. Deze 
activatie werd gevolgd en ging deels samen met een expansie van het TAC 
compartiment. Deze expansie werd gekarakteriseerd door een suprabasale 
expressie van β1 integrine zwak positieve cellen en een relatief kleiner cel op-
pervlak dat β1 integrine tot expressie bracht. Er werd tevens een toegenomen 
aantal ki-67 positieve cellen gezien in deze suprabasale epidermale lagen. Het 
snelle uitbreiden van dit TAC compartiment oefent druk uit op de dunne su-
prapapillaire platen, wat resulteert in een lokale, vlekkerige expressie van het 
stress gerelateerde keratine 6. Uiteindelijk werd de expressie van keratine 10, 
als een marker voor normale terminale differentiatie, vervangen door keratine 
6 expressie in de gehele epidermis, uiteindelijk resulterend in een volledige 
psoriasisplak.
In hoofdstuk 4 bestudeerden we het effect van 3 verschillende behandelingen 
voor psoriasis, met elk een eigen actiemechanisme, op de epidermale celpopu-
laties in de psoriatische epidermis. We vroegen ons af of het verschil in deze 
actiemechanismen zou worden gereflecteerd in verschillende effecten op de 
epidermale celpopulaties of dat deze effecten gebaseerd zouden zijn op een 
gemeenschappelijk anti-psoriatisch principe. We vonden dat succesvolle be-
handeling met al deze medicijnen resulteerde in een deactivatie van de basale 
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laag, welke werd gevisualiseerd door het terugkomen van de basale keratine 
15 expressie. Dit ging samen met een afname van het TAC compartiment, 
welke werd gevisualiseerd door een afname in de suprabasale cellagen met een 
zwakke β1 integrine expressie en een afname in het aantal suprabasale ki-67 
positieve celkernen. Er werd tevens een normalisatie gezien van het supraba-
sale compartiment, waarbij keratine 6 expressie werd vervangen door keratine 
10 expressie. De diverse therapieën verschilden in het celcompartiment waarop 
werd aangegrepen. Etanercept greep aan op het basale celcompartiment, het-
geen resulteerde in het snel terugkomen van de keratine 15 expressie, gevolgd 
door een afname van het TAC compartiment, en uiteindelijk het suprabasale 
compartiment. De vitamine D derivaten hadden een preferentieel effect op de 
vroege TAC, welke eerst resulteerde in een normalisatie van dit compartiment 
en werd gevolgd door een deactivatie  van het basale compartiment en een 
normalisatie van het suprabasele celcompartiment. Op welk celcompartiment 
alefacept aangreep was niet volledig duidelijk, maar behandeling met alefacept 
resulteerde in de eerste plaats in een normalisatie van de TAC en het supraba-
sale compartiment, hetgeen werd gevolgd door een deactivatie van de basale 
voorlopercellen. Keratine 15 keerde echter alleen terug bij die patiënten die 
goed reageerden op behandeling met alefacept of etanercept. De terugkeer van 
keratine 15 expressie na 4 weken behandeling met etanercept bleek een goede 
voorspeller van de klinische respons in deze patiënten na 24 weken.
In hoofdstuk 5 evalueerden we het effect van systemische behandeling met 
alefacept op klinische nagelpsoriasis. We concludeerden dat de verbetering in 
klinische symptomen van nagelpsoriasis minder uitgesproken was dan de ver-
beteringen in de symptomen van de huid. Tevens waren de verbeteringen in de 
nagelpsoriasis vergelijkbaar met de verbeteringen in studies met ciclosporine 
en etrinate. We concludeerden dat lange termijn studies naar de effecten van 
de verschillende biologicals op nagelpsoriasis nodig zijn, daar deze in de toe-
komst een veilige en niet toxische behandeling van nagelpsoriasis zouden kun-
nen bieden.
In hoofdstuk 6 worden in de algemene discussie de observaties van hoofd-
stukken 2-5 geïntegreerd en gepositioneerd in de context van de recente lit-
eratuur. We recapituleerden het model uit hoofdstuk 3 en integreerden de 
resultaten van hoofdstuk 4 in dit model, waardoor de verschillende werkings-
mechanismen van de verschillende therapieën inzichtelijk werden. Tenslotte 
worden slotconclusies getrokken en enkele suggesties voor toekomstig onder-
zoek gedaan.
 164
165
List of Publications
&
Curriculum Vitae
 166
 167
List of Publications
J.E.M. Körver, M.W.F.M. van Duijnhoven, M.C. Pasch, P.E.J. van Erp, 
P.C.M. van de Kerkhof.
Assessment of epidermal subpopulations and proliferation in healthy skin, 
symptomless and lesional skin of spreading psoriasis. 
Br J Dermatol, 2006 Oct;155(4): 688-94.
J.E.M. Körver, A.M.G. Langewouters, P.C.M. van de Kerkhof, M.C. Pasch. 
Therapeutic effects of a 12 week course of alefacept on nail psoriasis.  
J Eur Acad Dermatol Venereol. 2006 Nov;20(10): 1252-5.
J.E.M. Körver, P.C.M. van de Kerkhof, M.C. Pasch. 
Alefacept treatment of psoriatic nail disease, how severe should nail psoriasis 
be? 
J Am Acad Dermatol. 2006 Apr;54(4): 742-3.
J.E.M. Körver, W.H.P.M Vissers, D.W. van Rens, J.B.M. Boezeman, M.C. 
Pasch, P.E.J. van Erp, P.C.M. van de Kerkhof. 
A double blind, randomized, quantitative comparison of calcitriol ointment 
and calcipotriol ointment on epidermal cell populations, proliferation and dif-
ferentiation. 
Br J Dermatol. 2007 Jan;156(1): 130-7.
J.E.M. Körver, A.M.C. Bos, I.M.J.J van Vlijmen-Willems, P.E.J. van Erp, 
P.C.M. van de Kerkhof, M.C. Pasch. 
Co-expression of the putative stem cell markers keratin 15 and keratin 19 in 
the root of the nail apparatus; a third niche for epithelial stem cells? 
Submitted
J.E.M. Körver, M.A.M. Berends, D.W.A. van Rens, M.C. Pasch, E.M.G.J. de 
Jong, P.E.J. van Erp, P.C.M. van de Kerkhof. 
Reappearance of keratin 15 predicts clinical response in psoriasis patients dur-
ing etanercept treatment. 
Submitted
R.G. van Lingen, J.E.M. Körver, P.C.M. van de Kerkhof, M.A.M. Berends, 
D.W.A. van Rens, A.M.G. Langewouters, J.B.M. Boezeman, M.M. Seyger, 
E.M.G.J. de Jong. 
Relevance of compartmentalization of T-cell subsets for clinical improvement 
in psoriasis: effect of immune-targeted antipsoriatic therapies. 
Br J Dermatol. 2008 Jul;159(1): 91-6.
 168
M.W.F.M. van Duijnhoven, J.E.M. Körver, W.H.PM. Vissers, I.M.J.J van 
Vlijmen-Willems, M.C. Pasch, P.E.J. van Erp, P.C.M. van de Kerkhof. 
Effect of calcipotriol on epidermal cell populations in alefacept-treated psori-
atic lesions. 
J Eur Acad Dermatol Venereol. 2006 Jan; 20(1):27-33.
E.N. Kop, J.E.M. Körver, D. van Ruysevelt, E.M.G.J. de Jong, P.G.M. van der 
Valk, P.C.M. van de Kerkhof .
Erythroderma in two patients with psoriasis upon discontinuation of efalizu-
mab treatment.
J Dermatolog Treat. 2009; 20(1): 67-9.
H.J. Bovenschen, J.E.M. Körver, P.G.M van der Valk.
Contact dermatitis to self-tanning products
Contact Dermatitis. In press
 169
Curriculum Vitae
John Körver werd op 17 februari 1973 geboren in Heerlen. Na een verhuizing 
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Dankwoord
Het schrijven van een proefschrift is als een reis, waarbij het aantal reisgenoten 
gaande over de weg alleen maar toeneemt en waarbij heel veel mensen elk hun 
bijdrage leveren. Soms is deze bijdrage heel duidelijk, soms wat minder. Zonder 
al deze reisgenoten was ik echter waarschijnlijk al in een vroeg stadium ver-
dwaald. 
Er zijn twee dingen die een dankwoord kenmerken; het is waarschijnlijk het 
meeste en als eerste gelezen stuk in een proefschrift en er wordt vrijwel altijd 
iemand in vergeten. Dus voor ik een aantal reisgenoten met naam en toenaam 
ga noemen wil ik iedereen die in enige mate heeft bijgedragen aan dit boekje 
bedanken, jullie zijn echt niet vergeten!
Allereerst wil ik natuurlijk mijn promotor Prof. dr. dr. P.C.M. van de Kerkhof 
bedanken voor de mogelijkheid om dit promotieonderzoek te verrichten. Beste 
Peter, bedankt voor je enthousiasme, je vertrouwen en je opbeurende woorden 
wanneer de zoveelste kleuring (weer) mislukt was. Je deur was altijd open, hoe 
druk je ook was. Je energie is schijnbaar onuitputtelijk en daardoor was je de 
motor achter dit proefschrift.
Natuurlijk wil ik verder mijn 2 copromotores Dr. M.C. Pasch en Dr. P.E.J. van 
Erp bedanken. Marcel, je hebt het voor elkaar gekregen om me te interesseren 
voor een stukje van de menselijke huid waar weinigen iets mee op hebben; de 
nagel. Je kritische reflectie, gecombineerd met je humor hebben een grote bij-
drage aan dit proefschrift geleverd. Piet, de open deur zegt veel over hoe je was; 
toegankelijk. Ik verbaas me er dan nog steeds over dat de onderwerpen van onze 
gezamenlijke hobby nooit van je kamer zijn ontvreemd. Bedankt voor je inspi-
rerende inbreng en je kritische en reflecterende opmerkingen. Ik hoop dat ik 
nog vaak bij je binnen mag lopen om leuke gadgets te showen of te bewonderen. 
Alle labmedewerkers wil ik bedanken voor hun ondersteuning. Vooral Ivonne, 
Desiree en Mieke wil ik bedanken. Ivonne, zonder jou waren de nagels nog 
steeds geweest wat ze eerst waren, een groot stuk ijs van -80oC, bedankt voor al 
het nagelvoorwerk en je hulp in de begintijd in het lab. Desiree, je kreeg het voor 
elkaar om i.p.v. 1 biopt, 4 biopten per dag te kleuren, zonder jou had het dus 16 
jaar geduurd voor mijn proefschrift af was geweest, bedankt voor het vele werk 
dat je hebt verzet. Mieke, zonder jou was het lab niet alleen een rommeltje ge-
weest, je was er ook altijd als er iets te vragen was, dank je daarvoor.
Marisol, al die patiënten die gezien moesten worden voor onderzoek waren bij 
jou in goede handen, net als wij. Door jou werd labwerk en computerwerk af-
gewisseld met gezellige uurtjes met koffie. Dank je voor deze tijd en de fijne 
samenwerking.
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Mijn onderzoekskamergenoten Tsjing en Gijs wil ik bedanken voor zowel de 
steun als de welkome afleiding. Tsjing, je muizen fluoresceerden minder dan 
mijn coupes, maar je m&m’s waren van een onvergetelijke kwaliteit, evenals je 
verhalen. Ik hoop dat het je gaat bevallen in de “Big Apple.” Gijs, Je statistische 
hulp werd alleen overtroffen door je kennis ervan. Dat ik het niet altijd snapte 
lag dan ook geheel aan mij. Je humor maakte onze discussies over een open of 
gesloten deur meer dan goed ;-).
Ook mijn huidige en ex-kamergenoten, Maartje, Demia en Marloes wil ik 
bedanken voor de gezellige sfeer, maar ook de steun bij het schrijven van de 
laatste stukken van dit proefschrift. Eindelijk is het gemopper op die computer 
voorbij.
Al mijn onderzoekscollega’s, bedankt voor de fijne samenwerking en jullie nut-
tige inbreng en kritische reflectie tijdens de LOTO. 
Jan Boezeman bedankt voor al die keren dat je geprobeerd hebt om me de 
statische onderbouwing uit te leggen.
Annemieke, bedankt voor het kleuren en vooral ook het onmogelijke snijden 
van de nagels. Dat je er tussendoor ook nog je levenspartner hebt ontmoet is 
dan alleen nog maar mooi meegenomen en geheel in de stijl van de afdeling.
Natuurlijk wil ik ook de hele staf bedanken. De goede opleidingssfeer is vooral 
te danken aan jullie toegankelijkheid, interesse en enthousiasme. Carine, Dick, 
Elke, Marcel, Marieke, Michelle, Pieter en Rianne bedankt hiervoor.
Prof. E. Haneke, beste Eckart, je enthousiasme voor ons vak is aanstekelijk, 
bijzonder hoe iemand kan inspireren door er gewoon te zijn. Bedankt voor je 
continue interesse voor mijn nagelonderzoek.
Ook de dermatologen en doktersassistenten van de afdeling Dermatologie van 
het Canisius Wilhelmina Ziekenhuis wil ik bedanken voor de goede werksfeer. 
Bert, Hans en Nico, bedankt voor jullie enthousiaste begeleiding en begrip in 
deze laatste fase van dit proefschrift.
Verder wil ik alle verpleegkundigen, mensen van de administratie en secretari-
aat bedanken voor hun interesse en ondersteuning. Vooral Francis, bedankt 
voor je warme belangstelling en de gezellige gesprekken op momenten dat 
ik eigenlijk heel hard door moest schrijven. Diny, bedankt voor de goede ge-
sprekken over ons favoriete automerk. Eelke en Manon, bedankt voor al het 
geregel en het vele verzetten van afspraken de afgelopen jaren.
Verder wil ik al mijn collega’s en ex-collega’s bedanken voor de samenwerking 
en meeleven met het tot stand komen van dit proefschrift; Maartje, Demia, 
Marloes, Jeanette, Annechien, Jorn, Marijke, Bas, Tim, Manon, Marjolein, 
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Lenny, Else, Rosanne, Judith, Denise, Wynand, Milan, Mandy, Ilse, Jurgen, 
Jose, Angelina, Maria, Susan en Saskia, bedankt.
Matthijs Poll, bedankt voor al het werk dat je me uit handen hebt genomen en 
de enorme snelheid waarmee je van deze wanordelijke stapel papier een visueel 
aantrekkelijk boekje hebt weten te maken. 
Hoewel vaak vergeten, wil ik ook alle patiënten bedanken die geheel belangeloos 
mee hebben gedaan aan dit wetenschappelijk onderzoek.
 
Een groot deel van dit proefschrift werd geschreven in weekenden en doorde-
weekse avonden. Veel van mijn vrienden en familie hebben zich waarschijnlijk 
ook meer dan eens afgevraagd of ik nu echt van de aardbodem was verdwenen 
of dat mijn zoveelste mobiele telefoon het nu dan echt had begeven. 
Milan, bedankt voor je vriendschap, en de jaren waarin we het af en toe oneens 
waren over welke PDA nu echt de beste was, het waren gezellige tijden, bedankt 
ook voor je sms’je op exact het goede moment. 
Tevens wil ik al mijn vrienden bedanken voor al die keren dat ze me met poker-
en hebben laten winnen terwijl ik de laatste hand legde aan mijn proefschrift. 
Dank ook voor de continue interesse en steun op o.a. weekendjes in bijv. “foute” 
bungalowparken.
Jurgen en Maartje bedankt dat jullie me willen bijstaan als paranimfen. 
Jurgen, welk OS, was voor ons vanaf het begin niet de vraag. Je sms’je kwam 
ook precies op tijd. Bedankt voor de steun en vriendschap de afgelopen jaren, ik 
hoop dat er nog vele volgen.
Maartje, dank je voor je positieve schouderklopjes en de vele gesprekken, als 
partners in crime hebben we het hem toch maar mooi gelapt. Je wordt een fan-
tastische dermatoloog dat weet ik zeker.
Mijn familie en schoonfamilie wil ik bedanken voor hun getoonde interesse, 
motiverende gesprekken en gezellige avonden en middagen. Jos, bedankt dat je 
als laatste corrector het meest saaie werk wilde doen.
T. Elly en Jan-Karel, bedankt voor jullie steun en liefde, op alle fronten.
Ik kan me geen betere ouders wensen.
Tenslotte, maar zeker niet als laatste bedank ik Pauline. Lief, je betekent meer 
voor me dan je ooit zult weten. Bedankt voor je begrip, steun, onuitputtelijke 
liefde en het geluk dat je me gegeven hebt. 
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Figure 1: Cross-section through the finger, demonstrating the various compartments of the 
nail unit. The different parts of the nail unit have been given a differential colour.
Figure 2: Classical presentation of psoriasis vulgaris.
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Figure 3: Flexural psoriasis
Figure 5: Nail psoriasis showing pitting (A), dystrophy (B) and onycholysis (C)
Figure 4: Acrodermatitis continua of Hallopeau.
Chapter 1: Figures 3, 4 and 5
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Figure 2: Envision horseradish peroxidase staining of the nail apparatus. The antigen stained is 
noted in the diverse pictures. In A the keratin 15 staining in the whole nail apparatus is shown 
(magn: 50x). Pictures B-F show the expression of several markers in the nail matrix. Pictures 
G-I show the expression of keratin 15 at the dorsal PNF (G) and the ventral PNF (H) and the 
expression of keratin 6 at the border of the dorsal and ventral PNF (H). Pictures J & K show 
the expression of keratin 6 (J) and keratin 10 (K) in the nail bed. Picture L shows the keratin 10 
expression which abruptly emerges at the hyponychium in the suprabasal layers. (Pictures B-L: 
magn. 200x).
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Figure 3: Direct and indirect, immunofluorescent triple staining of the matrix of the nail unit. 
The diverse compartments of the nailapparatus are shown in the drawing at the bottom of the 
picture. The diverse parts of the intermediate matrix are colour coded and correspondent with 
the various pictures. The cell nucleoli are stained blue using DAPI (blue). Fig. A shows a double 
labelling of α-6 integrin (green) and keratin 19 (red) (magn: 100x). The expression of keratin 19 is 
extending to the more distal part of the intermediate matrix. Fig. B & C exhibit the double label-
ling of β1 integrin (green) and keratin 19 (red) in the matrix tip (B) and the more distal part of the 
intermediate matrix (C). There is no co-expression of these proteins. In fig. 3-D & E double label-
ling of β1 integrin (green) with ki-67 (red) is shown. Clearly visual is the higher number of ki-67 
positive cells in the intermediate matrix as compared to the dorsal matrix (D). The ki-67 positive 
cells are not only higher in number in the intermediate matrix; they are also expressed in the more 
suprabasal layers. β1 integrin expression in the more distal part of the intermediate matrix extends 
up to the 6th suprabasal cell layer. Note the cells co-expressing ki-67 and β1 integrin at this site, 
visual as orangepurple cells with a yellow ring (see inlay fig 3-E). (Fig. 3 B–E: magn. 200x).
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Figure 4: Triple staining of keratin 15 (green), keratin 19 (red) and the cell nucleus using DAPI 
(blue) in the intermediate matrix of the nail (A-C). The magnified part of the intermediate ma-
trix shown in E shows a part of the root of the nail in yellow where there is co-expression of 
keratin 15 and keratin 19. These cells are visible as yellow-orange cells in F. (magn. 200x)
Figure 5: Picture of the hypothetical model of the proliferation and differentiation process in 
the nail unit. The root of the nail plate incorporates a pool of keratin 15/keratin 19 co-expressing 
cells, a reservoir of alleged stem cells (1) supplying the underlying suprabasal layers of the in-
termediate matrix with cells with a high proliferative activity, the so called transit amplifying 
cells which are β1-integrin and ki-67 positive (2). This pool of transit amplifying cells provides
cells that terminally differentiate to the nail bed and nail plate (3). The stressed cells in the nail 
bed abundantly express keratin 6, while there is no keratin 15, ki-67 or keratin 10 expression (4). 
The keratin 10 expression abruptly returns as the nail leaves the nail bed at the hyperkeratotic 
hyponychium (5).
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Figure 2: Immunofluorescent photographs of the diverse markers. Shown from left to right is the 
psoriatic skin from the centre of the lesion to the distant uninvolved skin as compared with the 
healthy skin (far right). The lines drawn in the figure represent the regions of interest, containing the 
whole epidermis. First row shows Ki-67 expression (green), with a marked increase in expression 
in the inner margin and centre of the lesion. In the second row the β1 integrin expression is shown 
(green). The third row shows the keratin 6 expression (green), which is visible in the inner margin 
(patchy) and the  entre of the psoriatic plaque. Keratin 10 expression (red) is shown in the fourth row. 
The fifth row shows the expression of keratin 15 (red), which is only visible in the skin of the healthy 
controls. Cell nucleolus counterstaining with diamidino-2-phenylindole is visible in blue. Note that 
the section of healthy skin expressing Ki-67+ cells has been cut tangentially through the dermal pa-
pillae, resulting in a circular pattern of basal cells, some of which express Ki-67. (magn. 200x)
Ki-76
Beta1 Integrin
Keratin 6
Keratin 10
Keratin 15
Centre Inner Margin Outer Margin Distant 
Uninvolved
Healthy Skin
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Figure 3: Immunofluorescent photographs showing suprabasal, epidermal expression of Ki-67 
and β1 integrin. (A) Suprabasal expression of Ki-67+ nuclei (green) in the outer margin of the 
psoriasis plaque. (B) Weak suprabasal expression of β1 integrin on top of a basal cell layer ex-
pressing β1 integrin brightly in the distant uninvolved skin (green). Note the immunofluorescent 
staining in the dermal compartment of cells expressing β1 integrin, probably infiltrating T cells, 
fibroblasts or endothelia of the vasculature. (magn. 200x)
Fig. 3A Fig. 3B
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Figure 4: Keratin 6 (green) and keratin 10 (red) coexpression in the outer margin, inner mar-
gin and centre of the psoriatic plaque (from left to right). (A) Only keratin 10 expression in the 
outer margin. (B) Both keratin 6 and keratin 10 are expressed in the inner margin of the pso-
riatic plaque. Note the patchy expression of keratin 6 and the cells coexpressing both keratin 6 
and keratin 10 (visualized as the yellow cells). (C) In the centre of the psoriasis plaque most cells 
have coexpression of keratin 6 and keratin 10, visualized as yellow-stained cells. Only a few cells 
have single expression of one of these keratins. (magn. 200x)
Fig. 4A Fig. 4B Fig. 4C
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Figure 3: Qualitative changes in the expression of the various markers at baseline, after 4 and 
after 12 weeks of treatment and subdivided between the responder and non responder group.
Visible in (A) is the double labeling of keratin 6 (green) with keratin 10 (red). In this figure the 
shift from cells expressing keratin 6 towards cells expressing keratin 10 is seen. At baseline there 
are primarily cells with single expression of keratin 6 and a few cells co-expressing both keratins, 
visible as yellow-orange cells. After 4 weeks of treatment, in the responder group, there is a shift 
towards the cell population co-expressing keratin 6 and keratin 10 (yellow), also few cells with 
single expression of keratin 10 can be seen. Eventually after 12 weeks of treatment virtually all 
cells show single expression of keratin 10 (red). In the non responder group no such shift in 
keratin 6 and keratin 10 expressing cells is seen. 
In (B) the double labeling of ki-67 (green) and keratin 10 (red) is shown. Visible is that in the 
responder group the ki-67 positive cells are more confined to the basal layer after 4 and 12 
weeks of treatment. In the non responder group there are still ki-67 positive cells in the supra-
basal layers after 4 and 12 weeks of etanercept treatment. Counterstaining of the cell nuclei with 
diamidino-2-phenylindole (DAPI; blue). (magn. 200x)
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Figure 4: Qualitative changes in the expression of the various markers at baseline, after 4 and 
after 12 weeks of treatment and subdivided between the responder and non responder group. 
Visible in (A) is the double labeling of β1 integrin (green) with keratin 10 (red). Visible is that in 
the responder group, after 4, but even more after 12 weeks of treatment the β1 integrin expres-
sion is more confined to the basal layer as compared with the non responder group. Although 
not easily visible, after 12 weeks of treatment still suprabasal cells co-expressing β1 integrin and 
keratin 10 can be seen (red cells with a green border). This expression is not seen in the respond-
er group. In (B) single staining of basal keratin 15 expression is shown (red). Clearly visible is 
the return of keratin 15 expression after 4 and even more after 12 weeks of etanercept treatment 
in the responder group. No return of keratin 15 expression is seen in the non responder group. 
Counterstaining of the cell nuclei with diamidino-2-phenylindole (DAPI; blue). (magn. 200x)
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Figure 2: The expression of keratin (K) 15 (red) before and after treatment with calcipotriol 
(A,B) and calcitriol (C,D). Note the reappearance of basal K15 (visible as a patchy, basal red 
fluorescent staining) after treatment with calcipotriol. (magn. 200x)
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Figure 3: Double labelling of keratin (K) 6 (green) and K10 (red), before and after treatment 
with calcipotriol (A,B) and calcitriol (C,D). Co-expressing cells are visible as yellow or orange 
cells. Clearly visible is the disappearance of K6 expression after treatment with calcipotriol (B). 
(magn. 200x)
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Figure 4: Double labelling of β1 integrin (green) and keratin (K) 10 (red), before and after 
treatment with calcipotriol (A,B) and calcitriol (C,D). Just above the basal cell layer a popula-
tion of two to three cell layers coexpressing β1 integrin and K10 is seen, visible as cells with a 
red cytoplasm surrounded by a green cell membrane. These cell layers disappear after treatment 
with either calcipotriol or calcitriol. The cells coexpressing β1 integrin and K10 can be seen even 
more clearly in the magnified inlays. Note the dermal immunofluorescent staining of β1 integrin 
on fibroblasts and the endothelium of the vasculature. (magn. 200x)
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Figure 5: Double staining of Ki-67 with keratin 10 before treatment (A), after treatment with 
alefacept (B) and after treatment with alefacept/calcipotriol (C). Double staining of β1 integrin 
with keratin 10 before treatment (D), after treatment with alefacept (E) and after treatment with 
alefacept/calcipotriol (F ). Double staining of keratin 6 with keratin 10 before treatment (G), af-
ter treatment with alefacept (H) and after treatment with alefacept/calcipotriol (I). (magn. 200x)
H
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Figure 4: Keratin 15 staining pattern before treatment (A) and after treatment with alefacept (B). 
(magn. 200x)
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The growth and maintenance of the human skin and its appendages is 
warranted by the constant, dynamic changes in epidermal cell populations, 
epidermal proliferation, and differentiation. In normal, healthy epidermis 
there is a delicate balance between the production of young basal cells, and 
the shedding of terminally differentiated epidermal scales at the surface of 
the skin. In skin diseases like psoriasis, this balance is disturbed, resulting in 
changes in the various epidermal cell compartments. Also, very little is known 
about this differentiation process in the human nail apparatus.
This thesis focused on the dynamics of epidermal cell populations in healthy, 
diseased skin, and its appendages using a novel quantitative imaging technique. 
Furthermore, the effects of various treatments on the changes in these cell 
compartments were assessed.
